Diuretic	B
agents	I
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

ALDACTONE	B
has	O
been	O
shown	O
to	O
increase	O
the	O
half-life	O
of	O
digoxin	B-O
.	O

(	O
7.5	O
)	O
Strong	O
CYP3A	B
inhibitors	I
substantially	O
increase	O
ticagrelor	B-O
exposure	O
and	O
so	O
increase	O
the	O
risk	O
of	O
dyspnea	O
,	O
bleeding	O
,	O
and	O
other	O
adverse	O
events	O
.	O

BRILINTA	B
increases	O
serum	O
concentrations	O
of	O
simvastatin	B-O
and	O
lovastatin	B-O
because	O
these	O
drugs	O
are	O
metabolized	O
by	O
CYP3A4	O
.	O

Strong	O
CYP3A	B
inducers	I
substantially	O
reduce	O
ticagrelor	B-O
exposure	O
and	O
so	O
decrease	O
the	O
efficacy	O
of	O
ticagrelor	B-O
.	O

Cholestyramine	B
and	O
Colestipol	B
Resins	I
-	O
Both	O
cholestyramine	B
and	O
colestipol	B
resins	I
have	O
the	O
potential	O
of	O
binding	O
thiazide	B-O
diuretics	I-O
and	O
reducing	O
diuretic	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
.	O

Coadministration	O
of	O
inhibitors	O
of	O
the	O
uptake	O
transporter	O
(	O
rifampin	B
,	O
cyclosporine	B
)	O
or	O
efflux	O
transporter	O
(	O
ritonavir	B
)	O
may	O
increase	O
the	O
systemic	O
exposure	O
to	O
valsartan	B-O
.	O

Lithium	B-O
:	O
Increases	O
in	O
serum	O
lithium	B-O
concentrations	O
and	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-O
with	O
angiotensin	O
II	O
receptor	O
antagonists	O
,	O
including	O
Diovan	B
.	O

Lithium	B-O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
lithium	B-O
's	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

Patients	O
receiving	O
high	O
doses	O
of	O
salicylates	B-O
concomitantly	O
with	O
LASIX	B
,	O
as	O
in	O
rheumatic	O
disease	O
,	O
may	O
experience	O
salicylate	O
toxicity	O
at	O
lower	O
doses	O
because	O
of	O
competitive	O
renal	O
excretory	O
sites	O
.	O

There	O
is	O
evidence	O
that	O
treatment	O
with	O
phenytoin	B
leads	O
to	O
decrease	O
intestinal	O
absorption	O
of	O
LASIX	B-O
,	O
and	O
consequently	O
to	O
lower	O
peak	O
serum	O
furosemide	B-O
concentrations	O
.	O

Antiarrhythmics	O
:	O
The	O
metabolism	O
of	O
quinidine	B-O
,	O
procainamide	B-O
,	O
flecainide	B-O
can	O
be	O
inhibited	O
by	O
amiodarone	B
.	O

Cyclosporine	B-O
(	O
CYP3A	O
substrate	O
)	O
administered	O
in	O
combination	O
with	O
oral	O
amiodarone	B
has	O
been	O
reported	O
to	O
produce	O
persistently	O
elevated	O
plasma	O
concentrations	O
of	O
cyclosporine	B-O
resulting	O
in	O
elevated	O
creatinine	B-O
,	O
despite	O
reduction	O
in	O
dose	O
of	O
cyclosporine	B-O
.	O

Digoxin	B-O
:	O
In	O
patients	O
receiving	O
digoxin	B-O
therapy	O
,	O
administration	O
of	O
oral	O
amiodarone	B
results	O
in	O
an	O
increase	O
in	O
serum	O
digoxin	B-O
concentration	O
.	O

Increased	O
steady-state	O
levels	O
of	O
phenytoin	B-O
during	O
concomitant	O
therapy	O
with	O
amiodarone	B
have	O
been	O
reported	O
.	O

Limit	O
the	O
daily	O
dose	O
of	O
lovastatin	B-O
to	O
40	O
mg	O
.	O
Lower	O
starting	O
and	O
maintenance	O
doses	O
of	O
other	O
CYP3A4	B-O
substrates	I-O
(	O
e	O
.g.	O
,	O
atorvastatin	B-O
)	O
may	O
be	O
required	O
as	O
amiodarone	B
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
these	O
drugs	O
.	O

Lower	O
starting	O
and	O
maintenance	O
doses	O
of	O
other	O
CYP3A4	B-O
substrates	I-O
(	O
e.g	O
.	O
,	O
atorvastatin	B-O
)	O
may	O
be	O
required	O
as	O
amiodarone	B
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
these	O
drugs	O
.	O

Patients	O
should	O
avoid	O
grapefruit	B
juice	I
beverages	O
while	O
taking	O
amiodarone	B-O
because	O
exposure	O
to	O
amiodarone	B-O
is	O
significantly	O
increased	O
[see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)]	O
.	O

Amiodarone	B
inhibits	O
peripheral	O
conversion	O
of	O
thyroxine	B-O
(	O
T4	O
)	O
to	O
triiodothyronine	B-O
(	O
T3	O
)	O
and	O
may	O
cause	O
increased	O
T4	O
levels	O
,	O
decreased	O
T3	O
levels	O
,	O
and	O
increased	O
levels	O
of	O
inactive	O
reverse	O
T3	O
(	O
rT3	O
)	O
in	O
clinically	O
euthyroid	O
patients	O
.	O

Aspirin	B
:	O
increased	O
nitroglycerin	B-O
levels	O
(	O
7.3	O
)	O
.	O

Oral	O
administration	O
of	O
nitroglycerin	B
markedly	O
decreases	O
the	O
first-pass	O
metabolism	O
of	O
dihydroergotamine	B-O
and	O
subsequently	O
increases	O
its	O
oral	O
bioavailability	O
.	O

Plasma	O
levels	O
of	O
t-PA	B-O
are	O
reduced	O
when	O
coadministered	O
with	O
nitroglycerin	B
.	O

Co-administration	O
of	O
the	O
CYP2C8	O
enzyme	O
inducer	O
rifampin	B
decreases	O
exposure	O
to	O
treprostinil	B-O
.	O

Human	O
pharmacokinetic	O
studies	O
with	O
an	O
oral	O
formulation	O
of	O
treprostinil	B-O
(	O
treprostinil	B-O
diethanolamine	O
)	O
indicated	O
that	O
co-administration	O
of	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
2C8	O
enzyme	O
inhibitor	O
gemfibrozil	B
increases	O
exposure	O
(	O
both	O
Cmax	O
and	O
AUC	O
)	O
to	O
treprostinil	B-O
.	O

Co-administration	O
of	O
a	O
CYP2C8	B
enzyme	I
inducer	I
(	O
e.g	O
.	O
,	O
rifampin	B
)	O
decreases	O
exposure	O
to	O
treprostinil	B-O
see	O
Drug	O
Interactions	O
(	O
7.5	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
.	O

Co-administration	O
of	O
a	O
cytochrome	O
P450	B
(	I
CYP	I
)	I
2C8	I
enzyme	I
inhibitor	I
(	O
e.g	O
.	O
,	O
gemfibrozil	B
)	O
increases	O
exposure	O
(	O
both	O
Cmax	O
and	O
AUC	O
)	O
to	O
treprostinil	B-O
.	O

Co-administration	O
of	O
SAMSCA	B-O
with	O
potent	O
CYP3A	B
inducers	I
(	O
e.g	O
.	O
,	O
rifampin	B
)	O
reduces	O
tolvaptan	B-O
plasma	O
concentrations	O
by	O
85	O
%	O
.	O

Ketoconazole	B
200	O
mg	O
administered	O
with	O
tolvaptan	B-O
increased	O
tolvaptan	B-O
exposure	O
by	O
5-fold	O
.	O

A	O
substantial	O
increase	O
in	O
the	O
exposure	O
to	O
tolvaptan	B-O
would	O
be	O
expected	O
when	O
SAMSCA	B-O
is	O
co-administered	O
with	O
moderate	O
CYP3A	B
inhibitors	I
.	O

Co-administration	O
of	O
lovastatin	B-O
and	O
SAMSCA	B
increases	O
the	O
exposure	O
to	O
lovastatin	B-O
and	O
its	O
active	O
metabolite	O
lovastatin	B-O
-	I-O
hydroxyacid	I-O
by	O
factors	O
of	O
1.4	O
and	O
1.3	O
,	O
respectively	O
.	O

Co-administration	O
of	O
rifampin	B
and	O
SAMSCA	B-O
reduces	O
exposure	O
to	O
tolvaptan	B-O
by	O
85	O
%	O
.	O

Co-administration	O
of	O
SAMSCA	O
and	O
ketoconazole	B
200	O
mg	O
daily	O
results	O
in	O
a	O
5-fold	O
increase	O
in	O
exposure	O
to	O
tolvaptan	O
.	O

Co-administration	O
of	O
SAMSCA	B-O
and	O
ketoconazole	O
200mg	O
daily	O
results	O
in	O
a	O
5-fold	O
increase	O
in	O
exposure	O
to	O
tolvaptan	B-O
.	O

Co-administration	O
of	O
SAMSCA	B-O
with	O
400	O
mg	O
ketoconazole	B
daily	O
or	O
with	O
other	O
strong	O
CYP3A	B
inhibitors	I
(	O
e.g	O
.	O
,	O
clarithromycin	B
,	O
itraconazole	B
,	O
telithromycin	B
,	O
saquinavir	B
,	O
nelfinavir	B
,	O
ritonavir	B
and	O
nefazodone	B
)	O
at	O
the	O
highest	O
labeled	O
dose	O
would	O
be	O
expected	O
to	O
cause	O
an	O
even	O
greater	O
increase	O
in	O
tolvaptan	B-O
exposure	O
.	O

Co-administration	O
of	O
SAMSCA	B
with	O
digoxin	B-O
increased	O
digoxin	B-O
AUC	O
by	O
20	O
%	O
and	O
Cmax	O
by	O
30	O
%	O
.	O

CYP3A	B
Inducers	I
Avoid	O
co-administration	O
of	O
CYP3A	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
,	O
rifabutin	B
,	O
rifapentin	B
,	O
barbiturates	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
St	B
.	I
John	I
's	I
Wort	I
)	O
with	O
SAMSCA	B-O
,	O
as	O
this	O
can	O
lead	O
to	O
a	O
reduction	O
in	O
the	O
plasma	O
concentration	O
of	O
tolvaptan	B-O
and	O
decreased	O
effectiveness	O
of	O
SAMSCA	B-O
treatment	O
.	O

CYP3A	B
inhibitors	I
can	O
lead	O
to	O
a	O
marked	O
increase	O
in	O
tolvaptan	B-O
concentrations	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.1	O
)]	O
.	O

Furosemide	B-O
:	O
Oral	O
coadministration	O
of	O
aliskiren	B
and	O
furosemide	B-O
reduced	O
exposure	O
to	O
furosemide	B-O
.	O

When	O
aliskiren	B-O
was	O
given	O
with	O
cyclosporine	B
or	O
itraconazole	B
,	O
the	O
blood	O
concentrations	O
of	O
aliskiren	B-O
were	O
significantly	O
increased	O
.	O

Co-administration	O
of	O
cyclosporine	B
A	I
and	O
bosentan	B-O
resulted	O
in	O
markedly	O
increased	O
plasma	O
concentrations	O
of	O
bosentan	B-O
.	O

An	O
interaction	O
study	O
demonstrated	O
that	O
co-administration	O
of	O
bosentan	B
and	O
a	O
combination	O
oral	B-O
hormonal	I-O
contraceptive	I-O
produced	O
average	O
decreases	O
of	O
norethindrone	B-O
and	O
ethinyl	B-O
estradiol	I-O
levels	O
of	O
14	O
%	O
and	O
31	O
%	O
,	O
respectively	O
.	O

Concomitant	O
administration	O
of	O
both	O
a	O
CYP2C9	B
inhibitor	I
(	O
such	O
as	O
fluconazole	B
or	O
amiodarone	B
)	O
and	O
a	O
strong	O
CYP3A	B
inhibitor	I
(	O
e.g	O
.	O
,	O
ketoconazole	B
,	O
itraconazole	B
)	O
or	O
a	O
moderate	O
CYP3A	B
inhibitor	I
(	O
e.g	O
.	O
,	O
amprenavir	B
,	O
erythromycin	B
,	O
fluconazole	B
,	O
diltiazem	B
)	O
with	O
Tracleer	B-O
will	O
likely	O
lead	O
to	O
large	O
increases	O
in	O
plasma	O
concentrations	O
of	O
bosentan	B-O
.	O

Lithium	B-O
:	O
Lithium	B-O
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B-O
concomitantly	O
with	O
drugs	O
which	O
cause	O
elimination	O
of	O
sodium	O
,	O
including	O
ACE	B
inhibitors	I
.	O

A	O
few	O
cases	O
of	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
VASOTEC	B
and	O
lithium	B-O
and	O
were	O
reversible	O
upon	O
discontinuation	O
of	O
both	O
drugs	O
.	O

Administration	O
of	O
CMI	B
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
of	O
phenobarbital	B-O
,	O
if	O
given	O
concomitantly	O
.	O

Because	O
Anafranil	B
is	O
highly	O
bound	O
to	O
serum	O
protein	O
,	O
the	O
administration	O
of	O
Anafranil	B
to	O
patients	O
taking	O
other	O
drugs	B-O
that	I-O
are	I-O
highly	I-O
bound	I-O
to	I-O
protein	I-O
(	O
e	O
.g.	O
,	O
warfarin	B-O
,	O
digoxin	B-O
)	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Fluvoxamine	B
has	O
also	O
been	O
shown	O
to	O
inhibit	O
P450	B-O
1A2	I-O
,	O
an	O
isoform	O
also	O
involved	O
in	O
TCA	O
metabolism	O
.	O

The	O
plasma	O
concentration	O
of	O
CMI	B-O
has	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
haloperidol	B
;	O
plasma	O
levels	O
of	O
several	O
closely	O
related	O
tricyclic	B-O
antidepressants	I-O
have	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
methylphenidate	B
or	O
hepatic	B
enzyme	I
inhibitors	I
(	O
e	O
.g.	O
,	O
cimetidine	B
,	O
fluoxetine	B
)	O
and	O
decreased	O
by	O
the	O
concomitant	O
administration	O
of	O
hepatic	B
enzyme	I
inducers	I
(	O
e	O
.g.	O
,	O
barbiturates	B
,	O
phenytoin	B
)	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B-O
as	O
well	O
.	O

Decreased	O
exposure	O
of	O
some	O
antiretroviral	B-O
drugs	I-O
(	O
e	O
.g.	O
,	O
rilpivirine	B-O
,	O
atazanavir	B-O
,	O
and	O
nelfinavir	B-O
)	O
when	O
used	O
concomitantly	O
with	O
rabeprazole	B
may	O
reduce	O
antiviral	O
effect	O
and	O
promote	O
the	O
development	O
of	O
drug	O
resistance	O
.	O

Drugs	O
Dependent	O
on	O
Gastric	O
pH	O
for	O
Absorption	O
(	O
e	O
.g.	O
,	O
iron	B-O
salts	I-O
,	O
erlotinib	B-O
,	O
dasatinib	B-O
,	O
nilotinib	B-O
,	O
mycophenolate	B-O
mofetil	I-O
,	O
ketoconazole	B-O
,	O
itraconazole	B-O
)	O
Clinical	O
Impact	O
:	O
Rabeprazole	B
can	O
reduce	O
the	O
absorption	O
of	O
other	O
drugs	O
due	O
to	O
its	O
effect	O
on	O
reducing	O
intragastric	O
acidity	O
.	O

Increased	O
exposure	O
of	O
other	O
antiretroviral	B-O
drugs	I-O
(	O
e	O
.g.	O
,	O
saquinavir	B-O
)	O
when	O
used	O
concomitantly	O
with	O
rabeprazole	B
may	O
increase	O
toxicity	O
.	O

Intervention	O
:	O
Mycophenolate	B-O
mofetil	I-O
(	O
MMF)	O
:	O
Co-administration	O
of	O
PPIs	B
in	O
healthy	O
subjects	O
and	O
in	O
transplant	O
patients	O
receiving	O
MMF	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
exposure	O
to	O
the	O
active	O
metabolite	O
,	O
mycophenolic	B-O
acid	I-O
(	O
MPA	O
)	O
,	O
possibly	O
due	O
to	O
a	O
decrease	O
in	O
MMF	O
solubility	O
at	O
an	O
increased	O
gastric	O
pH.	O

Methotrexate	B-O
Clinical	O
Impact	O
:	O
Concomitant	O
use	O
of	O
rabeprazole	B
with	O
methotrexate	B-O
(	O
primarily	O
at	O
high	O
dose	O
)	O
may	O
elevate	O
and	O
prolong	O
serum	O
levels	O
of	O
methotrexate	B-O
and/or	O
its	O
metabolite	O
hydroxymethotrexate	B-O
,	O
possibly	O
leading	O
to	O
methotrexate	B-O
toxicities	O
.	O

Daily	O
treatment	O
with	O
any	O
acid-suppressing	B
medications	I
over	O
a	O
long	O
period	O
of	O
time	O
(	O
e	O
.g.	O
,	O
longer	O
than	O
3	O
years	O
)	O
may	O
lead	O
to	O
malabsorption	O
of	O
cyanocobalamin	B-O
(vitamin	B-O
B-12	I-O
)	O
caused	O
by	O
hypo-	O
or	O
achlorhydria	O
.	O

Interaction	O
with	O
Methotrexate	B-O
:	O
Concomitant	O
use	O
with	O
PPIs	B
may	O
elevate	O
and/or	O
prolong	O
serum	O
concentrations	O
of	O
methotrexate	B-O
and/or	O
its	O
metabolite	O
,	O
possibly	O
leading	O
to	O
toxicity	O
.	O

Failure	O
to	O
correctly	O
co-administer	O
APTIVUS	B-O
with	O
ritonavir	B
will	O
result	O
in	O
plasma	O
levels	O
of	O
tipranavir	B-O
that	O
will	O
be	O
insufficient	O
to	O
achieve	O
the	O
desired	O
antiviral	O
effect	O
and	O
will	O
alter	O
some	O
drug	O
interactions	O
.	O

Agents	O
for	O
Opportunistic	O
Infections	O
Antifungals	O
:	O
Fluconazole	B
traconazole	B
Ketoconazole	B
Voriconazole	B
Tipranavir	B-O
increases	O
tipranavir	B-O
concentrations	O
but	O
dose	O
adjustments	O
are	O
not	O
needed	O
.	O

Antidepressants	O
:	O
Trazodone	B-O
Concomitant	O
use	O
of	O
trazodone	B-O
and	I
APTIVUS/ritonavir	B
may	O
increase	O
plasma	O
concentrations	O
of	O
trazodone	B-O
.	O

Antipsychotics	O
:	O
Quetiapine	B-O
Initiation	O
of	O
APTIVUS	B
with	O
ritonavir	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
exposures	O
.	O

Co-administration	O
of	I-O
APTIVUS/ritonavir	B-O
and	O
drugs	B
that	I
induce	I
CYP3A	I
and/or	I
P-gp	I
may	O
decrease	O
tipranavir	O
plasma	O
concentrations	O
.	O

Co-administration	O
of	O
APTIVUS/ritonavir	O
and	O
drugs	O
that	O
inhibit	O
P-gp	O
may	O
increase	O
tipranavir	B-O
plasma	O
concentrations	O
.	O

Concomitant	O
use	O
of	O
rilpivirine	B-O
with	I
Aptivus/ritonavir	B
may	O
cause	O
an	O
increase	O
in	O
the	O
plasma	O
concentrations	O
of	O
rilpivirine	B-O
(	O
inhibition	O
of	O
CYP3A	O
enzymes	O
)	O
.	O

Desipramine	B-O
Combination	O
with	I
APTIVUS/ritonavir	B
not	O
studied<U+2191>	O
Desipramine	B-O
Dosage	O
reduction	O
and	O
concentration	O
monitoring	O
of	O
desipramine	B-O
is	O
recommended	O
.	O

If	O
trazodone	B-O
is	O
used	O
with	O
a	O
CYP3A4	B
inhibitor	I
such	O
as	I
APTIVUS/ritonavir	B
,	O
the	O
combination	O
should	O
be	O
used	O
with	O
caution	O
and	O
a	O
lower	O
dose	O
of	O
trazodone	B-O
should	O
be	O
considered	O
.	O

Inhaled/Nasal	O
Steroids	O
:	O
Fluticasone	O
Concomitant	O
use	O
of	O
fluticasone	B-O
propionate	I-O
and	I
APTIVUS/ritonavir	B
may	O
increase	O
plasma	O
concentrations	O
of	O
fluticasone	B-O
propionate	I-O
,	O
resulting	O
in	O
significantly	O
reduced	O
serum	O
cortisol	O
concentrations	O
.	O

Normeperidine	O
Methadone	B-O
,	O
Methadone	B-O
,	O
S-Methadone	B-O
,	O
R-Methadone	B-O
Dosage	O
of	O
methadone	B-O
may	O
need	O
to	O
be	O
increased	O
when	O
co-administered	O
with	O
APTIVUS	B
and	O
200	O
mg	O
of	O
ritonavir	B
.	O

Narcotic	O
Analgesics	O
:	O
Combinations	O
with	I
APTIVUS/ritonavir	B
not	O
studied	O
Dosage	O
increase	O
and	O
long-term	O
use	O
of	O
meperidine	B-O
are	O
not	O
recommended	O
due	O
to	O
increased	O
concentrations	O
of	O
the	O
metabolite	O
normeperidine	B-O
which	O
has	O
both	O
analgesic	O
activity	O
and	O
CNS	O
stimulant	O
activity	O
(	O
e	O
.g.	O
,	O
seizures	O
)	O
.	O

Non-Nucleoside	O
Reverse	O
Transcriptase	O
Inhibitors	O
:	I
APTIVUS/ritonavir	B
when	O
coadministered	O
with	O
etravirine	B-O
may	O
cause	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
concentrations	O
of	O
etravirine	B-O
and	O
loss	O
of	O
therapeutic	O
effect	O
of	O
etravirine	B-O
.	O

Protease	O
Inhibitors	O
(	O
co-administered	O
with	O
100	O
mg	O
of	O
ritonavir	B
)	O
:	O
Atazanavir	O
,	O
Tipranavir	O
.	O
Virus	O
Integrase	O
Strand	O
Transfer	O
Inhibitors	O
:	O
Raltegravir	B-O
,	I
APTIVUS/ritonavir	B
reduces	O
plasma	O
concentrations	O
of	O
raltegravir	B-O
.	O

Proton	O
Pump	O
Inhibitors	O
:	O
Omeprazole	B-O
,	O
Tipranavir	O
.	O
Dosage	O
of	O
omeprazole	B-O
may	O
need	O
to	O
be	O
increased	O
when	O
co-administered	O
with	O
APTIVUS	B
and	O
ritonavir	B
.	O

Valproic	B-O
acid	I-O
may	O
be	O
less	O
effective	O
due	O
to	O
decreased	O
valproic	B-O
acid	I-O
plasma	O
concentration	O
in	O
patients	O
taking	O
APTIVUS	B
concomitantly	O
.	O

Avoid	O
concomitant	O
use	O
of	O
St	B
.	I
John	I
's	I
Wort	I
because	O
it	O
can	O
decrease	O
vandetanib	B-O
exposure	O
unpredictably	O
.	O

Avoid	O
the	O
use	O
of	O
strong	O
CYP3A4	B
inducers	I
because	O
they	O
may	O
decrease	O
CAPRELSA	B-O
exposure	O
.	O

CAPRELSA	B
increased	O
plasma	O
concentrations	O
of	O
digoxin	B-O
.	O

CAPRELSA	B
increased	O
plasma	O
concentrations	O
of	O
metformin	B-O
that	O
is	O
transported	O
by	O
the	O
organic	O
cation	O
transporter	O
type	O
2	O
(	O
OCT2	O
)	O
.	O

Rifampicin	B
,	O
a	O
strong	O
CYP3A4	O
inducer	O
,	O
decreased	O
vandetanib	B-O
plasma	O
concentrations	O
.	O

Inhibition	O
of	O
CYP3A4	O
by	O
CRIXIVAN	B
can	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
following	O
drugs	O
,	O
potentially	O
causing	O
serious	O
and/or	O
life-threatening	O
reactions	O
:	O
Table	O
7	O
:	O
Drug	O
Interactions	O
With	O
Crixivan	B
:	O
Contraindicated	O
Drugs	O
Drug	O
Class	O
Drugs	O
Within	O
Class	O
That	O
Are	O
Contraindicated	O
With	O
CRIXIVAN	B
Alpha	O
1-adrenoreceptor	O
antagonist	O
alfuzosin	B-O
Antiarrhythmics	O
amiodarone	B-O
Antipsychotics	O
lurasidone	B-O
,	O
pimozide	O
Ergot	O
derivatives	O
dihydroergotamine	O
,	O
ergonovine	O
,	O
ergotamine	O
,	O
methylergonovine	O
GI	O
motility	O
agents	O
cisapride	O
HMG-CoA	O
Reductase	O
Inhibitors	O
lovastatin	O
,	O
simvastatin	O
PDE5	O
Inhibitors	O
RevatioRegistered	O
trademark	O
of	O
Pfizer	O
,	O
Inc.	O
(	O
sildenafil	O
)	O
[for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
]	O
Sedative/hypnotics	O
oral	O
midazolam	O
,	O
triazolam	O
,	O
alprazolam	O

Inhibition	O
of	O
CYP3A4	O
by	O
CRIXIVAN	O
can	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
following	O
drugs	O
,	O
potentially	O
causing	O
serious	O
and/or	O
life-threatening	O
reactions	O
:	O
Table	O
7	O
:	O
Drug	O
Interactions	O
With	O
Crixivan	O
:	O
Contraindicated	O
Drugs	O
Drug	O
Class	O
Drugs	O
Within	O
Class	O
That	O
Are	O
Contraindicated	O
With	O
CRIXIVAN	O
Alpha	O
1-adrenoreceptor	O
antagonist	O
alfuzosin	O
Antiarrhythmics	O
amiodarone	O
Antipsychotics	O
lurasidone	O
,	O
pimozide	B-O
.	O
Ergot	O
derivatives	O
dihydroergotamine	O
,	O
ergonovine	O
,	O
ergotamine	O
,	O
methylergonovine	O
GI	O
motility	O
agents	O
cisapride	O
HMG-CoA	O
Reductase	O
Inhibitors	O
lovastatin	O
,	O
simvastatin	O
PDE5	O
Inhibitors	O
RevatioRegistered	O
trademark	O
of	O
Pfizer	O
,	O
Inc.	O
(	O
sildenafil	O
)	O
[for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
]	O
Sedative/hypnotics	O
oral	O
midazolam	O
,	O
triazolam	O
,	O
alprazolam	O

Inhibition	O
of	O
CYP3A4	O
by	O
CRIXIVAN	O
can	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
following	O
drugs	O
,	O
potentially	O
causing	O
serious	O
and/or	O
life-threatening	O
reactions	O
:	O
Table	O
7	O
:	O
Drug	O
Interactions	O
With	O
Crixivan	O
:	O
Contraindicated	O
Drugs	O
Drug	O
Class	O
Drugs	O
Within	O
Class	O
That	O
Are	O
Contraindicated	O
With	O
CRIXIVAN	O
Alpha	O
1-adrenoreceptor	O
antagonist	O
alfuzosin	O
Antiarrhythmics	O
amiodarone	O
Antipsychotics	O
lurasidone	O
,	O
pimozide	O
Ergot	O
derivatives	O
dihydroergotamine	B-O
,	O
ergonovine	B-O
,	O
ergotamine	B-O
,	O
methylergonovine	B-O
GI	O
motility	O
agents	O
cisapride	O
HMG-CoA	O
Reductase	O
Inhibitors	O
lovastatin	O
,	O
simvastatin	O
PDE5	O
Inhibitors	O
RevatioRegistered	O
trademark	O
of	O
Pfizer	O
,	O
Inc.	O
(	O
sildenafil	O
)	O
[for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
]	O
Sedative/hypnotics	O
oral	O
midazolam	O
,	O
triazolam	O
,	O
alprazolam	O

Inhibition	O
of	O
CYP3A4	O
by	O
CRIXIVAN	O
can	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
following	O
drugs	O
,	O
potentially	O
causing	O
serious	O
and/or	O
life-threatening	O
reactions	O
:	O
Table	O
7	O
:	O
Drug	O
Interactions	O
With	O
Crixivan	O
:	O
Contraindicated	O
Drugs	O
Drug	O
Class	O
Drugs	O
Within	O
Class	O
That	O
Are	O
Contraindicated	O
With	O
CRIXIVAN	O
Alpha	O
1-adrenoreceptor	O
antagonist	O
alfuzosin	O
Antiarrhythmics	O
amiodarone	O
Antipsychotics	O
lurasidone	O
,	O
pimozide	O
Ergot	O
derivatives	O
dihydroergotamine	O
,	O
ergonovine	O
,	O
ergotamine	O
,	O
methylergonovine	B-O
.	O
GI	O
motility	O
agents	O
cisapride	O
HMG-CoA	O
Reductase	O
Inhibitors	O
lovastatin	O
,	O
simvastatin	O
PDE5	O
Inhibitors	O
RevatioRegistered	O
trademark	O
of	O
Pfizer	O
,	O
Inc.	O
(	O
sildenafil	O
)	O
[for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
]	O
Sedative/hypnotics	O
oral	O
midazolam	O
,	O
triazolam	O
,	O
alprazolam	O

Inhibition	O
of	O
CYP3A4	O
by	O
CRIXIVAN	O
can	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
following	O
drugs	O
,	O
potentially	O
causing	O
serious	O
and/or	O
life-threatening	O
reactions	O
:	O
Table	O
7	O
:	O
Drug	O
Interactions	O
With	O
Crixivan	O
:	O
Contraindicated	O
Drugs	O
Drug	O
Class	O
Drugs	O
Within	O
Class	O
That	O
Are	O
Contraindicated	O
With	O
CRIXIVAN	O
Alpha	O
1-adrenoreceptor	O
antagonist	O
alfuzosin	O
Antiarrhythmics	O
amiodarone	O
Antipsychotics	O
lurasidone	O
,	O
pimozide	O
Ergot	O
derivatives	O
dihydroergotamine	O
,	O
ergonovine	O
,	O
ergotamine	O
,	O
methylergonovine	O
GI	O
motility	O
agents	O
cisapride	B-O
HMG-CoA	O
Reductase	O
Inhibitors	O
lovastatin	B-O
,	O
simvastatin	B-O
PDE5	O
Inhibitors	O
RevatioRegistered	O
trademark	O
of	O
Pfizer	O
,	O
Inc.	O
(	O
sildenafil	O
)	O
[for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
]	O
Sedative/hypnotics	O
oral	O
midazolam	O
,	O
triazolam	O
,	O
alprazolam	O

Inhibition	O
of	O
CYP3A4	O
by	O
CRIXIVAN	O
can	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
following	O
drugs	O
,	O
potentially	O
causing	O
serious	O
and/or	O
life-threatening	O
reactions	O
:	O
Table	O
7	O
:	O
Drug	O
Interactions	O
With	O
Crixivan	O
:	O
Contraindicated	O
Drugs	O
Drug	O
Class	O
Drugs	O
Within	O
Class	O
That	O
Are	O
Contraindicated	O
With	O
CRIXIVAN	O
Alpha	O
1-adrenoreceptor	O
antagonist	O
alfuzosin	O
Antiarrhythmics	O
amiodarone	O
Antipsychotics	O
lurasidone	O
,	O
pimozide	O
Ergot	O
derivatives	O
dihydroergotamine	O
,	O
ergonovine	O
,	O
ergotamine	O
,	O
methylergonovine	O
GI	O
motility	O
agents	O
cisapride	O
HMG-CoA	O
Reductase	O
Inhibitors	O
lovastatin	O
,	O
simvastatin	O
PDE5	O
Inhibitors	O
Revatio	B-O
Registered	O
trademark	O
of	O
Pfizer	O
,	O
Inc.	O
(	O
sildenafil	B-O
)	O
[for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
]	O
Sedative/hypnotics	O
oral	O
midazolam	O
,	O
triazolam	O
,	O
alprazolam	O

Inhibition	O
of	O
CYP3A4	O
by	O
CRIXIVAN	O
can	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
following	O
drugs	O
,	O
potentially	O
causing	O
serious	O
and/or	O
life-threatening	O
reactions	O
:	O
Table	O
7	O
:	O
Drug	O
Interactions	O
With	O
Crixivan	O
:	O
Contraindicated	O
Drugs	O
Drug	O
Class	O
Drugs	O
Within	O
Class	O
That	O
Are	O
Contraindicated	O
With	O
CRIXIVAN	O
Alpha	O
1-adrenoreceptor	O
antagonist	O
alfuzosin	O
Antiarrhythmics	O
amiodarone	O
Antipsychotics	O
lurasidone	O
,	O
pimozide	O
Ergot	O
derivatives	O
dihydroergotamine	O
,	O
ergonovine	O
,	O
ergotamine	O
,	O
methylergonovine	O
GI	O
motility	O
agents	O
cisapride	O
HMG-CoA	O
Reductase	O
Inhibitors	O
lovastatin	O
,	O
simvastatin	O
PDE5	O
Inhibitors	O
RevatioRegistered	O
trademark	O
of	O
Pfizer	O
,	O
Inc.	O
(	O
sildenafil	O
)	O
[for	O
treatment	O
of	O
pulmonary	O
arterial	O
hypertension	O
]	O
Sedative/hypnotics	O
oral	O
midazolam	B-O
,	O
triazolam	B-O
,	O
alprazolam	B-O

Co-administration	O
with	O
CRIXIVAN	B
with	O
or	O
without	O
ritonavir	B
may	O
cause	O
a	O
large	O
increase	O
in	O
the	O
concentration	O
of	O
this	O
benzodiazepine	B-O
.	O

Coadministration	O
of	O
CRIXIVAN	B-O
and	O
St	B
.	I
John	I
's	I
wort	I
has	O
been	O
shown	O
to	O
substantially	O
decrease	O
indinavir	B-O
concentrations	O
and	O
may	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	B-O
or	O
to	O
the	O
class	O
of	O
protease	O
inhibitors	O
.	O

Coadministration	O
of	O
CRIXIVAN	B
with	O
these	O
medications	O
is	O
expected	O
to	O
substantially	O
increase	O
plasma	O
concentrations	O
of	O
sildenafil	B-O
,	O
tadalafil	B-O
,	O
and	O
vardenafil	B-O
and	O
may	O
result	O
in	O
an	O
increase	O
in	O
adverse	O
events	O
,	O
including	O
hypotension	O
,	O
visual	O
changes	O
,	O
and	O
priapism	O
,	O
which	O
have	O
been	O
associated	O
with	O
sildenafil	B-O
,	O
tadalafil	B-O
,	O
and	O
vardenafil	B-O
.	O

Data	O
from	O
concomitant	O
use	O
of	O
parenteral	O
midazolam	B-O
with	O
other	O
protease	B
inhibitors	I
suggest	O
a	O
possible	O
3-4	O
fold	O
increase	O
in	O
midazolam	B-O
plasma	O
levels	O
.	O

Average	O
sildenafil	B-O
AUC	O
was	O
increased	O
by	O
340	O
%	O
following	O
coadministration	O
of	O
sildenafil	B-O
and	O
indinavir	B
compared	O
to	O
historical	O
data	O
following	O
administration	O
of	O
sildenafil	B-O
alone	O
.	O

In	O
the	O
same	O
study	O
,	O
twice-daily	O
coadministration	O
of	O
indinavir	B
(	O
800	O
mg	O
)	O
and	O
ritonavir	B-O
(	O
100	O
or	O
200	O
mg	O
)	O
resulted	O
in	O
ritonavir	B-O
AUC24h	O
increases	O
versus	O
the	O
same	O
doses	O
of	O
ritonavir	B-O
alone	O
.	O

Ritonavir	B
:	O
Compared	O
to	O
historical	O
data	O
in	O
patients	O
who	O
received	O
indinavir	B-O
800	O
mg	O
every	O
8	O
hours	O
alone	O
,	O
twice-daily	O
coadministration	O
to	O
volunteers	O
of	O
indinavir	B-O
800	O
mg	O
and	O
ritonavir	B
with	O
food	O
for	O
two	O
weeks	O
resulted	O
in	O
a	O
2.7-fold	O
increase	O
of	O
indinavir	B-O
AUC24h	O
,	O
a	O
1.6-fold	O
increase	O
in	O
indinavir	B-O
Cmax	O
,	O
and	O
an	O
11-fold	O
increase	O
in	O
indinavir	B-O
Cmin	O
for	O
a	O
100-mg	O
ritonavir	B
dose	O
and	O
a	O
3.6-fold	O
increase	O
of	O
indinavir	B-O
AUC24h	O
,	O
a	O
1.8-	O
fold	O
increase	O
in	O
indinavir	B-O
Cmax	O
,	O
and	O
a	O
24-fold	O
increase	O
in	O
indinavir	B-O
Cmin	O
for	O
a	O
200-mg	O
ritonavir	B
dose	O
.	O

Sildenafil	B
:	O
The	O
results	O
of	O
one	O
published	O
study	O
in	O
HIV-infected	O
men	O
(	O
n=6	O
)	O
indicated	O
that	O
coadministration	O
of	O
indinavir	B-O
(	O
800	O
mg	O
every	O
8	O
hours	O
chronically	O
)	O
with	O
a	O
single	O
25-mg	O
dose	O
of	O
sildenafil	B
resulted	O
in	O
an	O
11	O
%	O
increase	O
in	O
average	O
AUC0-8hr	O
of	O
indinavir	B-O
and	O
a	O
48	O
%	O
increase	O
in	O
average	O
indinavir	B-O
peak	O
concentration	O
(	O
Cmax	O
)	O
compared	O
to	O
800	O
mg	O
every	O
8	O
hours	O
alone	O
.	O

Vardenafil	B-O
:	O
Indinavir	B
(	O
800	O
mg	O
every	O
8	O
hours	O
)	O
coadministered	O
with	O
a	O
single	O
10-mg	O
dose	O
of	O
vardenafil	B-O
resulted	O
in	O
a	O
16-fold	O
increase	O
in	O
vardenafil	B-O
AUC	O
,	O
a	O
7-fold	O
increase	O
in	O
vardenafil	B-O
Cmax	O
,	O
and	O
a	O
2-fold	O
increase	O
in	O
vardenafil	B-O
half-life	O
.	O

Zidovudine	O
200	O
three	O
times	O
daily	O
,	O
7	O
days	O
1000	O
three	O
times	O
daily	O
,	O
7	O
days	O
12	O
0.89(0.73	O
,	O
1.09	O
)	O
1.17(	O
1.07	O
,	O
1.29	O
)	O
1.51(0.71	O
,	O
3.20	O
)n=4	O
Zidovudine/Lamivudine	O
Zidovudine	O
200/150	O
three	O
times	O
daily	O
,	O
7	O
days	O
800	O
three	O
times	O
daily	O
,	O
7	O
days	O
6	O
,	O
7	O
1.23(0.74	O
,	O
2.03	O
)	O
1.39(	O
1.02	O
,	O
1.89	O
)	O
1.08(0.77	O
,	O
1.50)n=5	O
,	O
5	O
Zidovudine/Lamivudine	O
Lamivudine	O
200/150	O
three	O
times	O
daily	O
,	O
7	O
days	O
800	O
three	O
times	O
daily	O
,	O
7	O
days	O
6	O
,	O
7	O
0.73(0.52	O
,	O
1.02	O
)	O
0.91(0.66	O
,	O
1.26	O
)	O
0.88(0.59	O
,	O
1.33	O
)	O
Delavirdine	B
:	O
Delavirdine	B
inhibits	O
the	O
metabolism	O
of	O
indinavir	B-O
such	O
that	O
coadministration	O
of	O
400-mg	O
or	O
600-mg	O
indinavir	B-O
three	O
times	O
daily	O
with	O
400-mg	O
delavirdine	B
three	O
times	O
daily	O
alters	O
indinavir	B-O
AUC	O
,	O
Cmax	O
and	O
Cmin	O
.	O

Antidepressant	O
:	O
trazodone	B-O
concentration	O
.	O
Concomitant	O
use	O
of	O
trazodone	B-O
and	O
CRIXIVAN	B
may	O
increase	O
plasma	O
concentrations	O
of	O
trazodone	B-O
.	O

Antipsychotics	O
:	O
quetiapine	B-O
.	O
Initiation	O
of	O
CRIXIVAN	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
drug	O
exposures	O
.	O

Coadministration	O
of	O
CRIXIVAN	B
and	O
other	O
drugs	B
that	I
inhibit	I
CYP3A4	I
may	O
decrease	O
the	O
clearance	O
of	O
indinavir	B-O
and	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
indinavir	B-O
.	O

Drug	O
Name	O
Effect	O
Clinical	O
Comment	O
HIV	O
Antiviral	O
Agents	O
Note	O
:	O
Delavirdine	B
.	O
indinavir	O
concentration	O
Dose	O
reduction	O
of	O
CRIXIVAN	O
to	O
600	O
mg	O
every	O
8	O
hours	O
should	O
be	O
considered	O
when	O
taking	O
delavirdine	B
400	O
mg	O
three	O
times	O
a	O
day	O
.	O

Drug	O
Name	O
Effect	O
Clinical	O
Comment	O
HIV	O
Antiviral	O
Agents	O
Note	O
:	O
Delavirdine	O
.	O
Dose	O
reduction	O
of	O
CRIXIVAN	B-O
to	O
600	O
mg	O
every	O
8	O
hours	O
should	O
be	O
considered	O
when	O
taking	O
delavirdine	O
400	O
mg	O
three	O
times	O
a	O
day	O
.	O

Drugs	B
that	I
induce	I
CYP3A4	I
activity	I
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
indinavir	B-O
,	O
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
of	O
indinavir	B-O
.	O

HMG-CoA	O
Reductase	O
Inhibitors	O
:	O
atorvastatin	B
,rosuvastatin	O
,	O
atorvastatin	B
concentration	O
,	O
rosuvastatin	O
concentration	O
.	O
The	O
atorvastatin	B
and	O
rosuvastatin	O
doses	O
should	O
be	O
carefully	O
titrated	O
;	O
use	O
the	O
lowest	O
dose	O
necessary	O
with	O
careful	O
monitoring	O
during	O
treatment	O
with	I-O
CRIXIVAN.	B-O

Immunosuppressants	O
:	O
cyclosporine	B-O
,	O
tacrolimus	B-O
,	O
sirolimus	B-O
.	O
immunosuppressant	O
agents	O
concentration	O
Plasma	O
concentrations	O
may	O
be	O
increased	O
by	I
CRIXIVAN.	B

Increasing	O
the	O
indinavir	B-O
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B-O
metabolism	O
due	O
to	O
efavirenz	B
.	O

Ingestion	O
of	O
CRIXIVAN	B-O
with	O
a	O
meal	B
high	I
in	I
calories	I
,	I
fat	I
,	I
and	I
protein	I
reduces	O
the	O
absorption	O
of	O
indinavir	B-O
.	O

Inhaled/nasal	O
steroid	O
:	O
Fluticasone	O
.	O
Concomitant	O
use	O
of	O
fluticasone	B-O
propionate	I-O
and	O
CRIXIVAN	B
may	O
increase	O
plasma	O
concentrations	O
of	O
fluticasone	B-O
propionate	I-O
.	O

Midazolam	B-O
(	O
parenteral	O
administration	O
)	O
midazolam	B-O
concentration	O
Concomitant	O
use	O
of	O
parenteral	O
midazolam	B-O
with	O
CRIXIVAN	B
may	O
increase	O
plasma	O
concentrations	O
of	O
midazolam	B-O
.	O

Nevirapine	B
.	O
Indinavir	B-O
concentrations	O
may	O
be	O
decreased	O
in	O
the	O
presence	O
of	O
nevirapine	B
.	O

Venlafaxine	B
.	O
indinavir	B-O
concentration	O
In	O
a	O
study	O
of	O
9	O
healthy	O
volunteers	O
,	O
venlafaxine	B
administered	O
under	O
steady-state	O
conditions	O
at	O
150	O
mg/day	O
resulted	O
in	O
a	O
28	O
%	O
decrease	O
in	O
the	O
AUC	O
of	O
a	O
single	O
800	O
mg	O
oral	O
dose	O
of	O
indinavir	B-O
and	O
a	O
36	O
%	O
decrease	O
in	O
indinavir	B-O
Cmax	O
.	O

However	O
,	O
it	O
has	O
been	O
reported	O
that	O
chlorpromazine	B
may	O
interfere	O
with	O
the	O
metabolism	O
of	O
phenytoin	B-O
and	O
thus	O
precipitate	O
phenytoin	B-O
toxicity	O
.	O

However	O
,	O
simultaneous	O
administration	O
of	O
cimetidine	B-O
tablets	O
and	O
antacids	B
is	O
not	O
recommended	O
,	O
since	O
antacids	B
have	O
been	O
reported	O
to	O
interfere	O
with	O
the	O
absorption	O
of	O
cimetidine	B-O
.	O

Cimetidine	B
,	O
apparently	O
through	O
an	O
effect	O
on	O
certain	O
microsomal	O
enzyme	O
systems	O
,	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
hepatic	O
metabolism	O
of	O
warfarin-type	B-O
anticoagulants	I-O
,	O
phenytoin	B-O
,	O
propranolol	B-O
,	O
nifedipine	B-O
,	O
chlordiazepoxide	B-O
,	O
diazepam	B-O
,	O
certain	O
tricyclic	B-O
antidepressants	I-O
,	O
lidocaine	B-O
,	O
theophylline	B-O
and	O
metronidazole	B-O
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
blood	O
levels	O
of	O
these	O
drugs	O
.	O

Concomitant	O
administration	O
of	O
duloxetine	B-O
40mg	O
twice	O
daily	O
with	O
fluvoxamine	B
100mg	O
,	O
a	O
potent	O
CYP1A2	O
inhibitor	O
,	O
to	O
CYP2D6	O
poor	O
metabolizer	O
subjects	O
(	O
n=14	O
)	O
resulted	O
in	O
a	O
6-fold	O
increase	O
in	O
duloxetine	B-O
AUC	O
and	O
Cmax	O
.	O

Concomitant	O
use	O
of	O
duloxetine	B-O
(	O
40mg	O
once	O
daily	O
)	O
with	O
paroxetine	B
(	O
20mg	O
once	O
daily	O
)	O
increased	O
the	O
concentration	O
of	O
duloxetine	B-O
AUC	O
by	O
about	O
60	O
%	O
,	O
and	O
greater	O
degrees	O
of	O
inhibition	O
are	O
expected	O
with	O
higher	O
doses	O
of	O
paroxetine	B
.	O

Duloxetine	B
is	O
an	O
inhibitor	O
of	O
the	O
CYP1A2	O
isoform	O
in	O
in	O
vitro	O
studies	O
,	O
and	O
in	O
two	O
clinical	O
studies	O
the	O
average	O
(90	O
%	O
confidence	O
interval	O
)	O
increase	O
in	O
theophylline	B-O
AUC	O
was	O
7	O
%	O
(	O
1%-15	O
%	O
)	O
and	O
20	O
%	O
(	O
13%-27	O
%	O
)	O
when	O
co-administered	O
with	O
duloxetine	B
(60mg	O
twice	O
daily	O
)	O
.	O

Potent	O
inhibitors	B
of	I
CYP2D6	I
may	O
increase	O
CYMBALTA	B-O
concentrations	O
(	O
7.2	O
)	O
.	O

When	O
duloxetine	B-O
60mg	O
was	O
co-administered	O
with	O
fluvoxamine	B
100mg	O
,	O
a	O
potent	O
CYP1A2	O
inhibitor	O
,	O
to	O
male	O
subjects	O
(	O
n=14	O
)	O
duloxetine	B-O
AUC	O
was	O
increased	O
approximately	O
6-fold	O
,	O
the	O
Cmax	O
was	O
increased	O
about	O
2.5-fold	O
,	O
and	O
duloxetine	B-O
t1/2	O
was	O
increased	O
approximately	O
3-fold	O
.	O

When	O
duloxetine	B
was	O
administered	O
(	O
at	O
a	O
dose	O
of	O
60mg	O
twice	O
daily	O
)	O
in	O
conjunction	O
with	O
a	O
single	O
50mg	O
dose	O
of	O
desipramine	B-O
,	O
a	O
CYP2D6	O
substrate	O
,	O
the	O
AUC	O
of	O
desipramine	B-O
increased	O
3-fold	O
.	O

Because	O
of	O
the	O
risk	O
of	O
serious	O
ventricular	O
arrhythmias	O
and	O
sudden	O
death	O
potentially	O
associated	O
with	O
elevated	O
plasma	O
levels	O
of	O
thioridazine	B-O
,	O
CYMBALTA	B
and	O
thioridazine	B-O
should	O
not	O
be	O
co-administered	O
.	O

CYP2D6	B
Inhibitors	I
.	O
Because	O
CYP2D6	O
is	O
involved	O
in	O
CYMBALTA	B-O
metabolism	O
,	O
concomitant	O
use	O
of	O
CYMBALTA	B-O
with	O
potent	O
inhibitors	O
of	O
CYP2D6	O
would	O
be	O
expected	O
to	O
,	O
and	O
does	O
,	O
result	O
in	O
higher	O
concentrations	O
(	O
on	O
average	O
of	O
60	O
%	O
)	O
of	I-O
CYMBALTA.	B-O

Plasma	O
TCA	B-O
concentrations	O
may	O
need	O
to	O
be	O
monitored	O
and	O
the	O
dose	O
of	O
the	O
TCA	B-O
may	O
need	O
to	O
be	O
reduced	O
if	O
a	O
TCA	B-O
is	O
co-administered	O
with	I
CYMBALTA.	B

The	O
potential	O
for	O
a	O
pharmacokinetic	O
interaction	O
exists	O
with	O
the	O
co-administration	O
of	O
CYP2D6	B
inhibitors	I
which	O
may	O
increase	O
the	O
risk	O
with	O
increased	O
exposure	O
to	I-O
DESOXYN.	B-O

Acidifying	B
Agents	I
Lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	B-O
.	O

Alkalinizing	B
Agents	I
Increase	O
blood	O
levels	O
and	O
potentiate	O
the	O
action	O
of	O
amphetamine	B-O
.	O

CYP2D6	B
Inhibitors	I
The	O
concomitant	O
use	O
of	O
DESOXYN	B-O
and	O
CYP2D6	B
inhibitors	I
may	O
increase	O
the	O
exposure	O
of	O
DESOXYN	B-O
compared	O
to	O
the	O
use	O
of	O
the	O
drug	O
alone	O
and	O
increase	O
the	O
risk	O
of	O
serotonin	O
syndrome	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
:	O
Literature	O
reports	O
suggest	O
that	O
amphetamines	B
may	O
be	O
associated	O
with	O
significant	O
elevation	O
of	O
plasma	O
corticosteroids	B-O
.	O

Proton	B
Pump	I
Inhibitors	I
Time	O
to	O
maximum	O
concentration	O
(	O
Tmax	O
)	O
of	O
amphetamine	B-O
is	O
decreased	O
compared	O
to	O
when	O
administered	O
alone	O
.	O

Tricyclic	B
Antidepressants	I
May	O
enhance	O
the	O
activity	O
of	O
tricyclic	O
or	O
sympathomimetic	O
agents	O
causing	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d-amphetamine	B-O
in	O
the	O
brain	O
;	O
cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O

A	O
controlled	O
study	O
found	O
that	O
concomitant	O
fluconazole	B
200	O
mg	O
once	O
daily	O
and	O
cisapride	B-O
20	O
mg	O
four	O
times	O
a	O
day	O
yielded	O
a	O
significant	O
increase	O
in	O
cisapride	B-O
plasma	O
levels	O
and	O
prolongation	O
of	O
QTc	O
interval	O
.	O

A	O
study	O
observed	O
a	O
reduction	O
in	O
clearance	O
and	O
distribution	O
volume	O
as	O
well	O
as	O
prolongation	O
of	O
T	O
of	O
alfentanil	B-O
following	O
concomitant	O
treatment	O
with	O
fluconazole	B
.	O

Although	O
not	O
specifically	O
studied	O
,	O
fluconazole	B
has	O
the	O
potential	O
to	O
increase	O
the	O
systemic	O
exposure	O
of	O
other	O
NSAIDs	B-O
that	I-O
are	I-O
metabolized	I-O
by	I-O
CYP2C9	I-O
(	O
e	O
.g.	O
,	O
naproxen	B-O
,	O
lornoxicam	B-O
,	O
meloxicam	B-O
,	O
diclofenac	B-O
)	O
.	O

Although	O
not	O
studied	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
concomitant	O
administration	O
of	O
fluconazole	B
with	O
pimozide	B-O
may	O
result	O
in	O
inhibition	O
of	O
pimozide	B-O
metabolism	O
.	O

Although	O
not	O
studied	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
concomitant	O
administration	O
of	O
fluconazole	B
with	O
quinidine	B-O
may	O
result	O
in	O
inhibition	O
of	O
quinidine	B-O
metabolism	O
.	O

Although	O
not	O
studied	O
,	O
fluconazole	B
may	O
increase	O
the	O
plasma	O
levels	O
of	O
the	O
vinca	B-O
alkaloids	I-O
(	O
e	O
.g.	O
,	O
vincristine	B-O
and	O
vinblastine	B-O
)	O
and	O
lead	O
to	O
neurotoxicity	O
,	O
which	O
is	O
possibly	O
due	O
to	O
an	O
inhibitory	O
effect	O
on	O
CYP3A4	O
.	O

Another	O
study	O
at	O
a	O
400	O
mg	O
and	O
800	O
mg	O
daily	O
dose	O
of	O
fluconazole	B
demonstrated	O
that	O
DIFLUCAN	B
taken	O
in	O
doses	O
of	O
400	O
mg	O
per	O
day	O
or	O
greater	O
significantly	O
increases	O
plasma	O
levels	O
of	O
terfenadine	B-O
when	O
taken	O
concomitantly	O
.	O

Concomitant	O
administration	O
of	O
fluconazole	B
with	O
astemizole	B-O
may	O
decrease	O
the	O
clearance	O
of	O
astemizole	B-O
.	O

DIFLUCAN	B
increases	O
the	O
plasma	O
concentrations	O
of	O
phenytoin	B-O
.	O

DIFLUCAN	B
increases	O
the	O
serum	O
concentrations	O
of	O
theophylline	B-O
.	O

DIFLUCAN	B
reduces	O
the	O
metabolism	O
of	O
tolbutamide	B-O
,	O
glyburide	B-O
,	O
and	O
glipizide	B-O
and	O
increases	O
the	O
plasma	O
concentration	O
of	O
these	O
agents	O
.	O

DIFLUCAN	B
significantly	O
increases	O
cyclosporine	B-O
levels	O
in	O
renal	O
transplant	O
patients	O
with	O
or	O
without	O
renal	O
impairment	O
.	O

During	O
concomitant	O
treatment	O
with	O
fluconazole	B
(	O
200	O
mg	O
daily	O
)	O
and	O
celecoxib	B-O
(	O
200	O
mg	O
)	O
,	O
the	O
celecoxib	B-O
Cmax	O
and	O
AUC	O
increased	O
by	O
68	O
%	O
and	O
134	O
%	O
,	O
respectively	O
.	O

Fluconazole	B
can	O
increase	O
halofantrine	B-O
plasma	O
concentration	O
due	O
to	O
an	O
inhibitory	O
effect	O
on	O
CYP3A4	O
.	O

Fluconazole	B
has	O
the	O
potential	O
to	O
increase	O
the	O
systemic	O
exposure	O
of	O
the	O
calcium	B-O
channel	I-O
antagonists	I-O
.	O

Fluconazole	B
increases	O
Cmax	O
and	O
AUC	O
of	O
zidovudine	B-O
by	O
84	O
%	O
and	O
74	O
%	O
,	O
respectively	O
,	O
due	O
to	O
an	O
approximately	O
45	O
%	O
decrease	O
in	O
oral	O
zidovudine	B-O
clearance	O
.	O

Fluconazole	B
increases	O
plasma	O
concentrations	O
of	O
sirolimus	B-O
presumably	O
by	O
inhibiting	O
the	O
metabolism	O
of	O
sirolimus	B-O
via	O
CYP3A4	O
and	O
P-glycoprotein	O
.	O

Fluconazole	B
increases	O
the	O
AUC	O
of	O
saquinavir	B-O
by	O
approximately	O
50	O
%	O
,	O
Cmax	O
by	O
approximately	O
55	O
%	O
,	O
and	O
decreases	O
clearance	O
of	O
saquinavir	B-O
by	O
approximately	O
50	O
%	O
due	O
to	O
inhibition	O
of	O
saquinavir	B-O
's	O
hepatic	O
metabolism	O
by	O
CYP3A4	O
and	O
inhibition	O
of	O
P-glycoprotein	O
.	O

Fluconazole	B
increases	O
the	O
AUC	O
of	O
triazolam	B-O
(	O
single	O
dose	O
)	O
by	O
approximately	O
50	O
%	O
,	O
Cmax	O
by	O
20-32	O
%	O
,	O
and	O
increases	O
t	O
by	O
25-50	O
%	O
due	O
to	O
the	O
inhibition	O
of	O
metabolism	O
of	O
triazolam	B-O
.	O

Fluconazole	B
inhibits	O
the	O
metabolism	O
of	O
carbamazepine	B-O
and	O
an	O
increase	O
in	O
serum	O
carbamazepine	B-O
of	O
30	O
%	O
has	O
been	O
observed	O
.	O

Fluconazole	B
inhibits	O
the	O
metabolism	O
of	O
losartan	B-O
to	O
its	O
active	O
metabolite	O
(E-31	O
74)	O
which	O
is	O
responsible	O
for	O
most	O
of	O
the	O
angiotensin	O
Il-receptor	O
antagonism	O
which	O
occurs	O
during	O
treatment	O
with	O
losartan	B-O
.	O

Fluconazole	B
may	O
enhance	O
the	O
serum	O
concentration	O
of	O
methadone	B-O
.	O

Fluconazole	B
may	O
increase	O
the	O
serum	O
concentrations	O
of	O
orally	O
administered	O
tacrolimus	B-O
up	O
to	O
5	O
times	O
due	O
to	O
inhibition	O
of	O
tacrolimus	B-O
metabolism	O
through	O
CYP3A4	O
in	O
the	O
intestines	O
.	O

Following	O
oral	O
administration	O
of	O
midazolam	B-O
,	O
fluconazole	B
resulted	O
in	O
substantial	O
increases	O
in	O
midazolam	B-O
concentrations	O
and	O
psychomotor	O
effects	O
.	O

Furthermore	O
,	O
in	O
a	O
randomized	O
crossover	O
study	O
with	O
12	O
healthy	O
volunteers	O
it	O
was	O
shown	O
that	O
fluconazole	B
delayed	O
the	O
elimination	O
of	O
fentanyl	B-O
significantly	O
.	O

In	O
a	O
pharmacokinetic	O
interaction	O
study	O
,	O
coadministration	O
of	O
multiple	O
dose	O
hydrochlorothiazide	B
to	O
healthy	O
volunteers	O
receiving	O
fluconazole	B-O
increased	O
plasma	O
concentrations	O
of	O
fluconazole	B-O
by	O
40	O
%	O
.	O

Rifampin	B
enhances	O
the	O
metabolism	O
of	O
concurrently	O
administered	I-O
DIFLUCAN.	B-O

Similarly	O
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
the	O
pharmacologically	O
active	O
isomer	O
[S-(+)-ibuprofen	O
]	O
were	O
increased	O
by	O
15	O
%	O
and	O
82	O
%	O
,	O
respectively	O
,	O
when	O
fluconazole	B
was	O
coadministered	O
with	O
racemic	B-O
ibuprofen	I-O
(	O
400	O
mg	O
)	O
compared	O
to	O
administration	O
of	O
racemic	B-O
ibuprofen	I-O
alone	O
.	O

Systemic	O
exposure	O
to	O
tofacitinib	B-O
is	O
increased	O
when	O
tofacitinib	B-O
is	O
coadministered	O
with	O
fluconazole	B
,	O
a	O
combined	O
moderate	O
CYP3A4	O
and	O
potent	O
CYP2C19	O
inhibitor	O
.	O

The	O
Cmax	O
and	O
AUC	O
of	O
flurbiprofen	B-O
were	O
increased	O
by	O
23	O
%	O
and	O
81	O
%	O
,	O
respectively	O
,	O
when	O
coadministered	O
with	O
fluconazole	B
compared	O
to	O
administration	O
of	O
flurbiprofen	B-O
alone	O
.	O

The	O
discontinuation	O
of	O
fluconazole	B
presumably	O
caused	O
an	O
enhanced	O
CYP3A4	O
activity	O
which	O
led	O
to	O
increased	O
metabolism	O
of	O
prednisone	B-O
.	O

The	O
half-life	O
of	O
zidovudine	B-O
was	O
likewise	O
prolonged	O
by	O
approximately	O
128	O
%	O
following	O
combination	O
therapy	O
with	O
fluconazole	B
.	O

There	O
have	O
been	O
reports	O
that	O
an	O
interaction	O
exists	O
when	O
fluconazole	B
is	O
administered	O
concomitantly	O
with	O
rifabutin	B-O
,	O
leading	O
to	O
increased	O
serum	O
levels	O
of	O
rifabutin	B-O
up	O
to	O
80	O
%	O
.	O

There	O
were	O
no	O
relevant	O
effects	O
on	O
hormone	O
level	O
in	O
the	O
50	O
mg	O
fluconazole	B
study	O
,	O
while	O
at	O
200	O
mg	O
daily	O
,	O
the	O
AUCs	O
of	O
ethinyl	B-O
estradiol	I-O
and	O
levonorgestrel	B-O
were	O
increased	O
40	O
%	O
and	O
24	O
%	O
,	O
respectively	O
.	O

Inhibition	O
of	O
CYP3A4	O
by	O
aprepitant	B
could	O
result	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
this	O
drug	O
which	O
is	O
a	O
CYP3A4	O
substrate	O
,	O
potentially	O
causing	O
serious	O
or	O
life-threatening	O
reactions	O
,	O
such	O
as	O
QT	O
prolongation	O
,	O
a	O
known	O
adverse	O
reaction	O
of	O
pimozide	B-O
.	O

Co-administration	O
of	O
EMEND	B-O
with	O
drugs	O
that	O
are	O
inhibitors	B
or	I
inducers	I
of	I
CYP3A4	I
may	O
result	O
in	O
increased	O
or	O
decreased	O
plasma	O
concentrations	O
of	O
aprepitant	B-O
,	O
respectively	O
,	O
as	O
shown	O
in	O
Table	O
11	O
.	O

Intervention	O
Avoid	O
concomitant	O
use	O
of	O
EMEND	B-O
Examples	O
Moderate	O
inhibitor	O
:	O
diltiazem	O
Strong	O
inhibitors	O
:	O
ketoconazole	O
,	O
itraconazole	O
,	O
nefazodone	O
,	O
troleandomycin	O
,	O
clarithromycin	O
,	O
ritonavir	O
,	O
nelfinavir	O
Strong	O
CYP3A4	B
Inducers	O
Clinical	O
Impact	O
Substantially	O
decreased	O
exposure	O
of	O
aprepitant	B-O
in	O
patients	O
chronically	O
taking	O
a	O
strong	O
CYP3A4	B
inducer	I
may	O
decrease	O
the	O
efficacy	O
of	I-O
EMEND.	B-O

Use	O
of	O
EMEND	B
with	O
other	O
drugs	O
that	O
are	O
CYP3A4	B-O
substrates	I-O
,	O
may	O
result	O
in	O
increased	O
plasma	O
concentration	O
of	O
the	O
concomitant	O
drug	O
.	O

Use	O
of	O
EMEND	B-O
with	O
strong	O
CYP3A4	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
)	O
may	O
result	O
in	O
a	O
reduction	O
in	O
aprepitant	B-O
plasma	O
concentrations	O
and	O
decreased	O
efficacy	O
of	I-O
EMEND.	B-O

Use	O
of	O
EMEND	B-O
with	O
strong	O
or	O
moderate	O
CYP3A4	B
inhibitors	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
,	O
diltiazem	B
)	O
may	O
increase	O
plasma	O
concentrations	O
of	O
aprepitant	B-O
and	O
result	O
in	O
an	O
increased	O
risk	O
of	O
adverse	O
reactions	O
related	O
to	I-O
EMEND.	B-O

Use	O
of	O
pimozide	B-O
with	O
EMEND	B
is	O
contraindicated	O
due	O
to	O
the	O
risk	O
of	O
significantly	O
increased	O
plasma	O
concentrations	O
of	O
pimozide	B-O
,	O
potentially	O
resulting	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
,	O
a	O
known	O
adverse	O
reaction	O
of	O
pimozide	B-O
.	O

Focalin	B-O
XR	I-O
should	O
not	O
be	O
used	O
in	O
patients	O
being	O
treated	O
(	O
currently	O
or	O
within	O
the	O
preceding	O
two	O
weeks	O
)	O
with	O
MAO	O
Inhibitors	O
(	O
4.5	O
)	O
Focalin	B-O
XR	I-O
should	O
be	O
used	O
cautiously	O
with	O
pressor	O
agents	O
(	O
7	O
)	O
Antacids	B
or	O
acid	B
suppressants	I
could	O
alter	O
the	O
release	O
of	O
Focalin	B-O
XR	I-O
(	O
7	O
)	O
Racemic	O
methylphenidate	B
may	O
inhibit	O
the	O
metabolism	O
of	O
coumarin	B-O
anticoagulants	I-O
,	O
anticonvulsants	B-O
,	O
and	O
tricyclic	B-O
drugs	I-O
(	O
7	O
)	O

Human	O
pharmacologic	O
studies	O
have	O
shown	O
that	O
racemic	O
methylphenidate	B
may	O
inhibit	O
the	O
metabolism	O
of	O
coumarin	B-O
anticoagulants	I-O
,	O
anticonvulsants	B-O
(	O
e	O
.g.	O
,	O
phenobarbital	B-O
,	O
phenytoin	B-O
,	O
primidone	B-O
)	O
,	O
and	O
tricyclic	B-O
drugs	I-O
(	O
e	O
.g.	O
,	O
imipramine	B-O
,	O
clomipramine	B-O
,	O
desipramine	B-O
)	O
.	O

Drug	O
Interactions	O
:	O
Use	O
with	O
Allopurinol	B
:	O
One	O
of	O
the	O
pathways	O
for	O
inactivation	O
of	O
azathioprine	B-O
is	O
inhibited	O
by	O
allopurinol	B
.	O

INVIRASE	B-O
must	O
be	O
used	O
in	O
combination	O
with	O
ritonavir	B
because	O
ritonavir	B
significantly	O
inhibits	O
saquinavir	B-O
's	O
metabolism	O
to	O
provide	O
increased	O
plasma	O
saquinavir	B-O
levels	O
.	O

Coadministration	O
of	O
triazolam	B-O
or	O
orally	O
administered	O
midazolam	B-O
with	I
INVIRASE/ritonavir	B
may	O
cause	O
large	O
increases	O
in	O
the	O
concentration	O
of	O
these	O
benzodiazepines	O
.	O

Anticonvulsants	O
:	O
Carbamazepine	B
,	O
phenobarbital	B
,	O
phenytoin	B
.	O
Saquinavir	B-O
Effect	O
on	O
carbamazepine	B
,	O
phenobarbital	B
,	O
and	O
phenytoin	B
is	O
not	O
well	O
established	O
Saquinavir	B-O
may	O
be	O
less	O
effective	O
due	O
to	O
decreased	O
saquinavir	B-O
plasma	O
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O
.	O

Antifungal	O
:	O
Ketoconazole	B-O
,	O
itraconazole	O
,	O
Saquinavir	O
,	O
Ritonavir	B
.	O
When	I
INVIRASE/ritonavir	B
and	O
ketoconazole	B-O
are	O
coadministered	O
,	O
plasma	O
concentrations	O
of	O
ketoconazole	B-O
are	O
increased	O
.	O

Antipsychotic	O
:	O
Quetiapine	B-O
.	O
Quetiapine	B-O
Initiation	O
of	O
INVIRASE	B
with	O
ritonavir	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
drug	O
exposures	O
.	O

Coadministration	O
with	O
drugs	O
that	O
are	O
potent	O
inducers	B
of	I
CYP3A	I
(	O
e	O
.g.	O
,	O
phenobarbital	B
,	O
phenytoin	B
,	O
carbamazepine	B
)	O
may	O
result	O
in	O
decreased	O
plasma	O
concentrations	O
of	O
saquinavir	B-O
and	O
reduced	O
therapeutic	O
effect	O
.	O

Garlic	B
Capsules	I
.	O
Saquinavir	B-O
Coadministration	O
of	O
garlic	B
capsules	I
and	O
saquinavir	B-O
is	O
not	O
recommended	O
due	O
to	O
the	O
potential	O
for	O
garlic	B
capsules	I
to	O
induce	O
the	O
metabolism	O
of	O
saquinavir	B-O
which	O
may	O
result	O
in	O
sub-therapeutic	O
saquinavir	B-O
concentrations	O
.	O

HIV-1	O
protease	O
inhibitor	O
:	O
Indinavir	B-O
,	O
Saquinavir	O
.	O
Low	O
dose	O
ritonavir	B
increases	O
the	O
concentration	O
of	O
indinavir	B-O
.	O
Appropriate	O
doses	O
of	O
the	O
combination	O
of	O
indinavir	B-O
and	O
INVIRASE/ritonavir	B
with	O
respect	O
to	O
safety	O
and	O
efficacy	O
have	O
not	O
been	O
established	O
.	O

Inhaled/nasal	O
steroids	O
:	O
Fluticasone	O
Budesonide	O
.	O
Fluticasone	O
Concomitant	O
use	O
of	O
fluticasone	B-O
propionate	I-O
and	I
INVIRASE/ritonavir	B
may	O
increase	O
plasma	O
concentrations	O
of	O
fluticasone	B-O
propionate	I-O
,	O
resulting	O
in	O
significantly	O
reduced	O
serum	O
cortisol	O
concentrations	O
.	O

Other	O
antidepressants	O
:	O
Nefazodone	B
.	O
Saquinavir	B-O
,	O
Nefazodone	B
inhibits	O
CYP3A4	O
;	O
saquinavir	B-O
concentrations	O
may	O
be	O
increased	O
Monitoring	O
for	O
saquinavir	B-O
toxicity	O
is	O
recommended	O
.	O

Proton	O
pump	O
inhibitors	O
:	O
Omeprazole	B
,	O
Saquinavir	B-O
.	O
When	I-O
INVIRASE/ritonavir	B-O
is	O
co-administered	O
with	O
omeprazole	B
,	O
saquinavir	B-O
concentrations	O
are	O
increased	O
significantly	O
.	O

Streptogramin	B
antibiotics	I
(quinupristin/dalfopristin	B
)	O
Streptogramin	B
antibiotics	I
such	O
as	I
quinupristin/dalfopristin	B
inhibit	O
CYP3A4	O
;	O
saquinavir	B-O
concentrations	O
may	O
be	O
increased	O
Monitoring	O
for	O
saquinavir	B-O
toxicity	O
is	O
recommended	O
.	O

Coadministration	O
of	O
LEXIVA	B-O
and	O
drugs	B
that	I
induce	I
CYP3A4	I
,	O
such	O
as	O
rifampin	B
,	O
may	O
decrease	O
amprenavir	O
concentrations	O
and	O
reduce	O
its	O
therapeutic	O
effect	O
.	O

Coadministration	O
of	O
LEXIVA	B-O
and	O
drugs	B
that	I
inhibit	I
CYP3A4	I
may	O
increase	O
amprenavir	B-O
concentrations	O
and	O
increase	O
the	O
incidence	O
of	O
adverse	O
effects	O
.	O

Initiation	O
of	O
LEXIVA	B
with	O
ritonavir	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
drug	O
exposures	O
.	O

Administration	O
of	O
20	O
mg/day	O
Lexapro	B
for	O
21	O
days	O
in	O
healthy	O
volunteers	O
resulted	O
in	O
a	O
50	O
%	O
increase	O
in	O
Cmax	O
and	O
82	O
%	O
increase	O
in	O
AUC	O
of	O
the	O
beta-adrenergic	O
blocker	O
metoprolol	B-O
(	O
given	O
in	O
a	O
single	O
dose	O
of	O
100	O
mg	O
)	O
.	O

Although	O
trough	O
citalopram	O
plasma	O
levels	O
were	O
unaffected	O
,	O
given	O
the	O
enzyme-inducing	O
properties	O
of	O
carbamazepine	B
,	O
the	O
possibility	O
that	O
carbamazepine	B
might	O
increase	O
the	O
clearance	O
of	O
escitalopram	B-O
should	O
be	O
considered	O
if	O
the	O
two	O
drugs	O
are	O
coadministered	O
.	O

Combined	O
administration	O
of	O
racemic	O
citalopram	B
(	O
40	O
mg	O
)	O
and	O
ketoconazole	B-O
(	O
200	O
mg	O
)	O
,	O
a	O
potent	O
CYP3A4	O
inhibitor	O
,	O
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
ketoconazole	B-O
by	O
21	O
%	O
and	O
10	O
%	O
,	O
respectively	O
,	O
and	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
citalopram	B
.	O

However	O
,	O
there	O
are	O
limited	O
in	O
vivo	O
data	O
suggesting	O
a	O
modest	O
CYP2D6	O
inhibitory	O
effect	O
for	O
escitalopram	B
,	O
i	O
.e	O
.	O
,	O
coadministration	O
of	O
escitalopram	B
(	O
20	O
mg/day	O
for	O
21	O
days	O
)	O
with	O
the	O
tricyclic	O
antidepressant	O
desipramine	B-O
(	O
single	O
dose	O
of	O
50	O
mg	O
)	O
,	O
a	O
substrate	O
for	O
CYP2D6	O
,	O
resulted	O
in	O
a	O
40	O
%	O
increase	O
in	O
Cmax	O
and	O
a	O
100	O
%	O
increase	O
in	O
AUC	O
of	O
desipramine	B-O
.	O

In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg/day	O
racemic	O
citalopram	B-O
,	O
combined	O
administration	O
of	O
400	O
mg	O
twice	O
a	O
day	O
cimetidine	B
for	O
8	O
days	O
resulted	O
in	O
an	O
increase	O
in	O
citalopram	B-O
AUC	O
and	O
Cmax	O
of	O
43	O
%	O
and	O
39	O
%	O
,	O
respectively	O
.	O

Carbamazepine	B-O
:	O
Elevated	O
carbamazepine	B-O
levels	O
and	O
symptoms	O
of	O
toxicity	O
have	O
been	O
reported	O
with	O
the	O
coadministration	O
of	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
and	O
carbamazepine	B-O
.	O

Propranolol	B-O
and	O
Other	O
Beta-Blockers	O
:	O
Coadministration	O
of	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
100	O
mg	O
per	O
day	O
and	O
propranolol	B-O
160	O
mg	O
per	O
day	O
in	O
normal	O
volunteers	O
resulted	O
in	O
a	O
mean	O
five-fold	O
increase	O
(	O
range	O
2	O
to	O
17	O
)	O
in	O
minimum	O
propranolol	B-O
plasma	O
concentrations	O
.	O

Tacrine	B-O
:	O
In	O
a	O
study	O
of	O
13	O
healthy	O
,	O
male	O
volunteers	O
,	O
a	O
single	O
40	O
mg	O
dose	O
of	O
tacrine	B-O
added	O
to	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
100	O
mg/day	O
administered	O
at	O
steady-state	O
was	O
associated	O
with	O
5-	O
and	O
8-fold	O
increases	O
in	O
tacrine	B-O
Cmax	O
and	O
AUC	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
administration	O
of	O
tacrine	B-O
alone	O
.	O

Tricyclic	B-O
Antidepressants	I-O
(TCAs	O
)	O
:	O
Significantly	O
increased	O
plasma	O
TCA	O
levels	O
have	O
been	O
reported	O
with	O
the	O
coadministration	O
of	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
and	O
amitriptyline	B
,	O
clomipramine	B
or	O
imipramine	B
.	O

Alprazolam	B-O
-	O
When	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
(	O
100	O
mg	O
given	O
once	O
daily	O
)	O
and	O
alprazolam	B-O
(	O
1	O
mg	O
given	O
4	O
times	O
per	O
day	O
)	O
were	O
coadministered	O
to	O
steady	O
state	O
,	O
plasma	O
concentrations	O
and	O
other	O
pharmacokinetic	O
parameters	O
(	O
AUC	O
,	O
Cmax	O
,	O
T<U+00BD>	O
)	O
of	O
alprazolam	B-O
were	O
approximately	O
twice	O
those	O
observed	O
when	O
alprazolam	B-O
was	O
administered	O
alone	O
;	O
oral	O
clearance	O
was	O
reduced	O
by	O
about	O
50	O
%	O
.	O

Because	O
fluvoxamine	B
reduces	O
the	O
clearance	O
of	O
both	O
diazepam	B-O
and	O
its	O
active	O
metabolite	O
,	O
N-desmethyldiazepam	B-O
,	O
there	O
is	O
a	O
strong	O
likelihood	O
of	O
substantial	O
accumulation	O
of	O
both	O
species	O
during	O
chronic	O
coadministration	O
.	O

Benzodiazepines	O
:	O
Benzodiazepines	B-O
metabolized	I-O
by	I-O
hepatic	I-O
oxidation	I-O
(	O
e	O
.g.	O
,	O
alprazolam	B-O
,	O
midazolam	B-O
,	O
triazolam	B-O
,	O
etc.	O
)	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
clearance	O
of	O
these	O
drugs	O
is	O
likely	O
to	O
be	O
reduced	O
by	O
fluvoxamine	B
.	O

Clozapine	B-O
:	O
Elevated	O
serum	O
levels	O
of	O
clozapine	B-O
have	O
been	O
reported	O
in	O
patients	O
taking	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
and	O
clozapine	B-O
.	O

Concentrations	O
of	O
thioridazine	B-O
and	O
its	O
two	O
active	O
metabolites	O
,	O
mesoridazine	B-O
and	O
sulforidazine	B-O
,	O
increased	O
3-fold	O
following	O
coadministration	O
of	O
fluvoxamine	B
.	O

Fluvoxamine	B
increased	O
mean	O
alosetron	B-O
plasma	O
concentrations	O
(	O
AUC)	O
approximately	O
6-fold	O
and	O
prolonged	O
the	O
half-life	O
by	O
approximately	O
3-fold	O
.	O

Methadone	B-O
:	O
Significantly	O
increased	O
methadone	B-O
(	O
plasma	O
level	O
:dose	O
)	O
ratios	O
have	O
been	O
reported	O
when	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
were	O
administered	O
to	O
patients	O
receiving	O
maintenance	O
methadone	B-O
treatment	O
,	O
with	O
symptoms	O
of	O
opioid	O
intoxication	O
in	O
one	O
patient	O
.	O

The	O
clearance	O
of	O
mexiletine	B-O
was	O
reduced	O
by	O
38	O
%	O
following	O
coadministration	O
with	O
fluvoxamine	B
compared	O
to	O
mexiletine	B-O
alone	O
.	O

Therefore	O
,	O
if	O
theophylline	B-O
is	O
coadministered	O
with	O
fluvoxamine	B
maleate	I
,	O
its	O
dose	O
should	O
be	O
reduced	O
to	O
one-third	O
of	O
the	O
usual	O
daily	O
maintenance	O
dose	O
and	O
plasma	O
concentrations	O
of	O
theophylline	B-O
should	O
be	O
monitored	O
.	O

Warfarin	B-O
-	O
When	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
(	O
50	O
mg	O
given	O
three	O
times	O
daily	O
)	O
were	O
administered	O
concomitantly	O
with	O
warfarin	B-O
for	O
two	O
weeks	O
,	O
warfarin	B-O
plasma	O
concentrations	O
increased	O
by	O
98	O
%	O
and	O
prothrombin	O
times	O
were	O
prolonged	O
.	O

When	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
100	O
mg	O
twice	O
daily	O
were	O
administered	O
for	O
3	O
days	O
prior	O
to	O
single-dose	O
coadministration	O
of	O
ramelteon	B-O
16	O
mg	O
and	O
immediate-release	O
fluvoxamine	B
maleate	I
tablets	O
,	O
the	O
AUC	O
for	O
ramelteon	B-O
increased	O
approximately	O
190-fold	O
and	O
the	O
Cmax	O
increased	O
approximately	O
70-fold	O
compared	O
to	O
ramelteon	B-O
administered	O
alone	O
.	O

In	O
a	O
drug	O
interaction	O
study	O
,	O
when	O
MAXALT	B-O
10	O
mg	O
was	O
administered	O
to	O
subjects	O
(	O
n=12	O
)	O
receiving	O
concomitant	O
therapy	O
with	O
the	O
selective	O
,	O
reversible	O
MAO-A	O
inhibitor	O
,	O
moclobemide	B
150	O
mg	O
t.i.d.	O
,	O
there	O
were	O
mean	O
increases	O
in	O
rizatriptan	B-O
AUC	O
and	O
Cmax	O
of	O
119	O
%	O
and	O
41	O
%	O
respectively	O
;	O
and	O
the	O
AUC	O
of	O
the	O
active	O
N-monodesmethyl	B-O
metabolite	O
of	O
rizatriptan	B-O
was	O
increased	O
more	O
than	O
400	O
%	O
.	O

Plasma	O
concentrations	O
of	O
rizatriptan	B-O
may	O
be	O
increased	O
by	O
drugs	B
that	I
are	I
selective	I
MAO-A	I
inhibitors	I
(	O
e	O
.g.	O
,	O
moclobemide	B
)	O
or	O
nonselective	B
MAO	I
inhibitors	I
[type	O
A	O
and	O
B]	O
(	O
e	O
.g.	O
,	O
isocarboxazid	B
,	O
phenelzine	B
,	O
tranylcypromine	B
,	O
and	O
pargyline	B
)	O
.	O

Propranolol	B
:	O
In	O
a	O
study	O
of	O
concurrent	O
administration	O
of	O
propranolol	B
240	O
mg/day	O
and	O
a	O
single	O
dose	O
of	O
rizatriptan	B-O
10	O
mg	O
in	O
healthy	O
adult	O
subjects	O
(	O
n=11	O
)	O
,	O
mean	O
plasma	O
AUC	O
for	O
rizatriptan	B-O
was	O
increased	O
by	O
70	O
%	O
during	O
propranolol	B
administration	O
,	O
and	O
a	O
four-fold	O
increase	O
was	O
observed	O
in	O
one	O
subject	O
.	O

The	O
dose	O
of	O
MAXALT	B-O
should	O
be	O
adjusted	O
in	I
propranolol-treated	B
patients	O
,	O
as	O
propranolol	B
has	O
been	O
shown	O
to	O
increase	O
the	O
plasma	O
AUC	O
of	O
rizatriptan	B-O
by	O
70	O
%	O
.	O

The	O
concomitant	O
use	O
of	O
Meperidine	B-O
Hydrochloride	O
Injection	O
with	O
all	O
cytochrome	B
P450	I
3A4	I
inhibitors	I
may	O
result	O
in	O
an	O
increase	O
in	O
meperidine	B-O
plasma	O
concentrations	O
,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression	O
.	O

Concomitant	O
use	O
of	O
Meperidine	B-O
Hydrochloride	O
Injection	O
with	O
a	O
CYP3A4	B
inhibitor	I
,	O
such	O
as	O
macrolide	B
antibiotics	I
(	O
e	O
.g.	O
,	O
erythromycin	B
)	O
,	O
azole-antifungal	B
agents	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
)	O
,	O
and	O
protease	B
inhibitors	I
(	O
e	O
.g.	O
,	O
ritonavir	B
)	O
,	O
may	O
increase	O
plasma	O
concentrations	O
of	O
meperidine	B-O
and	O
prolong	O
opioid	O
adverse	O
reactions	O
,	O
which	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression	O
,	O
particularly	O
when	O
an	O
inhibitor	O
is	O
added	O
after	O
a	O
stable	O
dose	O
of	O
Meperidine	B-O
Hydrochloride	O
Injection	O
is	O
achieved	O
.	O

Concomitant	O
use	O
of	O
Meperidine	B-O
Hydrochloride	O
Injection	O
with	O
CYP3A4	B
inducers	I
or	O
discontinuation	B
of	I
a	I
CYP3A4	I
inhibitor	I
could	O
decrease	O
meperidine	B-O
plasma	O
concentrations	O
,	O
decrease	O
opioid	O
efficacy	O
or	O
,	O
possibly	O
,	O
lead	O
to	O
a	O
withdrawal	O
syndrome	O
in	O
a	O
patient	O
who	O
had	O
developed	O
physical	O
dependence	O
to	O
meperidine	B-O
.	O

Similarly	O
,	O
discontinuation	B
of	I
a	I
CYP3A4	I
inducer	I
,	O
such	O
as	O
rifampin	B
,	O
carbamazepine	B
,	O
and	O
phenytoin	B
,	O
in	O
Meperidine	B-O
Hydrochloride	O
Injection-treated	O
patients	O
may	O
increase	O
meperidine	B-O
plasma	O
concentrations	O
and	O
prolong	O
opioid	O
adverse	O
reactions	O
.	O

After	O
stopping	O
a	O
CYP3A4	B
or	I
CYP2B6	I
inducer	I
,	O
as	O
the	O
effects	O
of	O
the	O
inducer	O
decline	O
,	O
the	O
meperidine	B-O
plasma	O
concentration	O
will	O
increase	O
,	O
which	O
could	O
increase	O
or	O
prolong	O
both	O
the	O
therapeutic	O
effects	O
and	O
adverse	O
reactions	O
,	O
and	O
may	O
cause	O
serious	O
respiratory	O
depression	O
.	O

After	O
stopping	O
a	O
CYP3A4	B
or	I
CYP2B6	I
inhibitor	I
,	O
as	O
the	O
effects	O
of	O
the	O
inhibitor	O
decline	O
,	O
the	O
meperidine	B-O
plasma	O
concentration	O
will	O
decrease	O
,	O
resulting	O
in	O
decreased	O
opioid	O
efficacy	O
or	O
a	O
withdrawal	O
syndrome	O
in	O
patients	O
who	O
had	O
developed	O
physical	O
dependence	O
to	O
oxycodone	O
.	O

Additionally	O
,	O
in	O
one	O
controlled	O
study	O
in	O
five	O
normal	O
subjects	O
and	O
seven	O
patients	O
,	O
the	O
clearance	O
of	O
caffeine	B-O
was	O
decreased	O
50	O
%	O
following	O
the	O
administration	O
of	O
mexiletine	B
.	O

Concurrent	O
administration	O
of	O
cimetidine	B
and	O
mexiletine	B-O
has	O
been	O
reported	O
to	O
increase	O
,	O
decrease	O
,	O
or	O
leave	O
unchanged	O
mexiletine	B-O
plasma	O
levels	O
;	O
therefore	O
patients	O
should	O
be	O
followed	O
carefully	O
during	O
concurrent	O
therapy	O
.	O

Concurrent	O
use	O
of	O
mexiletine	B
and	O
theophylline	B-O
may	O
lead	O
to	O
increased	O
plasma	O
theophylline	B-O
levels	O
.	O

In	O
a	O
formal	O
,	O
single-dose	O
interaction	O
study	O
(	O
n	O
=	O
6	O
males	O
)	O
the	O
clearance	O
of	O
mexiletine	B-O
was	O
decreased	O
by	O
38	O
%	O
following	O
the	O
coadministration	O
of	O
fluvoxamine	B
,	O
an	O
inhibitor	O
of	O
CYP1A2	O
.	O

When	O
phenytoin	B
or	O
other	O
hepatic	B
enzyme	I
inducers	I
such	O
as	O
rifampin	B
and	O
phenobarbital	B
have	O
been	O
taken	O
concurrently	O
with	O
mexiletine	B-O
,	O
lowered	O
mexiletine	B-O
plasma	O
levels	O
have	O
been	O
reported	O
.	O

When	O
MYCOBUTIN	B-O
is	O
used	O
concomitantly	O
with	O
clarithromycin	B
for	O
MAC	O
treatment	O
,	O
a	O
decreased	O
dose	O
of	O
MYCOBUTIN	B-O
is	O
recommended	O
due	O
to	O
the	O
increase	O
in	O
plasma	O
concentrations	O
of	I-O
MYCOBUTIN.	B-O

In	O
a	O
separate	O
study	O
,	O
one	O
case	O
of	O
uveitis	O
was	O
associated	O
with	O
increased	O
serum	O
rifabutin	B-O
levels	O
following	O
co-administration	O
of	O
rifabutin	B-O
(	O
300	O
mg	O
QD	O
)	O
with	O
itraconazole	B
(600-900	O
mg	O
QD	O
)	O
.	O

The	O
coadministration	O
of	O
triazolam	B-O
and	O
nefazodone	B
causes	O
a	O
significant	O
increase	O
in	O
the	O
plasma	O
level	O
of	O
triazolam	B-O
,	O
and	O
a	O
75	O
%	O
reduction	O
in	O
the	O
initial	O
triazolam	B-O
dosage	O
is	O
recommended	O
if	O
the	O
two	O
drugs	O
are	O
to	O
be	O
given	O
together	O
.	O

Interaction	O
studies	O
of	O
nefazodone	B
with	O
two	O
triazolobenzodiazepines	O
,	O
i	O
.e	O
.	O
,	O
triazolam	B-O
and	O
alprazolam	B-O
,	O
metabolized	O
by	O
cytochrome	O
P450	O
3A4	O
,	O
have	O
revealed	O
substantial	O
and	O
clinically	O
important	O
increases	O
in	O
plasma	O
concentrations	O
of	O
these	O
compounds	O
when	O
administered	O
concomitantly	O
with	O
nefazodone	B
.	O

The	O
coadministration	O
of	O
carbamazepine	B
200	O
mg	O
BID	O
with	O
nefazodone	B-O
200	O
mg	O
BID	O
,	O
at	O
steady	O
state	O
for	O
both	O
drugs	O
,	O
resulted	O
in	O
almost	O
95	O
%	O
reductions	O
in	O
AUCs	O
for	O
nefazodone	B-O
and	O
hydroxynefazodone	B-O
,	O
likely	O
resulting	O
in	O
insufficient	O
plasma	O
nefazodone	B-O
and	O
hydroxynefazodone	B-O
concentrations	O
for	O
achieving	O
an	O
antidepressant	O
effect	O
for	O
nefazodone	B-O
.	O

When	O
a	O
single	O
oral	O
0.25	O
mg	O
dose	O
of	O
triazolam	B-O
was	O
coadministered	O
with	O
nefazodone	B
(	O
200	O
mg	O
BID	O
)	O
at	O
steady	O
state	O
,	O
triazolam	B-O
half-life	O
and	O
AUC	O
increased	O
4	O
fold	O
and	O
peak	O
concentrations	O
increased	O
1.7	O
fold	O
.	O

When	O
alprazolam	B-O
(	O
1	O
mg	O
BID	O
)	O
and	O
nefazodone	B
(	O
200	O
mg	O
BID	O
)	O
were	O
coadministered	O
,	O
steady-state	O
peak	O
concentrations	O
,	O
AUC	O
and	O
half-life	O
values	O
for	O
alprazolam	B-O
increased	O
by	O
approximately	O
2	O
fold	O
.	O

Buspirone	B-O
.	O
In	O
a	O
study	O
of	O
steady-state	O
pharmacokinetics	O
in	O
healthy	O
volunteers	O
,	O
coadministration	O
of	O
buspirone	B-O
(	O
2.5	O
or	O
5	O
mg	O
BID	O
)	O
with	O
nefazodone	B
(	O
250	O
mg	O
BID	O
)	O
resulted	O
in	O
marked	O
increases	O
in	O
plasma	O
buspirone	B-O
concentrations	O
(	O
increases	O
up	O
to	O
20	O
fold	O
in	O
Cmax	O
and	O
up	O
to	O
50	O
fold	O
in	O
AUC)	O
and	O
statistically	O
significant	O
decreases	O
(	O
about	O
50	O
%	O
)	O
in	O
plasma	O
concentrations	O
of	O
the	O
buspirone	B-O
metabolite	O
1-pyrimidinylpiperazine	B-O
.	O

Digoxin	B-O
.	O
When	O
nefazodone	B
(	O
200	O
mg	O
BID	O
)	O
and	O
digoxin	B-O
(	O
0.2	O
mg	O
QD	O
)	O
were	O
coadministered	O
for	O
9	O
days	O
to	O
healthy	O
male	O
volunteers	O
(	O
n	O
=	O
18	O
)	O
who	O
were	O
phenotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
,	O
Cmax	O
,	O
Cmin	O
,	O
and	O
AUC	O
of	O
digoxin	B-O
were	O
increased	O
by	O
29	O
%	O
,	O
27	O
%	O
,	O
and	O
15	O
%	O
,	O
respectively	O
.	O

Due	O
to	O
the	O
potential	O
for	O
coadministration	O
of	O
carbamazepine	B
to	O
result	O
in	O
insufficient	O
plasma	O
nefazodone	B-O
and	O
hydroxynefazodone	B-O
concentrations	O
for	O
achieving	O
an	O
antidepressant	O
effect	O
for	O
nefazodone	B-O
,	O
it	O
is	O
recommended	O
that	O
nefazodone	B-O
not	O
be	O
used	O
in	O
combination	O
with	O
carbamazepine	B
.	O

Haloperidol	B-O
.	O
When	O
a	O
single	O
oral	O
5	O
mg	O
dose	O
of	O
haloperidol	B-O
was	O
coadministered	O
with	O
nefazodone	B
(	O
200	O
mg	O
BID	O
)	O
at	O
steady	O
state	O
,	O
haloperidol	B-O
apparent	O
clearance	O
decreased	O
by	O
35	O
%	O
with	O
no	O
significant	O
increase	O
in	O
peak	O
haloperidol	B-O
plasma	O
concentrations	O
or	O
time	O
of	O
peak	O
.	O

HMG-CoA	O
Reductase	O
Inhibitors	O
.	O
When	O
single	O
40	O
mg	O
doses	O
of	O
simvastatin	B-O
or	O
atorvastatin	B-O
,	O
both	O
substrates	O
of	O
CYP3A4	O
,	O
were	O
given	O
to	O
healthy	O
adult	O
volunteers	O
who	O
had	O
received	O
nefazodone	B
hydrochloride	I
,	O
200	O
mg	O
BID	O
for	O
6	O
days	O
,	O
approximately	O
20	O
fold	O
increases	O
in	O
plasma	O
concentrations	O
of	O
simvastatin	B-O
and	O
simvastatin	B-O
acid	O
and	O
3	O
to	O
4	O
fold	O
increases	O
in	O
plasma	O
concentrations	O
of	O
atorvastatin	B-O
and	O
atorvastatin	B-O
lactone	O
were	O
seen	O
.	O

Propranolol	B-O
.	O
The	O
coadministration	O
of	O
nefazodone	B
(	O
200	O
mg	O
BID	O
)	O
and	O
propranolol	B-O
(	O
40	O
mg	O
BID	O
)	O
for	O
5.5	O
days	O
to	O
healthy	O
male	O
volunteers	O
(	O
n	O
=	O
18	O
)	O
,	O
including	O
3	O
poor	O
and	O
15	O
extensive	O
CYP2D6	O
metabolizers	O
,	O
resulted	O
in	O
30	O
%	O
and	O
14	O
%	O
reductions	O
in	O
Cmax	O
and	O
AUC	O
of	O
propranolol	B-O
,	O
respectively	O
,	O
and	O
a	O
14	O
%	O
reduction	O
in	O
Cmax	O
for	O
the	O
metabolite	O
,	O
4-hydroxypropranolol	B-O
.	O

There	O
have	O
been	O
reports	O
of	O
increased	O
blood	O
concentrations	O
of	O
cyclosporine	B-O
and	O
tacrolimus	B-O
into	O
toxic	O
ranges	O
when	O
patients	O
received	O
these	O
drugs	O
concomitantly	O
with	O
nefazodone	B
.	O

With	O
5	O
mg	O
BID	O
doses	O
of	O
buspirone	B
,	O
slight	O
increases	O
in	O
AUC	O
were	O
observed	O
for	O
nefazodone	B-O
(	O
23	O
%	O
)	O
and	O
its	O
metabolites	O
hydroxynefazodone	B-O
(	O
17	O
%	O
)	O
and	O
mCPP	B-O
(	O
9	O
%	O
)	O
.	O

The	O
concomitant	O
administration	O
of	O
quinidine	B
and	O
nortriptyline	B-O
may	O
result	O
in	O
a	O
significantly	O
longer	O
plasma	O
half-life	O
,	O
higher	O
AUC	O
,	O
and	O
lower	O
clearance	O
of	O
nortriptyline	B-O
.	O

Concurrent	O
administration	O
of	O
cimetidine	B
and	O
tricyclic	B-O
antidepressants	I-O
can	O
produce	O
clinically	O
significant	O
increases	O
in	O
the	O
plasma	O
concentrations	O
of	O
the	O
tricyclic	O
antidepressant	O
.	O

Anesthetic	O
:	O
meperidine/normeperidine	B-O
(	O
metabolite	O
)	O
Dosage	O
increase	O
and	O
long-term	O
use	O
of	O
meperidine	O
with	O
ritonavir	B
are	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
concentrations	O
of	O
the	O
metabolite	O
normeperidine	B-O
which	O
has	O
both	O
analgesic	O
activity	O
and	O
CNS	O
stimulant	O
activity	O
(	O
e	O
.g.	O
,seizures	O
)	O
.	O

Antipsychotics	O
:	O
quetiapine	B-O
.	O
Initiation	O
of	O
NORVIR	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
exposures	O
.	O

Digoxin	B-O
.	O
Concomitant	O
administration	O
of	O
ritonavir	B
with	O
digoxin	B-O
may	O
increase	O
digoxin	B-O
levels	O
.	O

Integrase	O
Inhibitor	O
:	O
raltegravir	B-O
.	O
The	O
effects	O
of	O
ritonavir	B
on	O
raltegravir	B-O
with	O
ritonavir	B
dosage	O
regimens	O
greater	O
than	O
100	O
mg	O
twice	O
daily	O
have	O
not	O
been	O
evaluated	O
,	O
however	O
raltegravir	B-O
concentrations	O
may	O
be	O
decreased	O
with	O
ritonavir	B
coadministration	O
.	O

Macrolide	B
antibiotics	I
are	O
inhibitors	O
of	O
CYP3A4	O
,	O
and	O
thus	O
could	O
potentially	O
impede	O
pimozide	B-O
metabolism	O
.	O

Because	O
substances	O
in	O
grapefruit	B
juice	I
may	O
inhibit	O
the	O
metabolism	O
of	O
pimozide	B-O
by	O
CYP3A4	O
,	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
grapefruit	B
juice	I
.	O

CYP2D6	O
inhibitors	O
:	O
In	O
healthy	O
subjects	O
,	O
co-administration	O
of	O
pimozide	B-O
2	O
mg	O
(	O
single	O
dose	O
)	O
and	O
paroxetine	B
60	O
mg	O
resulted	O
in	O
a	O
151	O
%	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
a	O
62	O
%	O
increase	O
in	O
pimozide	B-O
Cmax	O
compared	O
to	O
pimozide	B-O
administered	O
alone	O
.	O

The	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
Cmax	O
is	O
related	O
to	O
the	O
CYP2D6	O
inhibitory	O
properties	O
of	O
paroxetine	B
.	O

Co-administration	O
of	O
ONIVYDE	B-O
with	O
other	O
inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,clarithromycin	B
,	O
indinavir	B
,itraconazole	B
,	O
lopinavir	B
,	O
nefazodone	B
,	O
nelfinavir	B
,	O
ritonavir	B
,	O
saquinavir	B
,	O
telaprevir	B
,	O
voriconazole	B
)	O
orUGT1A1	O
(	O
e	O
.g.	O
,	O
atazanavir	B
,	O
gemfibrozil	B
,	O
indinavir	B
)	O
may	O
increase	O
systemic	O
exposure	O
to	O
irinotecan	B-O
or	I-O
SN-38.	B-O

Following	O
administration	O
of	O
non-liposomal	O
irinotecan	B-O
(	O
i	O
.e	O
.	O
,	O
irinotecan	B-O
HCl	O
)	O
,	O
exposure	O
to	O
irinotecan	B-O
or	O
its	O
active	O
metabolite	O
,	O
SN-38	B-O
,	O
is	O
substantially	O
reduced	O
in	O
adult	O
and	O
pediatric	O
patients	O
concomitantly	O
receiving	O
the	O
CYP3A4	O
enzyme-inducing	O
anticonvulsants	O
phenytoin	B
and	O
strong	O
CYP3A4	B
inducers	I
.	O

Following	O
administration	O
of	O
non-liposomal	O
irinotecan	B-O
(	O
i	O
.e	O
.	O
,	O
irinotecan	B-O
HCl	O
)	O
,	O
patients	O
receiving	O
concomitant	O
ketoconazole	B
,	O
a	O
CYP3A4	O
andUGT1A1	O
inhibitor	O
,	O
have	O
increased	O
exposure	O
to	O
irinotecan	B-O
and	O
its	O
active	O
metabolite	I-O
SN-38.	B-O

An	O
in	O
vivo	O
study	O
suggests	O
that	O
drugs	O
which	O
inhibit	O
CYP2D6	O
,	O
such	O
as	O
paroxetine	B
,	O
will	O
elevate	O
plasma	O
levels	O
of	O
thioridazine	B-O
.	O

Fosamprenavir/Ritonavir	B
.	O
Coadministration	O
of	I
fosamprenavir/	B
ritonavir	B
with	O
paroxetine	B-O
significantly	O
decreased	O
plasma	O
levels	O
of	O
paroxetine	B-O
.	O

In	O
a	O
separate	O
study	O
,	O
when	O
a	O
single	O
oral	O
300	O
mg	O
dose	O
of	O
phenytoin	B-O
was	O
administered	O
at	O
paroxetine	B
steady	O
state	O
(	O
30	O
mg	O
qd	O
for	O
14	O
days	O
)	O
,	O
phenytoin	B-O
AUC	O
was	O
slightly	O
reduced	O
(	O
12	O
%	O
on	O
average	O
)	O
compared	O
to	O
phenytoin	B-O
administered	O
alone	O
.	O

In	O
a	O
study	O
where	O
paroxetine	B
(	O
30	O
mg	O
qd	O
)	O
was	O
dosed	O
orally	O
for	O
4	O
weeks	O
,	O
steady-state	O
plasma	O
concentrations	O
of	O
paroxetine	B
were	O
increased	O
by	O
approximately	O
50	O
%	O
during	O
coadministration	O
with	O
oral	O
cimetidine	B-O
(	O
300	O
mg	O
tid	O
)	O
for	O
the	O
final	O
week	O
.	O

In	O
one	O
study	O
,	O
daily	O
dosing	O
of	O
paroxetine	B
(	O
20	O
mg	O
qd	O
)	O
under	O
steady-state	O
conditions	O
increased	O
single	O
dose	O
desipramine	B-O
(	O
100	O
mg	O
)	O
C	O
max	O
,	O
AUC	O
,	O
and	O
T	O
1/2	O
by	O
an	O
average	O
of	O
approximately	O
2-,	O
5-,	O
and	O
3-fold	O
,	O
respectively	O
.	O

In	O
one	O
study	O
,	O
daily	O
dosing	O
of	O
paroxetine	B
20	O
mg	O
in	O
patients	O
stabilized	O
on	O
risperidone	B-O
(	O
4	O
to	O
8	O
mg/day	O
)	O
increased	O
mean	O
plasma	O
concentrations	O
of	O
risperidone	B-O
approximately	O
4-fold	O
,	O
decreased	O
9-hydroxyrisperidone	B-O
concentrations	O
approximately	O
10	O
%	O
,	O
and	O
increased	O
concentrations	O
of	O
the	O
active	O
moiety	O
(	O
the	O
sum	O
of	O
risperidone	B-O
plus	O
9-hydroxyrisperidone	B-O
)	O
approximately	O
1.4-fold	O
.	O

Inhibition	O
of	O
CYP2D6	O
by	O
paroxetine	B
may	O
lead	O
to	O
reduced	O
plasma	O
concentrations	O
of	O
an	O
active	O
metabolite	O
(	O
endoxifen	B-O
)	O
and	O
hence	O
reduced	O
efficacy	O
of	O
tamoxifen	O
.	O

Mean	O
digoxin	B-O
AUC	O
at	O
steady	O
state	O
decreased	O
by	O
15	O
%	O
in	O
the	O
presence	O
of	O
paroxetine	B
.	O

Phenytoin	B
.	O
When	O
a	O
single	O
oral	O
30	O
mg	O
dose	O
of	O
paroxetine	B-O
was	O
administered	O
at	O
phenytoin	B
steady	O
state	O
(	O
300	O
mg	O
qd	O
for	O
14	O
days	O
)	O
,	O
paroxetine	B-O
AUC	O
and	O
T	O
1/2	O
were	O
reduced	O
(	O
by	O
an	O
average	O
of	O
50	O
%	O
and	O
35	O
%	O
,	O
respectively	O
)	O
compared	O
to	O
paroxetine	B-O
administered	O
alone	O
.	O

Pimozide	B-O
:	O
In	O
a	O
controlled	O
study	O
of	O
healthy	O
volunteers	O
,	O
after	O
paroxetine	B
was	O
titrated	O
to	O
60	O
mg	O
daily	O
,	O
coadministration	O
of	O
a	O
single	O
dose	O
of	O
2	O
mg	O
pimozide	B-O
was	O
associated	O
with	O
mean	O
increases	O
in	O
pimozide	B-O
AUC	O
of	O
151	O
%	O
and	O
C	O
max	O
of	O
62	O
%	O
,	O
compared	O
to	O
pimozide	B-O
administered	O
alone	O
.	O

Procyclidine	B-O
.	O
Daily	O
oral	O
dosing	O
of	O
paroxetine	B
(	O
30	O
mg	O
qd	O
)	O
increased	O
steady-state	O
AUC	O
0-24	O
,	O
C	O
max	O
,	O
and	O
C	O
min	O
values	O
of	O
procyclidine	B-O
(	O
5	O
mg	O
oral	O
qd	O
)	O
by	O
35	O
%	O
,	O
37	O
%	O
,	O
and	O
67	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
procyclidine	B-O
alone	O
at	O
steady	O
state	O
.	O

The	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
C	O
max	O
is	O
due	O
to	O
the	O
CYP2D6	O
inhibitory	O
properties	O
of	O
paroxetine	B
.	O

Theophylline	B-O
.	O
Reports	O
of	O
elevated	O
theophylline	B-O
levels	O
associated	O
with	O
paroxetine	B
treatment	O
have	O
been	O
reported	O
.	O

Tricyclic	B-O
Antidepressants	I-O
(TCA	O
)	O
:	O
Caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
tricyclic	B-O
antidepressants	I-O
(TCAs	O
)	O
with	O
PEXEVA	B
(	O
paroxetine	B
mesylate	O
)	O
,	O
because	O
paroxetine	B
may	O
inhibit	O
TCA	O
metabolism	O
.	O

When	O
a	O
single	O
oral	O
30	O
mg	O
dose	O
of	O
paroxetine	B-O
was	O
administered	O
at	O
phenobarbital	B
steady	O
state	O
(	O
100	O
mg	O
qd	O
for	O
14	O
days	O
)	O
,	O
paroxetine	B-O
AUC	O
and	O
T	O
1/2	O
were	O
reduced	O
(	O
by	O
an	O
average	O
of	O
25	O
%	O
and	O
38	O
%	O
,	O
respectively	O
)	O
compared	O
to	O
paroxetine	B-O
administered	O
alone	O
.	O

Failure	O
to	O
correctly	O
co-administer	O
PREZISTA	B-O
with	O
ritonavir	B
will	O
result	O
in	O
plasma	O
levels	O
of	O
darunavir	B-O
that	O
will	O
be	O
insufficient	O
to	O
achieve	O
the	O
desired	O
antiviral	O
effect	O
and	O
will	O
alter	O
some	O
drug	O
interactions	O
.	O

Co-administration	O
of	O
triazolam	B-O
or	O
orally	O
administered	O
midazolam	B-O
with	I
PREZISTA/ritonavir	B
may	O
cause	O
large	O
increases	O
in	O
the	O
concentrations	O
of	O
these	O
benzodiazepines	O
.	O

Herbal	O
product	O
St	B
.	I
John	I
's	I
wort	I
(	O
Hypericum	B
perforatum	I
)	O
Patients	O
taking	I-O
PREZISTA/ritonavir	B-O
should	O
not	O
use	O
products	O
containing	O
St	B
.	I
John	I
's	I
wort	I
because	O
co-administration	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
of	O
darunavir	B-O
.	O

PREZISTA/ritonavir	B-O
should	O
not	O
be	O
used	O
in	O
combination	O
with	O
rifampin	B
,	O
as	O
this	O
may	O
cause	O
significant	O
decreases	O
in	O
darunavir	B-O
plasma	O
concentrations	O
.	O

Antipsychotics	O
:	O
For	O
contraindicated	O
antipsychotics	O
,	O
quetiapine	B-O
.	O
Initiation	O
of	O
PREZISTA	B
with	O
ritonavir	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
exposures	O
.	O

Please	O
see	O
the	O
dabigatran	O
US	O
prescribing	O
information	O
for	O
specific	O
recommendations	O
.	O
rivaroxaban	O
Co-administration	O
of	I
PREZISTA/ritonavir	B
and	O
rivaroxaban	O
is	O
not	O
recommended	O
.	O
Warfarin	B-O
concentrations	O
are	O
decreased	O
when	O
co-administered	O
with	I
PREZISTA/ritonavir	B
.	O

Concomitant	O
use	O
of	O
allopurinol	B
with	O
PURIXAN	B-O
inhibits	O
the	O
first-pass	O
oxidative	O
metabolism	O
of	O
mercaptopurine	B-O
by	O
xanthine	O
oxidase	O
,	O
leading	O
to	O
mercaptopurine	B-O
toxicity	O
(	O
bone	O
marrow	O
suppression	O
,	O
nausea	O
,	O
vomiting	O
)	O
.	O

Administration	O
of	O
PRIFTIN	B-O
with	O
a	O
meal	B
increases	O
oral	O
bioavailability	O
and	O
may	O
reduce	O
the	O
incidence	O
of	O
gastrointestinal	O
upset	O
,	O
nausea	O
,	O
and/or	O
vomiting	O
.	O

Concomitant	O
use	O
of	O
PRIFTIN	B
with	O
other	O
drugs	O
metabolized	O
by	O
these	O
enzymes	O
,	O
such	O
as	O
protease	B-O
inhibitors	I-O
and	O
certain	O
reverse	B-O
transcriptase	I-O
inhibitors	I-O
,	O
may	O
cause	O
a	O
significant	O
decrease	O
in	O
plasma	O
concentrations	O
and	O
loss	O
of	O
therapeutic	O
effect	O
of	O
the	O
protease	O
inhibitor	O
or	O
reverse	O
transcriptase	O
inhibitor	O
.	O

The	O
concomitant	O
use	O
of	O
PRISTIQ	B-O
with	O
other	I-O
desvenlafaxine-containing	B-O
products	O
or	O
venlafaxine	B
will	O
increase	O
desvenlafaxine	B-O
blood	O
levels	O
and	O
increase	O
dose-related	O
adverse	O
reactions	O
.	O

Drugs	B-O
Dependent	I-O
on	I-O
Gastric	I-O
pH	I-O
for	I-O
Absorption	I-O
(	O
e	O
.g.	O
,	O
iron	B-O
salts	I-O
,	O
erlotinib	B-O
,	O
dasatinib	B-O
,	O
nilotinib	B-O
,	O
mycophenolate	B-O
mofetil	I-O
,	O
ketoconazole/itraconazole	B-O
)	O
Clinical	O
Impact	O
:	O
Pantoprazole	B
can	O
reduce	O
the	O
absorption	O
of	O
other	O
drugs	O
due	O
to	O
its	O
effect	O
on	O
reducing	O
intragastric	O
acidity	O
.	O

Intervention	O
:	O
Mycophenolate	B-O
mofetil	I-O
(	O
MMF)	O
:	O
Co-administration	O
of	O
pantoprazole	B
sodium	I
in	O
healthy	O
subjects	O
and	O
in	O
transplant	O
patients	O
receiving	O
MMF	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
exposure	O
to	O
the	O
active	O
metabolite	O
,	O
mycophenolic	B-O
acid	I-O
(	O
MPA	O
)	O
,	O
possibly	O
due	O
to	O
a	O
decrease	O
in	O
MMF	O
solubility	O
at	O
an	O
increased	O
gastric	O
pH.	O

Methotrexate	B-O
Clinical	O
Impact	O
:	O
Concomitant	O
use	O
of	O
PPIs	B
with	O
methotrexate	B-O
(	O
primarily	O
at	O
high	O
dose	O
)	O
may	O
elevate	O
and	O
prolong	O
serum	O
concentrations	O
of	O
methotrexate	B-O
and/or	O
its	O
metabolite	O
hydroxymethotrexate	B-O
,	O
possibly	O
leading	O
to	O
methotrexate	B-O
toxicities	O
.	O

Literature	O
suggests	O
that	O
concomitant	O
use	O
of	O
PPIs	B
with	O
methotrexate	B-O
(	O
primarily	O
at	O
high	O
dose	O
;	O
see	O
methotrexate	B-O
prescribing	O
information	O
)	O
may	O
elevate	O
and	O
prolong	O
serum	O
levels	O
of	O
methotrexate	B-O
and/or	O
its	O
metabolite	O
,	O
possibly	O
leading	O
to	O
methotrexate	B-O
toxicities	O
.	O

Antimycobacterials	O
Rifampin	B
Rifampin	B
substantially	O
decreases	O
plasma	O
concentrations	O
of	O
atazanavir	B-O
,	O
which	O
may	O
result	O
in	O
loss	O
of	O
therapeutic	O
effect	O
and	O
development	O
of	O
resistance	O
.	O

Antineoplastics	O
Irinotecan	B-O
Atazanavir	B
inhibits	O
UGT1A1	O
and	O
may	O
interfere	O
with	O
the	O
metabolism	O
of	O
irinotecan	B-O
,	O
resulting	O
in	O
increased	O
irinotecan	B-O
toxicities	O
.	O

Coadministration	O
of	O
triazolam	B-O
or	O
orally	O
administered	O
midazolam	B-O
with	O
REYATAZ	B
may	O
cause	O
large	O
increases	O
in	O
the	O
concentration	O
of	O
these	O
benzodiazepines	O
.	O

Drug	O
Class	O
Drugs	O
within	O
class	O
that	O
are	O
contraindicated	O
with	O
REYATAZ	B
Clinical	O
Comment	O
Alpha	O
1-Adrenoreceptor	O
Antagonist	O
Alfuzosin	B-O
Potential	O
for	O
increased	O
alfuzosin	B-O
concentrations	O
,	O
which	O
can	O
result	O
in	O
hypotension	O
.	O

Hepatitis	O
C	O
Direct-	O
Acting	O
Antivirals	I
Elbasvir/grazoprevir	B-O
May	O
increase	O
the	O
risk	O
of	O
ALT	O
elevations	O
due	O
to	O
a	O
significant	O
increase	O
in	O
grazoprevir	B-O
plasma	O
concentrations	O
.	O

Non-nucleoside	O
Reverse	O
Transcriptase	O
Inhibitors	O
Nevirapine	B
.	O
Nevirapine	B
substantially	O
decreases	O
atazanavir	B-O
exposure	O
which	O
may	O
result	O
in	O
loss	O
of	O
therapeutic	O
effect	O
and	O
development	O
of	O
resistance	O
.	O

Antiepileptics	O
:	O
carbamazepine	B
,	O
atazanavir	B-O
.	O
Plasma	O
concentrations	O
of	O
atazanavir	B-O
may	O
be	O
decreased	O
when	O
carbamazepine	B
is	O
administered	O
with	O
REYATAZ	B-O
without	O
ritonavir	O
.	O

Antipsychotics	O
:	O
quetiapine	B-O
and	O
lurasidone	O
.	O
Initiation	O
of	O
REYATAZ	B
with	O
ritonavir	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
exposures	O
.	O

Benzodiazepines	O
:	O
parenterally	O
administered	O
midazolam	B-O
.	O
Concomitant	O
use	O
of	O
parenteral	O
midazolam	B-O
with	O
REYATAZ	B
may	O
increase	O
plasma	O
concentrations	O
of	O
midazolam	B-O
.	O

Coadministration	O
of	O
buprenorphine	B
and	O
REYATAZ	B-O
without	O
ritonavir	O
may	O
decrease	O
atazanavir	B-O
plasma	O
concentrations	O
.	O

Due	O
to	O
the	O
effect	O
of	O
ritonavir	B
on	O
ketoconazole	B-O
,	O
high	O
doses	O
of	O
ketoconazole	B-O
and	O
itraconazole	O
(	O
>200	O
mg/day	O
)	O
should	O
be	O
used	O
cautiously	O
with	O
REYATAZ/ritonavir	B
.	O

Endothelin	O
receptor	O
antagonists	O
:	O
Bosentan	B
,	O
atazanavir	B-O
.	O
Plasma	O
concentrations	O
of	O
atazanavir	B-O
may	O
be	O
decreased	O
when	O
bosentan	B
is	O
administered	O
with	O
REYATAZ	B-O
without	O
ritonavir	O
.	O

H2	O
-Receptor	O
antagonists	O
:	O
atazanavir	B-O
.	O
Plasma	O
concentrations	O
of	O
atazanavir	B-O
were	O
substantially	O
decreased	O
when	O
REYATAZ	B-O
400	O
mg	O
once	O
daily	O
was	O
administered	O
simultaneously	O
with	O
famotidine	B
40	O
mg	O
twice	O
daily	O
in	O
adults	O
,	O
which	O
may	O
result	O
in	O
loss	O
of	O
therapeutic	O
effect	O
and	O
development	O
of	O
resistance	O
.	O

HCV	O
Antiviral	O
Agents	O
Protease	O
Inhibitors	O
:	O
boceprevir	B
,	O
atazanavir	B-O
,	O
ritonavir	B-O
.	O
Concomitant	O
administration	O
of	O
boceprevir	B
and	I-O
atazanavir/ritonavir	B-O
resulted	O
in	O
reduced	O
steady-state	O
exposures	O
to	O
atazanavir	B-O
and	O
ritonavir	B-O
.	O

HIV	O
Antiviral	O
Agents	O
Nucleoside	O
Reverse	O
Transcriptase	O
Inhibitors	O
(	O
NRTIs	O
)	O
:	O
didanosine	B
buffered	O
formulationsenteric-coated	O
(EC	O
)	O
capsules	O
,	O
atazanavir	B-O
,	O
didanosine	B
.	O
Coadministration	O
of	O
REYATAZ	B-O
with	O
didanosine	B
buffered	O
tablets	O
resulted	O
in	O
a	O
marked	O
decrease	O
in	O
atazanavir	B-O
exposure	O
.	O

If	O
patients	O
beginning	O
treatment	O
with	I-O
REYATAZ/ritonavir	B-O
have	O
been	O
titrated	O
to	O
a	O
stable	O
dose	O
of	O
carbamazepine	O
,	O
a	O
dose	O
reduction	O
for	O
carbamazepine	O
may	O
be	O
necessary	O
.	O
phenytoin	B
,	O
phenobarbital	B
,	O
atazanavir	B-O
,	O
phenytoin	B
,	O
phenobarbital	B
.	O
Plasma	O
concentrations	O
of	O
atazanavir	B-O
may	O
be	O
decreased	O
when	O
phenytoin	B
or	O
phenobarbital	B
is	O
administered	O
with	O
REYATAZ	B-O
without	O
ritonavir	O
.	O

In	O
treatment-experienced	O
adult	O
patients	O
:	O
Coadministration	O
of	O
REYATAZ	B-O
with	O
efavirenz	B
in	O
treatment-experienced	O
patients	O
is	O
not	O
recommended	O
due	O
to	O
decreased	O
atazanavir	B-O
exposure	O
.	O

Inhaled/nasal	O
steroid	O
:	O
fluticasone	O
,	I
REYATAZ.	B
Concomitant	O
use	O
of	O
fluticasone	B-O
propionate	I-O
and	O
REYATAZ	B
(	O
without	O
ritonavir	O
)	O
may	O
increase	O
plasma	O
concentrations	O
of	O
fluticasone	B-O
propionate	I-O
.	O

Lamotrigine	B-O
.	O
Coadministration	O
of	O
lamotrigine	B-O
and	O
REYATAZ	B
with	O
ritonavir	B
may	O
decrease	O
lamotrigine	B-O
plasma	O
concentrations	O
.	O

Macrolide	O
antibiotics	O
:	O
clarithromycin	B-O
,	O
14-OH	O
clarithromycin	B-O
,	O
atazanavir	B
.	O
Increased	O
concentrations	O
of	O
clarithromycin	B-O
may	O
cause	O
QTc	O
prolongations	O
;	O
therefore	O
,	O
a	O
dose	O
reduction	O
of	O
clarithromycin	B-O
by	O
50	O
%	O
should	O
be	O
considered	O
when	O
it	O
is	O
coadministered	O
with	I
REYATAZ.	B

Non-nucleoside	O
Reverse	O
Transcriptase	O
Inhibitors	O
(	O
NNRTIs	O
)	O
:	O
efavirenz	B
,	O
atazanavir	B-O
.	O
Efavirenz	B
decreases	O
atazanavir	B-O
exposure	O
.	O

Nucleotide	O
Reverse	O
Transcriptase	O
Inhibitors	O
:	O
tenofovir	O
disoproxil	O
fumarate	O
(	O
DF)	O
,	O
atazanavir	B-O
.	O
Tenofovir	B
DF	I
may	O
decrease	O
the	O
AUC	O
and	O
Cmin	O
of	O
atazanavir	B-O
.	O

Opioids	O
:	O
Buprenorphine	B-O
,	O
norbuprenorphine	B-O
.	O
Coadministration	O
of	O
buprenorphine	B-O
and	O
REYATAZ	B
with	O
or	O
without	O
ritonavir	B
increases	O
the	O
plasma	O
concentration	O
of	O
buprenorphine	B-O
and	O
norbuprenorphine	B-O
.	O

Other	O
Agents	O
Antacids	B
and	O
buffered	O
medications	O
:	O
atazanavir	B-O
.	O
Reduced	O
plasma	O
concentrations	O
of	O
atazanavir	B-O
are	O
expected	O
if	O
antacids	B
,	O
including	O
buffered	O
medications	O
,	O
are	O
administered	O
with	I-O
REYATAZ.	B-O

Although	O
not	O
studied	O
,	O
the	O
coadministration	O
of	I
REYATAZ/ritonavir	B
and	O
an	O
additional	O
protease	B-O
inhibitor	I-O
would	O
be	O
expected	O
to	O
increase	O
exposure	O
to	O
the	O
other	O
protease	B-O
inhibitor	I-O
.	O

Proton-pump	O
inhibitors	O
:	O
omeprazole	B
,	O
atazanavir	B-O
.	O
Plasma	O
concentrations	O
of	O
atazanavir	B-O
were	O
substantially	O
decreased	O
when	O
REYATAZ	B-O
400	O
mg	O
or	O
REYATAZ	B-O
300	O
mg/ritonavir	O
100	O
mg	O
once	O
daily	O
was	O
administered	O
with	O
omeprazole	B
40	O
mg	O
once	O
daily	O
in	O
adults	O
,	O
which	O
may	O
result	O
in	O
loss	O
of	O
therapeutic	O
effect	O
and	O
development	O
of	O
resistance	O
.	O

Reduced	O
plasma	O
concentrations	O
of	O
atazanavir	B-O
are	O
expected	O
if	O
proton-pump	B
inhibitors	I
,	O
antacids	B
,	O
buffered	B
medications	I
,	O
or	O
H2-receptor	B
antagonists	I
are	O
administered	O
with	I-O
REYATAZ.	B-O

REYATAZ	B
increases	O
tenofovir	B-O
concentrations	O
.	O

REYATAZ/ritonavir	B
,	O
fluticasone	O
.	O
Concomitant	O
use	O
of	O
fluticasone	B-O
propionate	I-O
and	I
REYATAZ/ritonavir	B
may	O
increase	O
plasma	O
concentrations	O
of	O
fluticasone	B-O
propionate	I-O
,	O
resulting	O
in	O
significantly	O
reduced	O
serum	O
cortisol	O
concentrations	O
.	O

Ritonavir	B
may	O
decrease	O
plasma	O
levels	O
of	O
phenytoin	B-O
and	O
phenobarbital	B-O
.	O

Ritonavir	B
may	O
increase	O
plasma	O
levels	O
of	O
carbamazepine	B-O
.	O

Simultaneous	O
administration	O
of	O
didanosine	B-O
EC	O
and	O
REYATAZ	B
with	O
food	B
results	O
in	O
a	O
decrease	O
in	O
didanosine	B-O
exposure	O
.	O

Trazodone	B-O
.	O
Concomitant	O
use	O
of	O
trazodone	B-O
and	O
REYATAZ	B
with	O
or	O
without	O
ritonavir	B
may	O
increase	O
plasma	O
concentrations	O
of	O
trazodone	B-O
.	O

Rifampin	B
is	O
contraindicated	O
in	O
patients	O
who	O
are	O
also	O
receiving	O
atazanavir	B-O
,	O
darunavir	B-O
,	O
fosamprenavir	B-O
,	O
saquinavir	B-O
,	O
or	O
tipranavir	B-O
due	O
to	O
the	O
potential	O
of	O
rifampin	B
to	O
substantially	O
decrease	O
plasma	O
concentrations	O
of	O
these	O
antiviral	O
drugs	O
,	O
which	O
may	O
result	O
in	O
loss	O
of	O
antiviral	O
efficacy	O
and/or	O
development	O
of	O
viral	O
resistance	O
.	O

Concomitant	O
antacid	B
administration	O
may	O
reduce	O
the	O
absorption	O
of	O
rifampin	B-O
.	O

Concurrent	O
use	O
of	O
rifampin	B
and	O
enalapril	O
has	O
resulted	O
in	O
decreased	O
concentrations	O
of	O
enalaprilat	B-O
,	O
the	O
active	O
metabolite	O
of	O
enalapril	O
.	O

Plasma	O
concentrations	O
of	O
sulfapyridine	B-O
may	O
be	O
reduced	O
following	O
the	O
concomitant	O
administration	O
of	O
sulfasalazine	O
and	O
rifampin	B
.	O

Probenecid	B
and	O
cotrimoxazole	B
have	O
been	O
reported	O
to	O
increase	O
the	O
blood	O
level	O
of	O
rifampin	B-O
.	O

Rifampin	B
has	O
been	O
reported	O
to	O
accelerate	O
the	O
metabolism	O
of	O
the	O
following	O
drugs	O
:	O
anticonvulsants	B-O
(	O
e	O
.g.	O
,	O
phenytoin	B-O
)	O
,	O
digitoxin	B-O
,	O
antiarrhythmics	B-O
(	O
e	O
.g.	O
,	O
disopyramide	B-O
,	O
mexiletine	B-O
,	O
quinidine	B-O
,	O
tocainide	B-O
)	O
,	O
oral	B-O
anticoagulants	I-O
,	O
antifungals	B-O
(	O
e	O
.g.	O
,	O
fluconazole	B-O
,	O
itraconazole	B-O
,	O
ketoconazole	B-O
)	O
,	O
barbiturates	B-O
,	O
beta-blockers	B-O
,	O
calcium	B-O
channel	I-O
blockers	I-O
(	O
e	O
.g.	O
,	O
diltiazem	B-O
,	O
nifedipine	B-O
,	O
verapamil	B-O
)	O
,	O
chloramphenicol	B-O
,	O
clarithromycin	B-O
,	O
corticosteroids	B-O
,	O
cyclosporine	B-O
,	O
cardiac	B-O
glycoside	I-O
preparations	I-O
,	O
clofibrate	B-O
,	O
oral	O
or	O
other	O
systemic	O
hormonal	B-O
contraceptives	I-O
,	O
dapsone	B-O
,	O
diazepam	B-O
,	O
doxycycline	B-O
,	O
fluoroquinolones	B-O
(	O
e	O
.g.	O
,	O
ciprofloxacin	B-O
)	O
,	O
haloperidol	B-O
,	O
oral	B-O
hypoglycemic	I-O
agents	I-O
(	O
sulfonylureas	B-O
)	O
,	O
levothyroxine	B-O
,	O
methadone	B-O
,	O
narcotic	B-O
analgesics	I-O
,	O
progestins	B-O
,	O
quinine	B-O
,	O
tacrolimus	B-O
,	O
theophylline	B-O
,	O
tricyclic	B-O
antidepressants	I-O
(	O
e	O
.g.	O
,	O
amitriptyline	B-O
,	O
nortriptyline	B-O
)	O
and	O
zidovudine	B-O
.	O

Rifampin	B
has	O
been	O
reported	O
to	O
substantially	O
decrease	O
the	O
plasma	O
concentrations	O
of	O
the	O
following	O
antiviral	O
drugs	O
:	O
atazanavir	B-O
,	O
darunavir	B-O
,	O
fosamprenavir	B-O
,	O
saquinavir	B-O
,	O
and	O
tipranavir	B-O
.	O

Rifampin	B
has	O
enzyme	O
induction	O
properties	O
that	O
can	O
enhance	O
the	O
metabolism	O
of	O
endogenous	O
substrates	O
including	O
adrenal	B-O
hormones	I-O
,	O
thyroid	B-O
hormones	I-O
,	O
and	O
vitamin	B-O
D.	O
Rifampin	B
and	O
isoniazid	O
have	O
been	O
reported	O
to	O
alter	O
vitamin	B-O
D	I-O
metabolism	O
.	O

Fluvoxamine	B
(	O
strong	O
CYP1A2	O
inhibitor	O
)	O
:	O
Increases	O
AUC	O
for	O
ramelteon	B-O
and	O
should	O
not	O
be	O
used	O
in	O
combination	O
.	O

Donepezil	B
increases	O
systemic	O
exposure	O
of	O
ramelteon	B-O
;	O
patients	O
should	O
be	O
closely	O
monitored	O
when	O
ramelteon	B-O
is	O
coadministered	O
with	O
donepezil	B
.	O

Donepezil	B
:	O
The	O
AUC0-inf	O
and	O
Cmax	O
of	O
ramelteon	B-O
increased	O
by	O
approximately	O
100	O
%	O
and	O
87	O
%	O
,	O
respectively	O
upon	O
coadministration	O
of	O
donepezil	B
with	I-O
ROZEREM.	B-O

Doxepin	B
:	O
The	O
AUC0-inf	O
and	O
Cmax	O
of	O
ramelteon	B-O
increased	O
by	O
approximately	O
66	O
%	O
and	O
69	O
%	O
,	O
respectively	O
,	O
upon	O
coadministration	O
of	O
doxepin	B
with	I-O
ROZEREM.	B-O

Fluconazole	B
(	O
strong	O
CYP2C9	O
inhibitor	O
)	O
:	O
Increases	O
systemic	O
exposure	O
of	O
ramelteon	B-O
;	O
administer	O
with	O
caution	O
.	O

Fluconazole	B
(	O
strong	O
CYP2C9	O
inhibitor	O
)	O
:	O
The	O
AUC0-inf	O
and	O
Cmax	O
of	O
ramelteon	B-O
was	O
increased	O
by	O
approximately	O
150	O
%	O
when	O
ROZEREM	B-O
was	O
coadministered	O
with	O
fluconazole	B
.	O

Fluvoxamine	B
(	O
strong	O
CYP1A2	O
inhibitor	O
)	O
:	O
AUC0-inf	O
for	O
ramelteon	B-O
increased	O
approximately	O
190-fold	O
,	O
and	O
the	O
Cmax	O
increased	O
approximately	O
70-fold	O
upon	O
coadministration	O
of	O
fluvoxamine	B
and	O
ROZEREM	B-O
,	O
compared	O
to	O
ROZEREM	B-O
administered	O
alone	O
.	O

Ketoconazole	B
(	O
strong	O
CYP3A4	O
inhibitor	O
)	O
:	O
Increases	O
AUC	O
for	O
ramelteon	B-O
;	O
administer	O
with	O
caution	O
.	O

Ketoconazole	B
(	O
strong	O
CYP3A4	O
inhibitor	O
)	O
:	O
The	O
AUC0-inf	O
and	O
Cmax	O
of	O
ramelteon	B-O
increased	O
by	O
approximately	O
84	O
%	O
and	O
36	O
%	O
upon	O
coadministration	O
of	O
ketoconazole	B
with	I-O
ROZEREM.	B-O

Rifampin	B
(	O
strong	O
CYP	O
enzyme	O
inducer	O
)	O
:	O
Administration	O
of	O
multiple	O
doses	O
of	O
rifampin	B
resulted	O
in	O
a	O
mean	O
decrease	O
of	O
approximately	O
80	O
%	O
in	O
total	O
exposure	O
to	O
ramelteon	B-O
and	O
metabolite	O
M-II	O
.	O

Rifampin	B
(	O
strong	O
CYP	O
enzyme	O
inducer	O
)	O
:	O
Decreases	O
exposure	O
to	O
and	O
effects	O
of	O
ramelteon	B-O
.	O

Cimetidine	B
:	O
Increases	O
exposure	O
to	O
doxepin	B-O
.	O

Silenor	B-O
exposure	O
is	O
doubled	O
with	O
concomitant	O
administration	O
of	O
cimetidine	B
,	O
a	O
nonspecific	O
inhibitor	O
of	O
CYP	O
isozymes	O
.	O

CYP3A	O
Substrate	O
(	O
e	O
.g.	O
,	O
Midazolam	B-O
)	O
:	O
Coadministration	O
of	O
STRATTERA	B
(60mg	O
BID	O
for	O
12days	O
)	O
with	O
midazolam	B-O
,	O
a	O
model	O
compound	O
for	O
CYP3A4	O
metabolized	O
drugs	O
(	O
single	O
dose	O
of	O
5mg	O
)	O
,	O
resulted	O
in	O
15	O
%	O
increase	O
in	O
AUC	O
of	O
midazolam	B-O
.	O

In	O
EM	O
individuals	O
treated	O
with	O
paroxetine	B
or	O
fluoxetine	B
,	O
the	O
AUC	O
of	O
atomoxetine	B-O
is	O
approximately	O
6-to8-fold	O
and	O
Css	O
,	O
max	O
is	O
about	O
3-to4-fold	O
greater	O
than	O
atomoxetine	B-O
alone	O
.	O

In	O
extensive	O
metabolizers	O
(	O
EMs)	O
,	O
inhibitors	B
of	I
CYP2D6	I
(	O
e	O
.g.	O
,	O
paroxetine	B
,	O
fluoxetine	B
,	O
and	O
quinidine	B
)	O
increase	O
atomoxetine	B-O
steady-state	O
plasma	O
concentrations	O
to	O
exposures	O
similar	O
to	O
those	O
observed	O
in	O
poor	O
metabolizers	O
(	O
PMs)	O
.	O

Cimetidine	B
.	O
There	O
is	O
evidence	O
that	O
cimetidine	B
inhibits	O
the	O
elimination	O
of	O
tricyclic	B-O
antidepressants	I-O
.	O

Also	O
inform	O
patients	O
not	O
to	O
take	O
St	B
.	I
John	I
's	I
Wort	I
since	O
these	O
agents	O
may	O
reduce	O
the	O
concentration	O
of	O
Tasigna	B-O
.	O

Drugs	O
such	O
as	O
proton	B
pump	I
inhibitors	I
that	I
inhibit	I
gastric	I
acid	I
secretion	I
to	O
elevate	O
the	O
gastric	O
pH	O
may	O
decrease	O
the	O
solubility	O
of	O
nilotinib	B-O
and	O
reduce	O
its	O
bioavailability	O
.	O

In	O
healthy	O
subjects	O
,	O
coadministration	O
of	O
a	O
single	O
400	O
mg	O
dose	O
of	O
Tasigna	B-O
with	O
multiple	O
doses	O
of	O
esomeprazole	B
(	O
a	O
proton-pump	O
inhibitor	O
)	O
at	O
40	O
mg	O
daily	O
decreased	O
the	O
nilotinib	B-O
AUC	O
by	O
34	O
%	O
.	O

In	O
patients	O
with	O
CML	O
,	O
multiple	O
doses	O
of	O
Tasigna	B
increased	O
the	O
systemic	O
exposure	O
of	O
oral	O
midazolam	B-O
(	O
a	O
substrate	O
of	O
CYP3A4	O
)	O
2.6-fold	O
.	O

Ketoconazole	B
:	O
In	O
healthy	O
subjects	O
receiving	O
ketoconazole	B
,	O
a	O
CYP3A4	O
inhibitor	O
,	O
at	O
400	O
mg	O
once	O
daily	O
for	O
6	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC)	O
to	O
nilotinib	B-O
was	O
increased	O
approximately	O
3-fold	O
.	O

Rifampicin	B
:	O
In	O
healthy	O
subjects	O
receiving	O
the	O
CYP3A4	O
inducer	O
,	O
rifampicin	B
,	O
at	O
600	O
mg	O
daily	O
for	O
12	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC)	O
to	O
nilotinib	B-O
was	O
decreased	O
approximately	O
80	O
%	O
.	O

Reduced	O
cytochrome	O
P450	O
2D6	O
isozyme	O
activity	O
drugs	O
that	O
inhibit	O
this	O
isozyme	O
(	O
e	O
.g.	O
,	O
fluoxetine	B
and	O
paroxetine	B
)	O
and	O
certain	O
other	O
drugs	O
(	O
e	O
.g.	O
,	O
fluvoxamine	B
,	O
propranolol	B
,	O
and	O
pindolol	B
)	O
appear	O
to	O
appreciably	O
inhibit	O
the	O
metabolism	O
of	O
thioridazine	B-O
.	O

Concentrations	O
of	O
thioridazine	B-O
and	O
its	O
two	O
active	O
metabolites	O
,	O
mesoridazine	B-O
and	O
sulforidazine	B-O
,	O
increased	O
3-fold	O
following	O
coadministration	O
of	O
fluvoxamine	B
.	O

Concurrent	O
administration	O
of	O
pindolol	B
and	O
thioridazine	B-O
have	O
resulted	O
in	O
moderate	O
,	O
dose	O
related	O
increases	O
in	O
the	O
serum	O
levels	O
of	O
thioridazine	B-O
and	O
two	O
of	O
its	O
metabolites	O
,	O
as	O
well	O
as	O
higher	O
than	O
expected	O
serum	O
pindolol	B
levels	O
.	O

Concurrent	O
administration	O
of	O
propranolol	B
(	O
100	O
mg	O
to	O
800	O
mg	O
daily	O
)	O
has	O
been	O
reported	O
to	O
produce	O
increases	O
in	O
plasma	O
levels	O
of	O
thioridazine	B-O
(	O
approximately	O
50	O
%	O
to	O
400	O
%	O
)	O
and	O
its	O
metabolites	O
(	O
approximately	O
80	O
%	O
to	O
300	O
%	O
)	O
.	O

Reduced	O
cytochrome	O
P450	O
2D6	O
isozyme	O
activity	O
,	O
drugs	O
which	O
inhibit	O
this	O
isozyme	O
(	O
e	O
.g.	O
,	O
fluoxetine	B
and	O
paroxetine	B
)	O
,	O
and	O
certain	O
other	O
drugs	O
(	O
e	O
.g.	O
,	O
fluvoxamine	B
,	O
propranolol	B
,	O
and	O
pindolol	B
)	O
appear	O
to	O
appreciably	O
inhibit	O
the	O
metabolism	O
of	O
thioridazine	B-O
.	O

Coadministration	O
of	O
standard	O
doses	O
of	O
voriconazole	B-O
with	O
efavirenz	B
doses	O
of	O
400	O
mg	O
q24h	O
or	O
higher	O
is	O
contraindicated	O
,	O
because	O
efavirenz	B
significantly	O
decreases	O
plasma	O
voriconazole	B-O
concentrations	O
in	O
healthy	O
subjects	O
at	O
these	O
doses	O
.	O

Coadministration	O
of	O
VFEND	B
with	O
ergot	B-O
alkaloids	I-O
(	O
ergotamine	B-O
and	O
dihydroergotamine	B-O
)	O
is	O
contraindicated	O
because	O
VFEND	B
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
ergot	B-O
alkaloids	I-O
,	O
which	O
may	O
lead	O
to	O
ergotism	O
.	O

Coadministration	O
of	O
VFEND	B-O
with	O
high-dose	O
ritonavir	B
(	O
400	O
mg	O
q12h	O
)	O
is	O
contraindicated	O
because	O
ritonavir	B
(	O
400	O
mg	O
q12h	O
)	O
significantly	O
decreases	O
plasma	O
voriconazole	B-O
concentrations	O
.	O

Coadministration	O
of	O
VFEND	B-O
with	O
rifampin	B
,	O
carbamazepine	B
and	O
long-acting	B
barbiturates	I
is	O
contraindicated	O
because	O
these	O
drugs	O
are	O
likely	O
to	O
decrease	O
plasma	O
voriconazole	B-O
concentrations	O
significantly	O
.	O

Coadministration	O
of	O
VFEND	B
with	O
sirolimus	B-O
is	O
contraindicated	O
because	O
VFEND	B
significantly	O
increases	O
sirolimus	B-O
concentrations	O
.	O

Coadministration	O
of	O
VFEND	B-O
with	O
St	B
.	I
John	I
's	I
Wort	I
is	O
contraindicated	O
because	O
this	O
herbal	O
supplement	O
may	O
decrease	O
voriconazole	B-O
plasma	O
concentration	O
.	O

Voriconazole	B
also	O
significantly	O
increases	O
efavirenz	B-O
plasma	O
concentrations	O
.	O

Everolimus(	B-O
CYP3A4	O
Inhibition	O
)	O
Not	O
Studied	O
In	O
Vivo	O
or	O
In	O
Vitro	O
,	O
but	O
Drug	O
Plasma	O
Exposure	O
Likely	O
to	O
be	O
Increased	O
Concomitant	O
administration	O
of	O
voriconazole	B
and	O
everolimus	B-O
is	O
not	O
recommended	O
.	O

Omeprazole	B-O
(	O
CYP2C19/3A4	O
Inhibition	O
)	O
Significantly	O
Increased	O
When	O
initiating	O
therapy	O
with	O
VFEND	B
in	O
patients	O
already	O
receiving	O
omeprazole	B-O
doses	O
of	O
40	O
mg	O
or	O
greater	O
,	O
reduce	O
the	O
omeprazole	B-O
dose	O
by	O
one-half	O
.	O

Antimycobacterial	O
Agents	O
Rifampin	B
Plasma	O
concentrations	O
of	O
nelfinavir	B-O
can	O
be	O
reduced	O
by	O
concomitant	O
use	O
of	O
rifampin	B
.	O

Herbal	O
products	O
St	B
.	I
John	I
's	I
wort	I
(	O
Hypericum	B
perforatum	I
)	O
Plasma	O
concentrations	O
of	O
nelfinavir	B-O
can	O
be	O
reduced	O
by	O
concomitant	O
use	O
of	O
the	O
herbal	O
preparation	O
St	B
.	I
John	I
's	I
wort	I
.	O

ANTIDEPRESSANT	O
Trazodone	B-O
trazodone	B-O
Concomitant	O
use	O
of	O
trazodone	B-O
and	O
VIRACEPT	B
may	O
increase	O
plasma	O
concentrations	O
of	O
trazodone	B-O
.	O

ANTIPSYCHOTICS	O
Quetiapine	B-O
quetiapine	B-O
Initiation	O
of	O
VIRACEPT	B
in	O
patients	O
taking	O
quetiapine	B-O
:	O
Consider	O
alternative	O
antiretroviral	O
therapy	O
to	O
avoid	O
increases	O
in	O
quetiapine	B-O
drug	O
exposures	O
.	O

Coadministration	O
of	O
VIRACEPT	B
and	O
drugs	B-O
primarily	I-O
metabolized	I-O
by	I-O
CYP3A	I-O
(	O
e	O
.g.	O
,	O
dihydropyridine	B-O
calcium	I-O
channel	I-O
blockers	I-O
,	O
HMG-CoA	B-O
reductase	I-O
inhibitors	I-O
,	O
immunosuppressants	B-O
and	O
PDE5	B-O
inhibitors	I-O
)	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
such	O
drugs	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Coadministration	O
of	O
VIRACEPT	B-O
and	O
drugs	B
that	I
induce	I
CYP3A	I
or	I
CYP2C19	I
,	O
such	O
as	O
rifampin	B
,	O
may	O
decrease	O
nelfinavir	B-O
plasma	O
concentrations	O
and	O
reduce	O
its	O
therapeutic	O
effect	O
.	O

ENDOTHELIN	O
RECEPTOR	O
ANTAGONIST	O
Bosentan	B-O
bosentan	B-O
Concentrations	O
of	O
bosentan	B-O
may	O
be	O
increased	O
when	O
coadministered	O
with	I
VIRACEPT.	B

HORMONAL	O
CONTRACEPTIVES	O
Ethinyl	B-O
estradiol	I-O
Norethindrone	B-O
,	O
ethinyl	B-O
estradiol	I-O
,	O
norethindrone	B-O
Concentrations	O
of	O
ethinyl	B-O
estradiol	I-O
and	O
norethindrone	B-O
were	O
decreased	O
when	O
coadministered	O
with	I
VIRACEPT.	B

IMMUNOSUPPRESSANTS	O
Cyclosporine	B-O
Tacrolimus	B-O
Sirolimus	B-O
immuno-suppressants	O
nelfinavir	B
Concentrations	O
of	O
these	O
immunosuppressants	O
and	O
nelfinavir	B
may	O
be	O
increased	O
by	O
coadministration	O
of	O
these	O
agents	O
with	O
nelfinavir	B
.	O

INHALED/NASAL	O
STEROID	O
Fluticasone	O
fluticasone	O
Concomitant	O
use	O
of	O
fluticasone	B-O
propionate	I-O
and	O
VIRACEPT	B
may	O
increase	O
plasma	O
concentrations	O
of	O
fluticasone	B-O
propionate	I-O
.	O

NARCOTIC	O
ANALGESIC	O
Methadone	B-O
methadone	B-O
Concentrations	O
of	O
methadone	B-O
were	O
decreased	O
when	O
coadministered	O
with	I
VIRACEPT.	B

Nevirapine	B
nelfinavir	B-O
(	O
Cmin	O
)	O
Concentrations	O
of	O
nelfinavir	B-O
were	O
decreased	O
when	O
coadministered	O
with	O
nevirapine	B
.	O

PROTON	O
PUMP	O
INHIBITORS	O
Omeprazole	B
nelfinavir	B-O
Omeprazole	B
decreases	O
the	O
plasma	O
concentrations	O
of	O
nelfinavir	B-O
.	O

Ritonavir	B
nelfinavir	B-O
ritonavir	B
Concentrations	O
of	O
nelfinavir	B-O
were	O
increased	O
when	O
coadministered	O
with	O
ritonavir	B
.	O

Acidifying	O
Agents	O
Clinical	O
Impact	O
Urinary	B
acidifying	I
agents	I
can	O
lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	B-O
.	O

Acidifying	B
agents	I
decrease	O
amphetamine	B-O
blood	O
levels	O
,	O
while	O
alkalinizing	B
agents	I
increase	O
amphetamine	B-O
blood	O
levels	O
.	O

Examples	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRI)	O
,	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(	O
SNRI)	O
,	O
triptans	O
,	O
tricyclic	O
antidepressants	O
,	O
fentanyl	O
,	O
lithium	O
,	O
tramadol	O
,	O
tryptophan	O
,	O
buspirone	O
,	O
St	O
.	O
John	O
's	O
Wort	O
CYP2D6	B
Inhibitors	I
Clinical	O
Impact	O
The	O
concomitant	O
use	O
of	O
VYVANSE	B
and	O
CYP2D6	B
inhibitors	I
may	O
increase	O
the	O
exposure	O
of	O
dextroamphetamine	B-O
,	O
the	O
active	O
metabolite	O
of	O
VYVANSE	B
compared	O
to	O
the	O
use	O
of	O
the	O
drug	O
alone	O
and	O
increase	O
the	O
risk	O
of	O
serotonin	O
syndrome	O
.	O

Tricyclic	O
Antidepressants	O
Clinical	O
Impact	O
May	O
enhance	O
the	O
activity	O
of	O
tricyclic	B
or	I
sympathomimetic	I
agents	I
causing	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d-amphetamine	B-O
in	O
the	O
brain	O
;	O
cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O

Simvastatin	B-O
exposure	O
is	O
approximately	O
doubled	O
with	O
concomitant	O
use	O
of	O
lomitapide	B
;	O
therefore	O
,	O
the	O
dose	O
of	O
ZOCOR	B-O
should	O
be	O
reduced	O
by	O
50	O
%	O
if	O
initiating	O
lomitapide	B
.	O

In	O
one	O
study	O
,	O
concomitant	O
administration	O
of	O
digoxin	B-O
with	O
simvastatin	B
resulted	O
in	O
a	O
slight	O
elevation	O
in	O
digoxin	B-O
concentrations	O
in	O
plasma	O
.	O

Alcohol	B
increases	O
the	O
overall	O
amount	O
of	O
drug	O
in	O
the	O
bloodstream	O
after	O
a	O
dose	O
of	O
Zanaflex	B-O
.	O

The	O
concomitant	O
use	O
of	O
ZOLOFT	B
with	O
a	O
CYP2D6	B-O
substrate	I-O
may	O
increase	O
the	O
exposure	O
of	O
the	O
CYP2D6	B-O
substrate	I-O
.	O

Strong	O
CYP3A4	O
Inducers	O
(	O
e	O
.g.	O
,	O
carbamazepine	B
)	O
The	O
concomitant	O
use	O
of	O
oral	O
aripiprazole	B-O
and	O
carbamazepine	B
decreased	O
the	O
exposure	O
of	O
aripiprazole	B-O
.	O

Some	O
patients	O
may	O
experience	O
a	O
large	O
increase	O
in	O
amitriptyline	B-O
concentration	O
in	O
the	O
presence	O
of	O
topiramate	B
and	O
any	O
adjustments	O
in	O
amitriptyline	B-O
dose	O
should	O
be	O
made	O
according	O
to	O
the	O
patient	O
's	O
clinical	O
response	O
and	O
not	O
on	O
the	O
basis	O
of	O
plasma	O
levels	O
.	O

Cimetidine	B
is	O
reported	O
to	O
reduce	O
hepatic	O
metabolism	O
of	O
certain	O
tricyclic	B-O
antidepressants	I-O
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
steady-state	O
concentrations	O
of	O
these	O
drugs	O
.	O

Increases	O
in	O
plasma	O
levels	O
of	O
tricyclic	B-O
antidepressants	I-O
,	O
and	O
in	O
the	O
frequency	O
and	O
severity	O
of	O
side	O
effects	O
,	O
particularly	O
anticholinergic	O
,	O
have	O
been	O
reported	O
when	O
cimetidine	B
was	O
added	O
to	O
the	O
drug	O
regimen	O
.	O

Discontinuation	O
of	O
cimetidine	B
in	O
well	O
controlled	O
patients	O
receiving	O
tricyclic	B-O
antidepressants	I-O
and	O
cimetidine	B
may	O
decrease	O
the	O
plasma	O
levels	O
and	O
efficacy	O
of	O
the	O
antidepressants	O
.	O

Serum	O
levels	O
of	O
several	O
tricyclic	B-O
antidepressants	I-O
have	O
been	O
reported	O
to	O
be	O
significantly	O
increased	O
when	O
cimetidine	B
is	O
administered	O
concurrently	O
.	O

Avoid	O
concomitant	O
use	O
of	O
ELIQUIS	B-O
with	O
strong	O
dual	B
inducers	I
of	I
CYP3A4	I
and	I
P-gp	I
(	O
e	O
.g.	O
,	O
rifampin	B
,	O
carbamazepine	B
,	O
phenytoin	B
,	O
St	B
.	I
John	I
's	I
wort	I
)	O
because	O
such	O
drugs	O
will	O
decrease	O
exposure	O
to	O
apixaban	B-O
.	O

Drugs	O
metabolized	O
by	O
CYP2C8	O
and	O
OAT3	O
transporters	O
:	O
Monitor	O
patients	O
because	O
teriflunomide	B
may	O
increase	O
exposure	O
of	O
these	O
drugs	O
(	O
7	O
)	O
Teriflunomide	B
may	O
increase	O
exposure	O
of	O
ethinylestradiol	B-O
and	O
levonorgestrel	B-O
.	O

In	O
patients	O
taking	O
AUBAGIO	B
,	O
exposure	O
of	O
drugs	B-O
metabolized	I-O
by	I-O
CYP2C8	I-O
(	O
e	O
.g.	O
,	O
paclitaxel	B-O
,	O
pioglitazone	B-O
,	O
repaglinide	B-O
,	O
rosiglitazone	B-O
)	O
may	O
be	O
increased	O
.	O

Effect	O
of	O
AUBAGIO	B
on	O
oral	O
contraceptives	O
AUBAGIO	B
may	O
increase	O
the	O
systemic	O
exposures	O
of	O
ethinylestradiol	B-O
and	O
levonorgestrel	B-O
.	O

In	O
patients	O
taking	O
AUBAGIO	B
,	O
exposure	O
of	O
drugs	B-O
metabolized	I-O
by	I-O
CYP1A2	I-O
(	O
e	O
.g.	O
,	O
alosetron	B-O
,	O
duloxetine	B-O
,	O
theophylline	B-O
,	O
tizanidine	B-O
)	O
may	O
be	O
reduced	O
.	O

In	O
patients	O
taking	O
AUBAGIO	B
,	O
exposure	O
of	O
drugs	B-O
which	I-O
are	I-O
OAT3	I-O
substrates	I-O
(	O
e	O
.g.	O
,	O
cefaclor	B-O
,	O
cimetidine	B-O
,	O
ciprofloxacin	B-O
,	O
penicillin	B-O
G	I-O
,	O
ketoprofen	B-O
,	O
furosemide	B-O
,	O
methotrexate	B-O
,	O
zidovudine	B-O
)	O
may	O
be	O
increased	O
.	O

For	O
other	O
substrates	B-O
of	I-O
BCRP	I-O
(	O
e	O
.g.	O
,	O
mitoxantrone	B-O
)	O
and	O
drugs	B-O
in	I-O
the	I-O
OATP	I-O
family	I-O
(	O
e	O
.g.	O
,	O
methotrexate	B-O
,	O
rifampin	B-O
)	O
,	O
especially	O
HMG-Co	B-O
reductase	I-O
inhibitors	I-O
(	O
e	O
.g.	O
,	O
atorvastatin	B-O
,	O
nateglinide	B-O
,	O
pravastatin	B-O
,	O
repaglinide	B-O
,	O
and	O
simvastatin	B-O
)	O
,	O
consider	O
reducing	O
the	O
dose	O
of	O
these	O
drugs	O
and	O
monitor	O
patients	O
closely	O
for	O
signs	O
and	O
symptoms	O
of	O
increased	O
exposures	O
to	O
the	O
drugs	O
while	O
patients	O
are	O
taking	I
AUBAGIO.	B

The	O
Potential	O
Effect	O
of	O
AUBAGIO	B
on	O
Other	O
Drugs	O
CYP2C8	O
Substrates	O
There	O
was	O
an	O
increase	O
in	O
mean	O
repaglinide	B-O
Cmax	O
and	O
AUC	O
(	O
1.7-	O
and	O
2.4-fold	O
,	O
respectively	O
)	O
,	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
and	O
a	O
single	O
dose	O
of	O
0.25	O
mg	O
repaglinide	B-O
,	O
suggesting	O
that	O
teriflunomide	B
is	O
an	O
inhibitor	O
of	O
CYP2C8	O
in	O
vivo	O
.	O

CYP1A2	O
Substrates	O
Repeated	O
doses	O
of	O
teriflunomide	B
decreased	O
mean	O
Cmax	O
and	O
AUC	O
of	O
caffeine	B-O
by	O
18	O
%	O
and	O
55	O
%	O
,	O
respectively	O
,	O
suggesting	O
that	O
teriflunomide	B
may	O
be	O
a	O
weak	O
inducer	O
of	O
CYP1A2	O
in	O
vivo	O
.	O

OAT3	O
Substrates	O
There	O
was	O
an	O
increase	O
in	O
mean	O
cefaclor	B-O
Cmax	O
and	O
AUC	O
(	O
1.43-	O
and	O
1.54-fold	O
,	O
respectively	O
)	O
,	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
,	O
suggesting	O
that	O
teriflunomide	B
is	O
an	O
inhibitor	O
of	O
organic	O
anion	O
transporter	O
3	O
(	O
OAT3	O
)	O
in	O
vivo	O
.	O

BCRP	O
and	O
OATP1B1/1B3	O
Substrates	O
There	O
was	O
an	O
increase	O
in	O
mean	O
rosuvastatin	B-O
Cmax	O
and	O
AUC	O
(	O
2.65-	O
and	O
2.51-fold	O
,	O
respectively	O
)	O
,	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
,	O
suggesting	O
that	O
teriflunomide	B
is	O
an	O
inhibitor	O
of	O
BCRP	O
transporter	O
and	O
organic	O
anion	O
transporting	O
polypeptide	O
1B1	O
and	O
1B3	O
(	O
OATP1B1/1B3	O
)	O
.	O

Oral	O
Contraceptives	O
There	O
was	O
an	O
increase	O
in	O
mean	O
ethinylestradiol	B-O
Cmax	O
and	O
AUC	O
(	O
1.58-	O
and	O
1.54-fold	O
,	O
respectively	O
)	O
and	O
levonorgestrel	B-O
Cmax	O
and	O
AUC	O
(	O
1.33-	O
and	O
1.41-fold	O
,	O
respectively	O
)	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
with	O
co-administration	O
of	O
bicalutamide	B
,	O
mean	O
midazolam	B-O
(	O
a	O
CYP3A4	O
substrate	O
)	O
levels	O
may	O
be	O
increased	O
1.5-fold	O
(	O
for	O
C	O
max	O
)	O
and	O
1.9-fold	O
(	O
for	O
AUC)	O
.	O

The	O
plasma	O
concentration	O
of	O
CMI	B-O
has	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
haloperidol	B
;	O
plasma	O
levels	O
of	O
several	O
closely	O
related	O
tricyclic	O
antidepressants	O
have	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
methylphenidate	B
or	O
hepatic	B
enzyme	I
inhibitors	I
(	O
e	O
.g.	O
,	O
cimetidine	B
,	O
fluoxetine	B
)	O
and	O
decreased	O
by	O
the	O
concomitant	O
administration	O
of	O
hepatic	B
enzyme	I
inducers	I
(	O
e	O
.g.	O
,	O
barbiturates	B
,	O
phenytoin	B
)	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B-O
as	O
well	O
.	O

Administration	O
of	O
CMI	B
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
of	O
phenobarbital	B-O
,	O
if	O
given	O
concomitantly	O
.	O

Because	O
clomipramine	B
is	O
highly	O
bound	O
to	O
serum	O
protein	O
,	O
the	O
administration	O
of	O
clomipramine	B
to	O
patients	O
taking	O
other	O
drugs	B-O
that	I-O
are	I-O
highly	I-O
bound	I-O
to	I-O
protein	I-O
(	O
e	O
.g.	O
,	O
warfarin	B-O
,	O
digoxin	B-O
)	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Co-administration	O
of	O
haloperidol	B
with	O
CMI	B-O
increases	O
plasma	O
concentrations	O
of	O
CMI	B-O
.	O

Co-administration	O
of	O
CMI	B
with	O
phenobarbital	B-O
increases	O
plasma	O
concentrations	O
of	O
phenobarbital	B-O
.	O

Cyclosporine	B
:	O
Combination	O
increases	O
rosuvastatin	B-O
exposure	O
.	O

Lopinavir/Ritonavir	B
or	I
atazanavir/ritonavir	B
:	O
Combination	O
increases	O
rosuvastatin	B-O
exposure	O
.	O

Cyclosporine	B
increased	O
rosuvastatin	B-O
exposure	O
(	O
AUC)	O
7-fold	O
.	O

Gemfibrozil	B
significantly	O
increased	O
rosuvastatin	B-O
exposure	O
.	O

The	O
protease	O
inhibitor	O
combinations	I
lopinavir/ritonavir	B
and	I
atazanavir/ritonavir	B
increase	O
rosuvastatin	B-O
exposure	O
(	O
AUC)	O
up	O
to	O
threefold	O
.	O

Concomitant	O
administration	O
of	O
CRESTOR	B-O
with	O
medications	O
that	O
are	O
inhibitors	O
of	O
these	O
transporter	O
proteins	O
(	O
e	O
.g	O
.	O
cyclosporine	B
,	O
certain	O
HIV	B
protease	I
inhibitors	I
)	O
may	O
result	O
in	O
increased	O
rosuvastatin	B-O
plasma	O
concentrations	O
and	O
an	O
increased	O
risk	O
of	O
myopathy	O
.	O

Cimetidine	B
-	O
In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg/day	O
Celexa	B-O
,	O
combined	O
administration	O
of	O
400	O
mg	O
twice	O
a	O
day	O
cimetidine	B
for	O
8	O
days	O
resulted	O
in	O
an	O
increase	O
in	O
citalopram	B-O
AUC	O
and	O
Cmax	O
of	O
43	O
%	O
and	O
39	O
%	O
,	O
respectively	O
.	O

Although	O
trough	O
citalopram	B-O
plasma	O
levels	O
were	O
unaffected	O
,	O
given	O
the	O
enzyme-inducing	O
properties	O
of	O
carbamazepine	B
,	O
the	O
possibility	O
that	O
carbamazepine	B
might	O
increase	O
the	O
clearance	O
of	O
citalopram	B-O
should	O
be	O
considered	O
if	O
the	O
two	O
drugs	O
are	O
coadministered	O
.	O

Ketoconazole	B-O
-	O
Combined	O
administration	O
of	O
Celexa	B
(	O
40	O
mg	O
)	O
and	O
ketoconazole	B-O
(	O
200	O
mg	O
)	O
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
ketoconazole	B-O
by	O
21	O
%	O
and	O
10	O
%	O
,	O
respectively	O
,	O
and	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
citalopram	B
.	O

Metoprolol	B-O
-	O
Administration	O
of	O
40	O
mg/day	O
Celexa	B
for	O
22	O
days	O
resulted	O
in	O
a	O
two-fold	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
the	O
beta-adrenergic	O
blocker	O
metoprolol	B-O
.	O

CYP3A4	O
and	O
CYP2C19	O
inhibitors	O
:	O
Since	O
CYP3A4	O
and	O
CYP2C19	O
are	O
the	O
primary	O
enzymes	O
involved	O
in	O
the	O
metabolism	O
of	O
citalopram	B-O
,	O
it	O
is	O
expected	O
that	O
potent	O
inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
and	O
macrolide	B
antibiotics	I
)	O
and	O
potent	O
inhibitors	B
of	I
CYP2C19	I
(	O
e	O
.g.	O
,	O
omeprazole	B
)	O
might	O
decrease	O
the	O
clearance	O
of	O
citalopram	B-O
.	O

CYP1A2	B
Inhibitors	I
Concomitant	O
use	O
of	O
CLOZARIL	B-O
and	O
CYP1A2	B
inhibitors	I
can	O
increase	O
plasma	O
levels	O
of	O
clozapine	B-O
,	O
potentially	O
resulting	O
in	O
adverse	O
reactions	O
.	O

CYP2D6	O
and	O
CYP3A4	O
Inhibitors	O
Concomitant	O
treatment	O
with	O
CLOZARIL	B-O
and	O
CYP2D6	B
or	I
CYP3A4	I
inhibitors	I
(	O
e	O
.g.	O
,	O
cimetidine	B
,	O
escitalopram	B
,	O
erythromycin	B
,	O
paroxetine	B
,	O
bupropion	B
,	O
fluoxetine	B
,	O
quinidine	B
,	O
duloxetine	B
,	O
terbinafine	B
,	O
or	O
sertraline	B
)	O
can	O
increase	O
clozapine	B-O
levels	O
and	O
lead	O
to	O
adverse	O
reactions	O
.	O

CYP1A2	O
and	O
CYP3A4	O
Inducers	O
Concomitant	O
treatment	O
with	O
drugs	B
that	I
induce	I
CYP1A2	I
or	I
CYP3A4	I
can	O
decrease	O
the	O
plasma	O
concentration	O
of	O
clozapine	B-O
,	O
resulting	O
in	O
decreased	O
effectiveness	O
of	I-O
CLOZARIL.	B-O

After	O
coadministration	O
of	O
fluvoxamine	B
for	O
14	O
days	O
,	O
mean	O
trough	O
concentrations	O
of	O
clozapine	B-O
and	O
its	O
metabolites	O
,	O
N-desmethylclozapine	B-O
and	O
clozapine	B-O
N-oxide	I-O
,	O
were	O
elevated	O
about	O
3-fold	O
compared	O
to	O
baseline	O
steady-state	O
concentrations	O
.	O

However	O
,	O
other	O
published	O
reports	O
describe	O
modest	O
elevations	O
(	O
less	O
than	O
2-fold	O
)	O
of	O
clozapine	B-O
and	O
metabolite	O
concentrations	O
when	O
clozapine	B-O
was	O
taken	O
with	O
paroxetine	B
,	O
fluoxetine	B
,	O
and	O
sertraline	B
.	O

P-gp	B
inducers	I
rifampin	B
:	O
Avoid	O
coadministration	O
with	O
PRADAXA	B-O
(	O
5.5	O
)	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
CrCl	O
30-50	O
mL/min	O
:	O
Reduce	O
dose	O
or	O
avoid	O
(	O
7	O
)	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
CrCl	O
<30	O
mL/min	O
:	O
Not	O
recommended	O
(	O
7	O
)	O
The	O
concomitant	O
use	O
of	O
PRADAXA	B-O
with	O
P-gp	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
)	O
reduces	O
exposure	O
to	O
dabigatran	B-O
and	O
should	O
generally	O
be	O
avoided	O
.	O

Concomitant	O
use	O
of	O
P-gp	B
inhibitors	I
in	O
patients	O
with	O
renal	O
impairment	O
is	O
expected	O
to	O
produce	O
increased	O
exposure	O
of	O
dabigatran	B-O
compared	O
to	O
that	O
seen	O
with	O
either	O
factor	O
alone	O
.	O

Coadministration	O
of	O
PRADAXA	B-O
with	O
a	O
high-fat	B
meal	I
delays	O
the	O
time	O
to	O
Cmax	O
by	O
approximately	O
2	O
hours	O
but	O
has	O
no	O
effect	O
on	O
the	O
bioavailability	O
of	O
dabigatran	B-O
;	O
PRADAXA	B-O
may	O
be	O
administered	O
with	O
or	O
without	O
food	O
.	O

Cimetidine	B
:	O
Serious	O
anticholinergic	O
symptoms	O
(	O
i	O
.e	O
.	O
,	O
severe	O
dry	O
mouth	O
,	O
urinary	O
retention	O
and	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	B-O
antidepressant	I-O
when	O
cimetidine	B
therapy	O
is	O
initiated	O
.	O

Additionally	O
,	O
higher	O
than	O
expected	O
tricyclic	B-O
antidepressant	I-O
levels	O
have	O
been	O
observed	O
when	O
they	O
are	O
begun	O
in	O
patients	O
already	O
taking	O
cimetidine	B
.	O

Potent	O
inhibitors	B
of	I
CYP2D6	I
may	O
increase	O
duloxetine	B-O
concentrations	O
(	O
7.2	O
)	O
.	O

When	O
duloxetine	B-O
60mg	O
was	O
co-administered	O
with	O
fluvoxamine	B
100mg	O
,	O
a	O
potent	O
CYP1A2	O
inhibitor	O
,	O
to	O
male	O
subjects	O
(	O
n=14	O
)	O
duloxetine	B-O
AUC	O
was	O
increased	O
approximately	O
6-fold	O
,	O
the	O
Cmax	O
was	O
increased	O
about	O
2.5-fold	O
,	O
and	O
duloxetine	B-O
t1/2	O
was	O
increased	O
approximately	O
3-fold	O
.	O

Concomitant	O
use	O
of	O
duloxetine	B-O
(	O
40	O
mg	O
once	O
daily	O
)	O
with	O
paroxetine	B
(	O
20	O
mg	O
once	O
daily	O
)	O
increased	O
the	O
concentration	O
of	O
duloxetine	B-O
AUC	O
by	O
about	O
60	O
%	O
,	O
and	O
greater	O
degrees	O
of	O
inhibition	O
are	O
expected	O
with	O
higher	O
doses	O
of	O
paroxetine	B
.	O

Concomitant	O
administration	O
of	O
duloxetine	B-O
40	O
mg	O
twice	O
daily	O
with	O
fluvoxamine	B
100	O
mg	O
,	O
a	O
potent	O
CYP1A2	O
inhibitor	O
,	O
to	O
CYP2D6	O
poor	O
metabolizer	O
subjects	O
(	O
n=14	O
)	O
resulted	O
in	O
a	O
6-fold	O
increase	O
in	O
duloxetine	B-O
AUC	O
and	O
Cmax	O
.	O

Duloxetine	B
is	O
an	O
inhibitor	O
of	O
the	O
CYP1A2	O
isoform	O
in	O
in	O
vitro	O
studies	O
,	O
and	O
in	O
two	O
clinical	O
studies	O
the	O
average	O
(90	O
%	O
confidence	O
interval	O
)	O
increase	O
in	O
theophylline	B-O
AUC	O
was	O
7	O
%	O
(	O
1	O
%	O
to	O
15	O
%	O
)	O
and	O
20	O
%	O
(	O
13	O
%	O
to	O
27	O
%	O
)	O
when	O
co-administered	O
with	O
duloxetine	B
(	O
60	O
mg	O
twice	O
daily	O
)	O
.	O

When	O
duloxetine	B
was	O
administered	O
(	O
at	O
a	O
dose	O
of	O
60	O
mg	O
twice	O
daily	O
)	O
in	O
conjunction	O
with	O
a	O
single	O
50	O
mg	O
dose	O
of	O
desipramine	B-O
,	O
a	O
CYP2D6	O
substrate	O
,	O
the	O
AUC	O
of	O
desipramine	B-O
increased	O
3-fold	O
.	O

Food	B
does	O
not	O
affect	O
the	O
Cmax	O
of	O
duloxetine	B-O
,	O
but	O
delays	O
the	O
time	O
to	O
reach	O
peak	O
concentration	O
from	O
6	O
to	O
10	O
hours	O
and	O
it	O
marginally	O
decreases	O
the	O
extent	O
of	O
absorption	O
(	O
AUC)	O
by	O
about	O
10	O
%	O
.	O

Carbamazepine	B
is	O
an	O
enzyme	O
inducer	O
and	O
typically	O
causes	O
decreases	O
in	O
drug	O
exposure	O
;	O
however	O
,	O
approximately	O
2-fold	O
increased	O
systemic	O
exposure	O
of	O
selegiline	B-O
and	O
its	O
metabolites	O
,	O
L-amphetamine	B-O
and	O
L-methamphetamine	B-O
were	O
seen	O
after	O
single	O
application	O
of	O
EMSAM	B-O
6	O
mg	O
per	O
24	O
hours	O
in	O
subjects	O
who	O
had	O
received	O
carbamazepine	B
(	O
400mg	O
per	O
day	O
)	O
for	O
14	O
days	O
.	O

While	O
no	O
in	O
vivo	O
drug-drug	O
interaction	O
studies	O
were	O
conducted	O
between	O
estazolam	B-O
and	O
inducers	O
of	O
CYP3A	O
,	O
compounds	O
that	O
are	O
potent	O
CYP3A	B
inhibitors	I
(	O
such	O
as	O
carbamazepine	B
,	O
phenytoin	B
,	O
rifampin	B
,	O
and	O
barbiturates	B
)	O
would	O
be	O
expected	O
to	O
decrease	O
estazolam	B-O
concentrations	O
.	O

The	O
following	O
are	O
examples	O
of	O
drugs	O
known	O
to	O
inhibit	O
the	O
metabolism	O
of	O
other	O
related	O
benzodiazepines	B-O
,	O
presumably	O
through	O
inhibition	O
of	O
CYP3A	O
:	O
nefazodone	B
,	O
fluvoxamine	B
,	O
cimetidine	B
,	O
diltiazem	B
,	O
isoniazide	B
,	O
and	O
some	O
macrolide	B
antibiotics	I
.	O

While	O
no	O
in	O
vivo	O
drug-drug	O
interaction	O
studies	O
were	O
conducted	O
between	O
estazolam	B-O
and	O
inhibitors/inducers	O
of	O
CYP3A	O
,	O
compounds	O
that	O
are	O
potent	O
CYP3A	B
inhibitors	I
(	O
such	O
as	O
ketoconazole	B
,	O
itraconazole	B
,	O
nefazodone	B
,	O
fluvoxamine	B
,	O
and	O
erythromycin	B
)	O
would	O
be	O
expected	O
to	O
increase	O
plasma	O
estazolam	B-O
concentrations	O
and	O
CYP3A	B
inducers	I
(	O
such	O
as	O
carbamazepine	B
,	O
phenytoin	B
,	O
rifampin	B
and	O
barbiturates	B
)	O
would	O
be	O
expected	O
to	O
decrease	O
estazolam	B-O
concentrations	O
.	O

Use	O
with	O
ethanol	O
causes	O
additive	O
psychomotor	O
impairment	O
(	O
7.1	O
)	O
Rifampicin	B
:	O
Combination	O
use	O
may	O
decrease	O
exposure	O
and	O
effects	O
of	O
LUNESTA	B-O
(	O
7.2	O
)	O
Ketoconazole	B
:	O
Combination	O
use	O
increases	O
exposure	O
and	O
effect	O
of	I-O
LUNESTA.	B-O

The	O
exposure	O
of	O
eszopiclone	B-O
was	O
increased	O
by	O
coadministration	O
of	O
ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
.	O

Drugs	O
that	O
Induce	O
CYP3A4	O
(	O
Rifampicin	B
)	O
Racemic	B-O
zopiclone	I-O
exposure	O
was	O
decreased	O
80	O
%	O
by	O
concomitant	O
use	O
of	O
rifampicin	B
,	O
a	O
potent	O
inducer	O
of	O
CYP3A4	O
.	O

Combination	O
use	O
with	O
CYP3A4	B
inducer	I
may	O
decrease	O
the	O
exposure	O
and	O
effects	O
of	I-O
LUNESTA.	B-O

Effect	O
of	O
Food	O
In	O
healthy	O
adults	O
,	O
administration	O
of	O
a	O
3	O
mg	O
dose	O
of	O
eszopiclone	B-O
after	O
a	O
high-fat	B
meal	I
resulted	O
in	O
no	O
change	O
in	O
AUC	O
,	O
a	O
reduction	O
in	O
mean	O
Cmax	O
of	O
21	O
%	O
,	O
and	O
delayed	O
tmax	O
by	O
approximately	O
1	O
hour	O
.	O

Coadministration	O
of	O
eszopiclone	B-O
3	O
mg	O
to	O
subjects	O
receiving	O
ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
400mg	O
daily	O
for	O
5	O
days	O
,	O
resulted	O
in	O
a	O
2.2-fold	O
increase	O
in	O
exposure	O
to	O
eszopiclone	B-O
.	O

Inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
)	O
or	O
CYP2D6	O
(	O
e	O
.g.	O
,	O
fluoxetine	B
,	O
paroxetine	B
)	O
can	O
inhibit	O
iloperidone	B-O
elimination	O
and	O
cause	O
increased	O
blood	O
levels	O
.	O

Ketoconazole	B
:	O
Co-administration	O
of	O
ketoconazole	B
(	O
200	O
mg	O
twice	O
daily	O
for	O
4	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
with	O
a	O
3	O
mg	O
single	O
dose	O
of	O
iloperidone	B-O
to	O
19	O
healthy	O
volunteers	O
,	O
ages	O
18	O
to	O
45	O
years	O
,	O
increased	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC)	O
of	O
iloperidone	B-O
and	O
its	O
metabolites	O
P88	B-O
and	O
P95	B-O
by	O
57	O
%	O
,	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

Fluoxetine	B
:	O
Co-administration	O
of	O
fluoxetine	B
(	O
20	O
mg	O
twice	O
daily	O
for	O
21	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
with	O
a	O
single	O
3	O
mg	O
dose	O
of	O
iloperidone	B-O
to	O
23	O
healthy	O
volunteers	O
,	O
ages	O
29	O
to	O
44	O
years	O
,	O
who	O
were	O
classified	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
,	O
increased	O
the	O
AUC	O
of	O
iloperidone	B-O
and	O
its	O
metabolite	O
P88	B-O
,	O
by	O
about	O
2-	O
to	O
3-fold	O
,	O
and	O
decreased	O
the	O
AUC	O
of	O
its	O
metabolite	O
P95	B-O
by	O
one-half	O
.	O

Paroxetine	B
:	O
Co-administration	O
of	O
paroxetine	B
(	O
20	O
mg/day	O
for	O
5-8	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
with	O
multiple	O
doses	O
of	O
iloperidone	B-O
(	O
8	O
or	O
12	O
mg	O
twice	O
daily	O
)	O
to	O
patients	O
with	O
schizophrenia	O
ages	O
18-65	O
resulted	O
in	O
increased	O
mean	O
steady-state	O
peak	O
concentrations	O
of	O
iloperidone	B-O
and	O
its	O
metabolite	O
P88	B-O
,	O
by	O
about	O
1.6	O
fold	O
,	O
and	O
decreased	O
mean	O
steady-state	O
peak	O
concentrations	O
of	O
its	O
metabolite	O
P95	B-O
by	O
one-half	O
.	O

Paroxetine	B
and	O
Ketoconazole	B
:	O
Co-administration	O
of	O
paroxetine	B
(	O
20	O
mg	O
once	O
daily	O
for	O
10	O
days	O
)	O
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
and	O
ketoconazole	B
(	O
200	O
mg	O
twice	O
daily	O
)	O
with	O
multiple	O
doses	O
of	O
iloperidone	B-O
(	O
8	O
or	O
12	O
mg	O
twice	O
daily	O
)	O
to	O
patients	O
with	O
schizophrenia	O
ages	O
18-65	O
resulted	O
in	O
a	O
1.4	O
fold	O
increase	O
in	O
steady-state	O
concentrations	O
of	O
iloperidone	B-O
and	O
its	O
metabolite	O
P88	B-O
and	O
a	O
1.4	O
fold	O
decrease	O
in	O
the	O
P95	B-O
in	O
the	O
presence	O
of	O
paroxetine	B
.	O

Dextromethorphan	B-O
:	O
A	O
study	O
in	O
healthy	O
volunteers	O
showed	O
that	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
dextromethorphan	B-O
(	O
80	O
mg	O
dose	O
)	O
when	O
a	O
3	O
mg	O
dose	O
of	O
iloperidone	B
was	O
co-administered	O
resulted	O
in	O
a	O
17	O
%	O
increase	O
in	O
total	O
exposure	O
and	O
a	O
26	O
%	O
increase	O
in	O
the	O
maximum	O
plasma	O
concentrations	O
(	O
Cmax	O
)of	O
dextromethorphan	B-O
.	O

Midazolam	B-O
(	O
a	O
sensitive	O
CYP3A4	O
substrate	O
)	O
:	O
A	O
study	O
in	O
patients	O
with	O
schizophrenia	O
showed	O
a	O
less	O
than	O
50	O
%	O
increase	O
in	O
midazolam	B-O
total	O
exposure	O
at	O
iloperidone	B
steady	O
state	O
(	O
14	O
days	O
of	O
oral	O
dosing	O
at	O
up	O
to	O
10	O
mg	O
iloperidone	B
twice	O
daily	O
)	O
and	O
no	O
effect	O
on	O
midazolam	B-O
Cmax	O
.	O

Administration	O
of	O
iloperidone	B-O
with	O
a	O
standard	O
high-fat	B
meal	I
did	O
not	O
significantly	O
affect	O
the	O
Cmax	O
or	O
AUC	O
of	O
iloperidone	B-O
,	O
P88	B-O
,	O
or	O
P95	B-O
,	O
but	O
delayed	O
Tmax	O
by	O
1	O
hour	O
for	O
iloperidone	B-O
,	O
2	O
hours	O
for	O
P88	B-O
and	O
6	O
hours	O
for	O
P95	B-O
.	O

Co-administration	O
of	O
FANAPT	O
with	O
known	O
strong	O
inhibitors	O
of	O
CYP2D6	O
like	O
fluoxetine	B
results	O
in	O
a	O
2.3-fold	O
increase	O
in	O
iloperidone	O
plasma	O
exposure	O
,	O
and	O
therefore	O
one-half	O
of	O
the	O
FANAPT	O
dose	O
should	O
be	O
administered	O
.	O

Co-administration	O
of	O
FANAPT	B-O
with	O
known	O
strong	O
inhibitors	O
of	O
CYP2D6	O
like	O
fluoxetine	O
results	O
in	O
a	O
2.3-fold	O
increase	O
in	O
iloperidone	B-O
plasma	O
exposure	O
,	O
andtherefore	O
one-half	O
of	O
the	O
FANAPT	B-O
dose	O
should	O
be	O
administered	O
.	O

An	O
in	O
vivo	O
study	O
showed	O
a	O
clinically	O
meaningful	O
increase	O
in	O
levomilnacipran	B-O
exposure	O
when	O
FETZIMA	B-O
was	O
co-administered	O
with	O
the	O
CYP3A4	O
inhibitor	O
ketoconazole	B
.	O

Cyclosporine	B
:	O
Combination	O
increases	O
fluvastatin	B-O
exposure	O
.	O

Limit	O
fluvastatin	B-O
dose	O
to	O
20	O
mg	O
(	O
2.4	O
,	O
7.1	O
)	O
Fluconazole	B
:	O
Combination	O
increases	O
fluvastatin	B-O
exposure	O
.	O

Caution	O
should	O
be	O
used	O
when	O
prescribing	O
with	O
fluvastatin	B-O
(	O
5.1	O
,	O
7.3	O
,	O
7.4)	O
Glyburide	O
:	O
Monitor	O
blood	O
glucose	O
levels	O
when	O
fluvastatin	B-O
dose	O
is	O
changed	O
(	O
7	O
)	O
Phenytoin	O
:	O
Monitor	O
plasma	O
phenytoin	O
levels	O
when	O
fluvastatin	B-O
treatment	O
is	O
initiated	O
or	O
when	O
the	O
dosage	O
is	O
changed	O
(	O
7	O
)	O
Warfarin	O
and	O
coumarin	O
derivates	O
:	O
Monitor	O
prothrombin	O
times	O
when	O
fluvastatin	B-O
coadministration	O
is	O
initiated	O
,	O
discontinued	O
,	O
or	O
the	O
dosage	O
changed	O
(	O
7	O
)	O
Cyclosporine	B
coadministration	O
increases	O
fluvastatin	B-O
exposure	O
.	O

Administration	O
of	O
fluvastatin	B-O
40	O
mg	O
single	O
dose	O
to	O
healthy	O
volunteers	O
pre-treated	O
with	O
fluconazole	B
for	O
4	O
days	O
results	O
in	O
an	O
increase	O
of	O
fluvastatin	B-O
exposure	O
.	O

Concomitant	O
administration	O
of	O
fluvastatin	B
and	O
glyburide	B-O
increased	O
glyburide	B-O
exposures	O
.	O

Concomitant	O
administration	O
of	O
fluvastatin	B
and	O
phenytoin	B-O
increased	O
phenytoin	B-O
exposures	O
.	O

Elevated	O
carbamazepine	B-O
levels	O
and	O
symptoms	O
of	O
toxicity	O
have	O
been	O
reported	O
with	O
the	O
coadministration	O
of	O
fluvoxamine	B
maleate	I
and	O
carbamazepine	B-O
.	O

In	O
a	O
study	O
of	O
13	O
healthy	O
,	O
male	O
volunteers	O
,	O
a	O
single	O
40	O
mg	O
dose	O
of	O
tacrine	B-O
added	O
to	O
fluvoxamine	B
100	O
mg/day	O
administered	O
at	O
steady-state	O
was	O
associated	O
with	O
5-	O
and	O
8-fold	O
increases	O
in	O
tacrine	B-O
Cmax	O
and	O
AUC	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
administration	O
of	O
tacrine	B-O
alone	O
.	O

Caution	O
is	O
indicated	O
with	O
the	O
coadministration	O
of	O
fluvoxamine	B
maleate	I
tablets	O
and	I-O
TCAs	B-O
;	O
plasma	O
TCA	B-O
concentrations	O
may	O
need	O
to	O
be	O
monitored	O
,	O
and	O
the	O
dose	O
of	O
TCA	B-O
may	O
need	O
to	O
be	O
reduced	O
.	O

Coadministration	O
of	O
fluvoxamine	B
maleate	I
100	O
mg	O
per	O
day	O
and	O
propranolol	B-O
160	O
mg	O
per	O
day	O
in	O
normal	O
volunteers	O
resulted	O
in	O
a	O
mean	O
five-fold	O
increase	O
(	O
range	O
2	O
to	O
17	O
)	O
in	O
minimum	O
propranolol	B-O
plasma	O
concentrations	O
.	O

The	O
blood	O
levels	O
of	O
fingolimod	B-O
and	I-O
fingolimod-phosphate	B-O
are	O
increased	O
by	O
1.7-fold	O
when	O
used	O
concomitantly	O
with	O
ketoconazole	B
.	O

Drug	O
Interactions	O
Ketoconazole	B
The	O
coadministration	O
of	O
ketoconazole	B
(	O
a	O
potent	O
inhibitor	O
of	O
CYP3A	O
and	O
CYP4F	O
)	O
200	O
mg	O
twice-daily	O
at	O
steady-state	O
and	O
a	O
single	O
dose	O
of	O
fingolimod	B-O
5	O
mg	O
led	O
to	O
a	O
70	O
%	O
increase	O
in	O
AUC	O
of	O
fingolimod	B-O
and	I-O
fingolimod-phosphate	B-O
.	O

Carbamazepine	B
The	O
coadministration	O
of	O
carbamazepine	B
(	O
a	O
potent	O
CYP450	O
enzyme	O
inducer	O
)	O
600	O
mg	O
twice-daily	O
at	O
steady-state	O
and	O
a	O
single	O
dose	O
of	O
fingolimod	B-O
2	O
mg	O
decreased	O
blood	O
concentrations	O
(	O
AUC)	O
of	O
fingolimod	B-O
and	I-O
fingolimod-phosphate	B-O
by	O
approximately	O
40	O
%	O
.	O

Other	O
strong	O
CYP450	B
enzyme	I
inducers	I
,	O
e.g.	O
,	O
rifampicin	B
,	O
phenytoin	B
,	O
phenobarbital	B
,	O
and	O
St	B
.	I
John	I
's	I
wort	I
,	O
may	O
also	O
reduce	O
AUC	O
of	O
fingolimod	B-O
and	I-O
fingolimod-phosphate	B-O
.	O

Coadministration	O
of	O
isoniazid	B
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
triazolam	B-O
by	O
20	O
%	O
,	O
decreased	O
clearance	O
by	O
42	O
%	O
,	O
and	O
increased	O
half-life	O
by	O
31	O
%	O
.	O

Coadministration	O
of	O
grapefruit	B
juice	I
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
triazolam	B-O
by	O
25	O
%	O
,	O
increased	O
the	O
area	O
under	O
the	O
concentration	O
curve	O
by	O
48	O
%	O
,	O
and	O
increased	O
half-life	O
by	O
18	O
%	O
.	O

Coadministration	O
of	O
ranitidine	B
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
triazolam	B-O
by	O
30	O
%	O
,	O
increased	O
the	O
area	O
under	O
the	O
concentration	O
curve	O
by	O
27	O
%	O
,	O
and	O
increased	O
half-life	O
by	O
3.3	O
%	O
.	O

Coadministration	O
of	O
HARVONI	B
with	O
digoxin	B-O
may	O
increase	O
the	O
concentration	O
of	O
digoxin	B-O
.	O

Anticonvulsants	O
:	O
carbamazepine	B
phenytoin	B
phenobarbital	B
oxcarbazepine	B
,	O
ledipasvir	B-O
,	O
sofosbuvir	B-O
.	O
GS-331007	O
Coadministration	O
of	O
HARVONI	B-O
with	O
carbamazepine	B
,	O
phenytoin	B
,	O
phenobarbital	B
,	O
or	O
oxcarbazepine	B
is	O
expected	O
to	O
decrease	O
the	O
concentration	O
of	O
ledipasvir	B-O
and	O
sofosbuvir	B-O
,	O
leading	O
to	O
reduced	O
therapeutic	O
effect	O
of	I-O
HARVONI.	B-O

Antimycobacterials	O
:	O
rifabutin	B
,	O
rifampin	O
,	O
rifapentine	B
,	O
ledipasvir	B-O
,	O
sofosbuvir	B-O
.	O
GS-331007	O
Coadministration	O
of	O
HARVONI	B-O
with	O
rifabutin	B
or	O
rifapentine	B
is	O
expected	O
to	O
decrease	O
the	O
concentration	O
of	O
ledipasvir	B-O
and	O
sofosbuvir	B-O
,	O
leading	O
to	O
reduced	O
therapeutic	O
effect	O
of	I-O
HARVONI.	B-O

Refer	O
to	O
VIREAD	O
or	O
TRUVADA	O
prescribing	O
information	O
for	O
recommendations	O
on	O
renal	O
monitoring	O
.	O
elvitegravir	O
,	O
cobicistat	O
,	O
emtricitabine	O
,	O
tenofovir	O
DF.	O
tenofovir	O
The	O
safety	O
of	O
increased	O
tenofovir	O
concentrations	O
in	O
the	O
setting	O
of	O
HARVONI	B-O
and	O
the	O
combination	O
of	O
elvitegravir	O
,	O
cobicistat	O
,	O
emtricitabine	O
and	O
tenofovir	O
DF	O
has	O
not	O
been	O
established	O
.	I
tipranavir/ritonavir	B
,	O
ledipasvir	B-O
,	O
sofosbuvir	B-O
.	O
GS-331007	O
Coadministration	O
of	O
HARVONI	B-O
with	I
tipranavir/ritonavir	B
is	O
expected	O
to	O
decrease	O
the	O
concentration	O
of	O
ledipasvir	B-O
and	O
sofosbuvir	B-O
,	O
leading	O
to	O
reduced	O
therapeutic	O
effect	O
of	I-O
HARVONI.	B-O

HMG-CoA	O
Reductase	O
Inhibitors	O
:	O
rosuvastatin	B-O
.	O
Coadministration	O
of	O
HARVONI	B
with	O
rosuvastatin	B-O
may	O
significantly	O
increase	O
the	O
concentration	O
of	O
rosuvastatin	B-O
which	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
myopathy	O
,	O
including	O
rhabdomyolysis	O
.	O

Effect	O
of	O
Food	O
Relative	O
to	O
fasting	O
conditions	O
,	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
HARVONI	B-O
with	O
a	O
moderate	O
fat	O
(	O
~600	O
kcal	O
,	O
25	O
%	O
to	O
30	O
%	O
fat	O
)	O
or	O
high	O
fat	O
(	O
~1000	O
kcal	O
,	O
50	O
%	O
fat	O
)	O
meal	B
increased	O
sofosbuvir	B-O
AUC0-inf	O
by	O
approximately	O
2-fold	O
,	O
but	O
did	O
not	O
significantly	O
affect	O
sofosbuvir	B-O
Cmax	O
.	O

P-gp	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
or	O
St	B
.	I
John	I
's	I
wort	I
)	O
may	O
decrease	O
ledipasvir	B-O
and	O
sofosbuvir	B-O
plasma	O
concentrations	O
,	O
leading	O
to	O
reduced	O
therapeutic	O
effect	O
of	O
HARVONI	B-O
,	O
and	O
the	O
use	O
with	O
P-gp	B
inducers	I
is	O
not	O
recommended	O
with	I-O
HARVONI.	B-O

Therefore	O
,	O
tenofovir	B-O
exposure	O
is	O
approximately	O
130	O
%	O
higher	O
when	O
administered	O
as	O
tenofovir	B-O
DF	O
+	I
atazanavir/ritonavir	B
+	O
HARVONI	B
or	O
tenofovir	B-O
DF	O
+	I
darunavir/ritonavir	B
+	O
HARVONI	B
and	O
with	O
food	B
as	O
compared	O
to	O
the	O
tenofovir	B-O
exposure	O
observed	O
following	O
fasted	O
administration	O
of	O
tenofovir	B-O
DF-based	O
regimens	O
that	O
do	O
not	O
contain	O
an	O
HIV	O
PI/ritonavir	B
and	I
HARVONI.	B

Co-administration	O
of	O
divalproex	B
sodium	I
increased	O
Cmax	O
and	O
AUC	O
of	O
paliperidone	B-O
by	O
approximately	O
50	O
%	O
.	O

Co-administration	O
of	O
INVEGA	B-O
6	O
mg	O
once	O
daily	O
with	O
carbamazepine	B
,	O
a	O
strong	O
inducer	O
of	O
both	O
CYP3A4	O
and	O
P-glycoprotein	O
(P-gp	O
)	O
,	O
at	O
200	O
mg	O
twice	O
daily	O
caused	O
a	O
decrease	O
of	O
approximately	O
37	O
%	O
in	O
the	O
mean	O
steady-state	O
Cmax	O
and	O
AUC	O
of	O
paliperidone	B-O
.	O

In	O
an	O
interaction	O
study	O
in	O
healthy	O
subjects	O
in	O
which	O
a	O
single	O
3	O
mg	O
dose	O
of	O
INVEGA	B-O
was	O
administered	O
concomitantly	O
with	O
20	O
mg	O
per	O
day	O
of	O
paroxetine	B
(	O
a	O
potent	O
CYP2D6	O
inhibitor	O
)	O
,	O
paliperidone	B-O
exposures	O
were	O
on	O
average	O
16	O
%	O
(90	O
%	O
CI	O
:	O
4	O
,	O
30	O
)	O
higher	O
in	O
CYP2D6	O
extensive	O
metabolizers	O
.	O

Co-administration	O
of	O
a	O
single	O
dose	O
of	O
INVEGA	B-O
12	O
mg	O
with	O
divalproex	B
sodium	I
extended-release	O
tablets	O
(	O
two	O
500	O
mg	O
tablets	O
once	O
daily	O
)	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
50	O
%	O
in	O
the	O
Cmax	O
and	O
AUC	O
of	O
paliperidone	B-O
.	O

Administration	O
of	O
a	O
12	O
mg	O
paliperidone	B-O
extended-release	O
tablet	O
to	O
healthy	O
ambulatory	O
subjects	O
with	O
a	O
standard	O
high-fat/high-caloric	B
meal	I
gave	O
mean	O
Cmax	O
and	O
AUC	O
values	O
of	O
paliperidone	B-O
that	O
were	O
increased	O
by	O
60	O
%	O
and	O
54	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
administration	O
under	O
fasting	O
conditions	O
.	O

While	O
INVEGA	B-O
can	O
be	O
taken	O
without	O
regard	O
to	O
food	B
,	O
the	O
presence	O
of	O
food	B
at	O
the	O
time	O
of	O
INVEGA	B-O
administration	O
may	O
increase	O
exposure	O
to	O
paliperidone	B-O
.	O

Inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
)	O
or	O
CYP2D6	O
(	O
e	O
.g.	O
,	O
fluoxetine	B
,	O
paroxetine	B
)	O
can	O
inhibit	O
iloperidone	B-O
elimination	O
and	O
cause	O
increased	O
blood	O
levels	O
.	O

Ketoconazole	B
:	O
Co-administration	O
of	O
ketoconazole	B
(	O
200	O
mg	O
twice	O
daily	O
for	O
4	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
with	O
a	O
3	O
mg	O
single	O
dose	O
of	O
iloperidone	B-O
to	O
19	O
healthy	O
volunteers	O
,	O
ages	O
18	O
to	O
45	O
years	O
,	O
increased	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC)	O
of	O
iloperidone	B-O
and	O
its	O
metabolites	O
P88	B-O
and	O
P95	B-O
by	O
57	O
%	O
,	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

Fluoxetine	B
:	O
Co-administration	O
of	O
fluoxetine	B
(	O
20	O
mg	O
twice	O
daily	O
for	O
21	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
with	O
a	O
single	O
3	O
mg	O
dose	O
of	O
iloperidone	B-O
to	O
23	O
healthy	O
volunteers	O
,	O
ages	O
29	O
to	O
44	O
years	O
,	O
who	O
were	O
classified	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
,	O
increased	O
the	O
AUC	O
of	O
iloperidone	B-O
and	O
its	O
metabolite	O
P88	B-O
,	O
by	O
about	O
2-	O
to	O
3-fold	O
,	O
and	O
decreased	O
the	O
AUC	O
of	O
its	O
metabolite	O
P95	B-O
by	O
one-half	O
.	O

Paroxetine	B
:	O
Co-administration	O
of	O
paroxetine	B
(	O
20	O
mg/day	O
for	O
5	O
to	O
8	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
with	O
multiple	O
doses	O
of	O
iloperidone	B-O
(	O
8	O
or	O
12	O
mg	O
twice	O
daily	O
)	O
to	O
patients	O
with	O
schizophrenia	O
ages	O
18	O
to	O
65	O
years	O
resulted	O
in	O
increased	O
mean	O
steady-state	O
peak	O
concentrations	O
of	O
iloperidone	B-O
and	O
its	O
metabolite	O
P88	B-O
,	O
by	O
about	O
1.6-fold	O
,	O
and	O
decreased	O
mean	O
steady-state	O
peak	O
concentrations	O
of	O
its	O
metabolite	O
P95	B-O
by	O
one-half	O
.	O

Paroxetine	B
and	O
Ketoconazole	B
:	O
Co-administration	O
of	O
paroxetine	B
(	O
20	O
mg	O
once	O
daily	O
for	O
10	O
days	O
)	O
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
and	O
ketoconazole	B
(	O
200	O
mg	O
twice	O
daily	O
)	O
with	O
multiple	O
doses	O
of	O
iloperidone	B-O
(	O
8	O
or	O
12	O
mg	O
twice	O
daily	O
)	O
to	O
patients	O
with	O
schizophrenia	O
ages	O
18	O
to	O
65	O
years	O
resulted	O
in	O
a	O
1.4-fold	O
increase	O
in	O
steady-state	O
concentrations	O
of	O
iloperidone	B-O
and	O
its	O
metabolite	O
P88	B-O
and	O
a	O
1.4-fold	O
decrease	O
in	O
the	O
P95	B-O
in	O
the	O
presence	O
of	O
paroxetine	B
.	O

Dextromethorphan	B-O
:	O
A	O
study	O
in	O
healthy	O
volunteers	O
showed	O
that	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
dextromethorphan	B-O
(	O
80	O
mg	O
dose	O
)	O
when	O
a	O
3	O
mg	O
dose	O
of	O
iloperidone	B
was	O
co-administered	O
resulted	O
in	O
a	O
17	O
%	O
increase	O
in	O
total	O
exposure	O
and	O
a	O
26	O
%	O
increase	O
in	O
the	O
maximum	O
plasma	O
concentrations	O
(	O
Cmax	O
)of	O
dextromethorphan	B-O
.	O

Midazolam	B-O
(	O
a	O
sensitive	O
CYP3A4	O
substrate	O
)	O
:	O
A	O
study	O
in	O
patients	O
with	O
schizophrenia	O
showed	O
a	O
less	O
than	O
50	O
%	O
increase	O
in	O
midazolam	B-O
total	O
exposure	O
at	O
iloperidone	B
steady	O
state	O
(	O
14	O
days	O
of	O
oral	O
dosing	O
at	O
up	O
to	O
10	O
mg	O
iloperidone	B
twice	O
daily	O
)	O
and	O
no	O
effect	O
on	O
midazolam	B-O
Cmax	O
.	O

Administration	O
of	O
iloperidone	B-O
with	O
a	O
standard	O
high-fat	B
meal	I
did	O
not	O
significantly	O
affect	O
the	O
Cmax	O
or	O
AUC	O
of	O
iloperidone	B-O
,	O
P88	B-O
,	O
or	O
P95	B-O
,	O
but	O
delayed	O
Tmax	O
by	O
1	O
hour	O
for	O
iloperidone	B-O
,	O
2	O
hours	O
for	O
P88	B-O
and	O
6	O
hours	O
for	O
P95	B-O
.	O

Co-administration	O
of	O
FANAPT	B-O
with	O
known	O
strong	O
inhibitors	B
of	I
CYP2D6	I
like	O
fluoxetine	B
results	O
in	O
a	O
2.3-fold	O
increase	O
in	O
iloperidone	B-O
plasma	O
exposure	O
,	O
andtherefore	O
one-half	O
of	O
the	O
FANAPT	B-O
dose	O
should	O
be	O
administered	O
.	O

The	O
plasma	O
concentration	O
of	O
imipramine	B-O
may	O
increase	O
when	O
the	O
drug	O
is	O
given	O
concomitantly	O
with	O
hepatic	B
enzyme	I
inhibitors	I
(	O
e	O
.g.	O
,	O
cimetidine	B
,	O
fluoxetine	B
)	O
and	O
decrease	O
by	O
concomitant	O
administration	O
with	O
hepatic	B
enzyme	I
inducers	I
(	O
e	O
.g.	O
,	O
barbiturates	B
,	O
phenytoin	B
)	O
,	O
and	O
adjustment	O
of	O
the	O
dosage	O
of	O
imipramine	B-O
may	O
therefore	O
be	O
necessary	O
.	O

In	O
a	O
study	O
to	O
assess	O
the	O
effects	O
of	O
terbinafine	B
on	O
desipramine	B-O
in	O
healthy	O
volunteers	O
characterized	O
as	O
normal	O
metabolizers	O
,	O
the	O
administration	O
of	O
terbinafine	B
resulted	O
in	O
a	O
2-fold	O
increase	O
in	O
Cmax	O
and	O
a	O
5-fold	O
increase	O
in	O
area	O
under	O
the	O
curve	O
(	O
AUC)	O
.	O

Terbinafine	B
decreases	O
the	O
clearance	O
of	O
caffeine	B-O
by	O
19	O
%	O
.	O

Terbinafine	B
increases	O
the	O
clearance	O
of	O
cyclosporine	B-O
by	O
15	O
%	O
.	O

Coadministration	O
of	O
a	O
single	O
dose	O
of	O
fluconazole	B
(	O
100	O
mg	O
)	O
with	O
a	O
single	O
dose	O
of	O
terbinafine	B-O
resulted	O
in	O
a	O
52	O
%	O
and	O
69	O
%	O
increase	O
in	O
terbinafine	B-O
Cmax	O
and	O
AUC	O
,	O
respectively	O
.	O

Based	O
on	O
this	O
finding	O
,	O
it	O
is	O
likely	O
that	O
other	O
inhibitors	B
of	I
both	I
CYP2C9	I
and	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
,	O
amiodarone	B
)	O
may	O
also	O
lead	O
to	O
a	O
substantial	O
increase	O
in	O
the	O
systemic	O
exposure	O
(	O
Cmax	O
and	O
AUC)	O
of	O
terbinafine	B-O
when	O
concomitantly	O
administered	O
.	O

Terbinafine	B-O
clearance	O
is	O
increased	O
100	O
%	O
by	O
rifampin	B
,	O
a	O
CYP450	O
enzyme	O
inducer	O
,	O
and	O
decreased	O
33	O
%	O
by	O
cimetidine	B
,	O
a	O
CYP450	O
enzyme	O
inhibitor	O
.	O

An	O
increase	O
of	O
less	O
than	O
20	O
%	O
of	O
the	O
AUC	O
of	O
terbinafine	B-O
was	O
observed	O
when	O
LAMISIL	B-O
Tablets	O
were	O
administered	O
with	O
food	B
.	O

Table	O
34	O
:	O
Clinically	O
Important	O
Drug	O
Interactions	O
with	O
LATUDA	B-O
Strong	O
CYP3A4	B
Inhibitors	I
Clinical	O
Impact	O
:	O
Concomitant	O
use	O
of	O
LATUDA	B-O
with	O
strong	O
CYP3A4	B
inhibitors	I
increased	O
the	O
exposure	O
of	O
lurasidone	B-O
compared	O
to	O
the	O
use	O
of	O
LATUDA	B-O
alone	O
.	O

Examples	O
:	O
Ketoconazole	O
,	O
clarithromycin	O
,	O
ritonavir	O
,	O
voriconazole	O
,	O
mibefradil	O
Moderate	O
CYP3A4	B
Inhibitors	I
Clinical	O
Impact	O
:	O
Concomitant	O
use	O
of	O
LATUDA	B-O
with	O
moderate	O
CYP3A4	B
inhibitors	I
increased	O
the	O
exposure	O
of	O
lurasidone	B-O
compared	O
to	O
the	O
use	O
of	O
LATUDA	B-O
alone	O
.	O

Examples	O
:	O
Diltiazem	O
,	O
atazanavir	O
,	O
erythromycin	O
,	O
fluconazole	O
,	O
verapamil	O
Strong	O
CYP3A4	B
Inducers	I
Clinical	O
Impact	O
:	O
Concomitant	O
use	O
of	O
LATUDA	B-O
with	O
strong	O
CYP3A4	B
inducers	I
decreased	O
the	O
exposure	O
of	O
lurasidone	B-O
compared	O
to	O
the	O
use	O
of	O
LATUDA	B-O
alone	O
.	O

Examples	O
:	O
Rifampin	O
,	O
avasimibe	O
,	O
St	O
.	O
John	O
's	O
wort	O
,	O
phenytoin	O
,	O
carbamazepine	O
Moderate	O
CYP3A4	B
Inducers	I
Clinical	O
Impact	O
:	O
Concomitant	O
use	O
of	O
LATUDA	B-O
with	O
moderate	O
CYP3A4	B
inducers	I
decreased	O
the	O
exposure	O
of	O
lurasidone	B-O
compared	O
to	O
the	O
use	O
of	O
LATUDA	B-O
alone	O
.	O

In	O
a	O
food	B
effect	O
study	O
,	O
LATUDA	B-O
mean	O
Cmax	O
and	O
AUC	O
were	O
about	O
3-times	O
and	O
2-times	O
,	O
respectively	O
,	O
when	O
administered	O
with	O
food	B
compared	O
to	O
the	O
levels	O
observed	O
under	O
fasting	O
conditions	O
.	O

Concomitant	O
administration	O
of	O
LIPITOR	B-O
with	O
strong	O
inhibitors	B
of	I
CYP3A4	I
can	O
lead	O
to	O
increases	O
in	O
plasma	O
concentrations	O
of	O
atorvastatin	B-O
.	O

Clarithromycin	B
Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
LIPITOR	B-O
80	O
mg	O
with	O
clarithromycin	B
(	O
500	O
mg	O
twice	O
daily	O
)	O
compared	O
to	O
that	O
of	O
LIPITOR	B-O
alone	O
.	O

Combination	O
of	O
Protease	O
Inhibitors	O
:	O
Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
LIPITOR	B-O
with	O
several	O
combinations	O
of	O
HIV	B
protease	I
inhibitors	I
,	O
as	O
well	O
as	O
with	O
the	O
hepatitis	O
C	O
protease	O
inhibitor	O
telaprevir	B
,	O
compared	O
to	O
that	O
of	O
LIPITOR	B-O
alone	O
.	O

Itraconazole	B
Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
LIPITOR	B-O
40	O
mg	O
and	O
itraconazole	B
200	O
mg	O
.	O

Inhibitors	B
of	I
the	I
OATP1B1	I
(	O
e	O
.g.	O
,	O
cyclosporine	B
)	O
can	O
increase	O
the	O
bioavailability	O
of	O
atorvastatin	B-O
.	O

Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
LIPITOR	B-O
10	O
mg	O
and	O
cyclosporine	B
5.2	O
mg/kg/day	O
compared	O
to	O
that	O
of	O
LIPITOR	B-O
alone	O
.	O

Concomitant	O
administration	O
of	O
LIPITOR	B-O
with	O
inducers	B
of	I
cytochrome	I
P450	I
3A4	I
(	O
e	O
.g.	O
,	O
efavirenz	B
,	O
rifampin	B
)	O
can	O
lead	O
to	O
variable	O
reductions	O
in	O
plasma	O
concentrations	O
of	O
atorvastatin	B-O
.	O

Due	O
to	O
the	O
dual	O
interaction	O
mechanism	O
of	O
rifampin	B
,	O
simultaneous	O
co-administration	O
of	O
LIPITOR	B-O
with	O
rifampin	B
is	O
recommended	O
,	O
as	O
delayed	O
administration	O
of	O
LIPITOR	B-O
after	O
administration	O
of	O
rifampin	B
has	O
been	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
atorvastatin	B-O
plasma	O
concentrations	O
.	O

When	O
multiple	O
doses	O
of	O
LIPITOR	B
and	O
digoxin	B-O
were	O
co-administered	O
,	O
steady	O
state	O
plasma	O
digoxin	B-O
concentrations	O
increased	O
by	O
approximately	O
20	O
%	O
.	O

In	O
vitro	O
studies	O
suggest	O
the	O
importance	O
of	O
LIPITOR	B-O
metabolism	O
by	O
cytochrome	O
P450	O
3A4	O
,	O
consistent	O
with	O
increased	O
plasma	O
concentrations	O
of	O
LIPITOR	B-O
in	O
humans	O
following	O
co-administration	O
with	O
erythromycin	B
,	O
a	O
known	O
inhibitor	O
of	O
this	O
isozyme	O
.	O

Due	O
to	O
the	O
dual	O
interaction	O
mechanism	O
of	O
rifampin	B
,	O
simultaneous	O
co-administration	O
of	O
atorvastatin	B-O
with	O
rifampin	B
is	O
recommended	O
,	O
as	O
delayed	O
administration	O
of	O
atorvastatin	B-O
after	O
administration	O
of	O
rifampin	B
has	O
been	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
atorvastatin	B-O
plasma	O
concentrations	O
.	O

Erythromycin	B
:	O
Combination	O
increases	O
pitavastatin	B-O
exposure	O
.	O

Limit	O
LIVALO	B-O
to	O
1	O
mg	O
once	O
daily	O
(	O
2.3	O
,	O
7.2	O
)	O
Rifampin	B
:	O
Combination	O
increases	O
pitavastatin	B-O
exposure	O
.	O

Cyclosporine	B
significantly	O
increased	O
pitavastatin	B-O
exposure	O
.	O

Erythromycin	B
significantly	O
increased	O
pitavastatin	B-O
exposure	O
.	O

Rifampin	B
significantly	O
increased	O
pitavastatin	B-O
exposure	O
.	O

Administration	O
of	O
LIVALO	B-O
with	O
a	O
high	B
fat	I
meal	I
(	O
50	O
%	O
fat	O
content	O
)	O
decreases	O
pitavastatin	B-O
Cmax	O
by	O
43	O
%	O
but	O
does	O
not	O
significantly	O
reduce	O
pitavastatin	B-O
AUC.	O

Strong	O
inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
itraconazole	B
,	O
ketoconazole	B
,	O
posaconazole	B
,	O
voriconazole	B
,	O
clarithromycin	B
,	O
telithromycin	B
,	O
HIV	B
protease	I
inhibitors	I
,	O
boceprevir	B
,	O
telaprevir	B
,	O
nefazodone	B
,	O
erythromycin	B
,	O
and	O
cobicistat-containing	B
products	I
)	O
,	O
and	O
grapefruit	B
juice	I
increase	O
the	O
risk	O
of	O
myopathy	O
by	O
reducing	O
the	O
elimination	O
of	O
lovastatin	B-O
.	O

Although	O
the	O
mechanism	O
is	O
not	O
fully	O
understood	O
,	O
cyclosporine	B
has	O
been	O
shown	O
to	O
increase	O
the	O
AUC	O
of	O
HMG-CoA	B-O
reductase	I-O
inhibitors	I-O
.	O

This	O
regimen	O
of	O
grapefruit	B
juice	I
resulted	O
in	O
a	O
mean	O
increase	O
in	O
the	O
serum	O
concentration	O
of	O
lovastatin	B-O
and	O
its	O
hydroxyacid	O
metabolite	O
(	O
as	O
measured	O
by	O
the	O
area	O
under	O
the	O
concentration-time	O
curve	O
)	O
of	O
15-fold	O
and	O
5-fold	O
,	O
respectively	O
[as	O
measured	O
using	O
a	O
chemical	O
assay	O
high	O
performance	O
liquid	O
chromatography]	O
.	O

Because	O
of	O
the	O
pharmacologic	O
similarity	O
of	O
maprotiline	B-O
hydrochloride	O
to	O
the	O
tricyclic	B
antidepressants	I
,	O
the	O
plasma	O
concentration	O
of	O
maprotiline	B-O
may	O
be	O
increased	O
when	O
the	O
drug	O
is	O
given	O
concomitantly	O
with	O
hepatic	B
enzyme	I
inhibitors	I
(	O
e	O
.g.	O
,	O
cimetidine	B
,	O
fluoxetine	B
)	O
and	O
decreased	O
by	O
concomitant	O
administration	O
with	O
hepatic	B
enzyme	I
inducers	I
(	O
e	O
.g.	O
,	O
barbiturates	B
,	O
phenytoin	B
)	O
,	O
as	O
has	O
occurred	O
with	O
tricyclic	B
antidepressants	I
.	O

In	O
patients	O
treated	O
with	O
potent	O
inducers	B
of	I
CYP3A4	I
(	O
i	O
.e	O
.	O
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
and	O
rifampin	B
)	O
,	O
the	O
clearance	O
of	O
ondansetron	B-O
was	O
significantly	O
increased	O
and	O
ondansetron	B-O
blood	O
concentrations	O
were	O
decreased	O
.	O

Concurrent	O
administration	O
of	O
cimetidine	B
and	O
tricyclic	B-O
antidepressants	I-O
can	O
produce	O
clinically	O
significant	O
increases	O
in	O
the	O
plasma	O
concentrations	O
of	O
the	O
tricyclic	O
antidepressant	O
.	O

In	O
a	O
controlled	O
study	O
of	O
healthy	O
volunteers	O
,	O
after	O
paroxetine	B
was	O
titrated	O
to	O
60	O
mg	O
daily	O
,	O
co-administration	O
of	O
a	O
single	O
dose	O
of	O
2	O
mg	O
pimozide	B-O
was	O
associated	O
with	O
mean	O
increases	O
in	O
pimozide	B-O
AUC	O
of	O
151	O
%	O
and	O
Cmax	O
of	O
62	O
%	O
,	O
compared	O
to	O
pimozide	B-O
administered	O
alone	O
.	O

The	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
Cmax	O
is	O
due	O
to	O
the	O
CYP2D6	O
inhibitory	O
properties	O
of	O
paroxetine	B
.	O

In	O
a	O
study	O
where	O
paroxetine	B-O
(	O
30	O
mg	O
once	O
daily	O
)	O
was	O
dosed	O
orally	O
for	O
4	O
weeks	O
,	O
steady-state	O
plasma	O
concentrations	O
of	O
paroxetine	B-O
were	O
increased	O
by	O
approximately	O
50	O
%	O
during	O
coadministration	O
with	O
oral	O
cimetidine	B
(	O
300	O
mg	O
three	O
times	O
daily	O
)	O
for	O
the	O
final	O
week	O
.	O

When	O
a	O
single	O
oral	O
30	O
mg	O
dose	O
of	O
paroxetine	B-O
was	O
administered	O
at	O
phenobarbital	B
steady	O
state	O
(	O
100	O
mg	O
once	O
daily	O
for	O
14	O
days	O
)	O
,	O
paroxetine	B-O
AUC	O
and	O
T-1/2	O
were	O
reduced	O
(	O
by	O
an	O
average	O
of	O
25	O
%	O
and	O
38	O
%	O
,	O
respectively	O
)	O
compared	O
to	O
paroxetine	B-O
administered	O
alone	O
.	O

When	O
a	O
single	O
oral	O
30-mg	O
dose	O
of	O
paroxetine	B-O
was	O
administered	O
at	O
phenytoin	B
steady	O
state	O
(	O
300mg	O
once	O
daily	O
for	O
14days	O
)	O
,	O
paroxetine	B-O
AUC	O
and	O
T-1/2	O
were	O
reduced	O
(	O
by	O
an	O
average	O
of	O
50	O
%	O
and	O
35	O
%	O
,	O
respectively	O
)	O
compared	O
to	O
paroxetine	B-O
administered	O
alone	O
.	O

In	O
a	O
separate	O
study	O
,	O
when	O
a	O
single	O
oral	O
300	O
mg	O
dose	O
of	O
phenytoin	B-O
was	O
administered	O
at	O
paroxetine	B
steady	O
state	O
(	O
30	O
mg	O
once	O
daily	O
for	O
14	O
days	O
)	O
,	O
phenytoin	B-O
AUC	O
was	O
slightly	O
reduced	O
(	O
12	O
%	O
on	O
average	O
)	O
compared	O
to	O
phenytoin	B-O
administered	O
alone	O
.	O

In	O
1	O
study	O
,	O
daily	O
dosing	O
of	O
paroxetine	B
(	O
20	O
mg	O
once	O
daily	O
)	O
under	O
steady-state	O
conditions	O
increased	O
single	O
dose	O
desipramine	B-O
(	O
100	O
mg	O
)	O
Cmax	O
,	O
AUC	O
,	O
and	O
T-1/2	O
by	O
an	O
average	O
of	O
approximately	O
2-,	O
5-,	O
and	O
3-fold	O
,	O
respectively	O
.	O

In	O
1	O
study	O
,	O
daily	O
dosing	O
of	O
paroxetine	B
20	O
mg	O
in	O
patients	O
stabilized	O
on	O
risperidone	B-O
(	O
4	O
to	O
8	O
mg/day	O
)	O
increased	O
mean	O
plasma	O
concentrations	O
of	O
risperidone	B-O
approximately	O
4-fold	O
,	O
decreased	O
9-hydroxyrisperidone	B-O
concentrations	O
approximately	O
10	O
%	O
,	O
and	O
increased	O
concentrations	O
of	O
the	O
active	O
moiety	O
(	O
the	O
sum	O
of	O
risperidone	B-O
plus	O
9-hydroxyrisperidone	B-O
)	O
approximately	O
1.4-fold	O
.	O

Inhibition	O
of	O
CYP2D6	O
by	O
paroxetine	B
may	O
lead	O
to	O
reduced	O
plasma	O
concentrations	O
of	O
an	O
active	O
metabolite	O
(	O
endoxifen	B-O
)	O
and	O
hence	O
reduced	O
efficacy	O
of	O
tamoxifen	O
.	O

Caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
tricyclic	B-O
antidepressants	I-O
(TCAs	O
)	O
with	O
paroxetine	B
,	O
because	O
paroxetine	B
may	O
inhibit	O
TCA	O
metabolism	O
.	O

Mean	O
digoxin	B-O
AUC	O
at	O
steady	O
state	O
decreased	O
by	O
15	O
%	O
in	O
the	O
presence	O
of	O
paroxetine	B
.	O

Daily	O
oral	O
dosing	O
of	O
paroxetine	B
(	O
30mg	O
once	O
daily	O
)	O
increased	O
steady-state	O
AUC0-24	O
,	O
Cmax	O
,	O
and	O
Cmin	O
values	O
of	O
procyclidine	B-O
(	O
5mg	O
oral	O
once	O
daily	O
)	O
by	O
35	O
%	O
,	O
37	O
%	O
and	O
67	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
procyclidine	B-O
alone	O
at	O
steady	O
state	O
.	O

Reports	O
of	O
elevated	O
theophylline	B-O
levels	O
associated	O
with	O
treatment	O
with	O
paroxetine	B
have	O
been	O
reported	O
.	O

Co-administration	O
of	O
fosamprenavir/ritonavir	B
with	O
paroxetine	B-O
significantly	O
decreased	O
plasma	O
levels	O
of	O
paroxetine	B-O
.	O

Clinical	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
substrates	O
of	O
CYP2D6	O
and	O
show	O
that	O
paroxetine	B
can	O
inhibit	O
the	O
metabolism	O
of	O
drugs	B-O
metabolized	I-O
by	I-O
CYP2D6	I-O
including	O
desipramine	B-O
,	O
risperidone	B-O
,	O
and	O
atomoxetine	B-O
.	O

Pimozide	B-O
In	O
a	O
controlled	O
study	O
of	O
healthy	O
volunteers	O
,	O
after	O
paroxetine	B
was	O
titrated	O
to	O
60	O
mg	O
daily	O
,	O
coadministration	O
of	O
a	O
single	O
dose	O
of	O
2	O
mg	O
pimozide	B-O
was	O
associated	O
with	O
mean	O
increases	O
in	O
pimozide	B-O
AUC	O
of	O
151	O
%	O
and	O
Cmax	O
of	O
62	O
%	O
,	O
compared	O
to	O
pimozide	B-O
administered	O
alone	O
.	O

The	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
Cmax	O
is	O
due	O
to	O
the	O
CYP2D6	O
inhibitory	O
properties	O
of	O
paroxetine	B
.	O

In	O
a	O
study	O
where	O
paroxetine	B-O
(	O
30	O
mg	O
once	O
daily	O
)	O
was	O
dosed	O
orally	O
for	O
4	O
weeks	O
,	O
steady-state	O
plasma	O
concentrations	O
of	O
paroxetine	B-O
were	O
increased	O
by	O
approximately	O
50	O
%	O
during	O
coadministration	O
with	O
oral	O
cimetidine	B
(	O
300	O
mg	O
three	O
times	O
daily	O
)	O
for	O
the	O
final	O
week	O
.	O

When	O
a	O
single	O
oral	O
30	O
mg	O
dose	O
of	O
paroxetine	B-O
was	O
administered	O
at	O
phenobarbital	B
steady	O
state	O
(	O
100	O
mg	O
once	O
daily	O
for	O
14	O
days	O
)	O
,	O
paroxetine	B-O
AUC	O
and	O
T-1/2	O
were	O
reduced	O
(	O
by	O
an	O
average	O
of	O
25	O
%	O
and	O
38	O
%	O
,	O
respectively	O
)	O
compared	O
to	O
paroxetine	B-O
administered	O
alone	O
.	O

Phenytoin	B
When	O
a	O
single	O
oral	O
30	O
mg	O
dose	O
of	O
paroxetine	B-O
was	O
administered	O
at	O
phenytoin	B
steady	O
state	O
(	O
300	O
mg	O
once	O
daily	O
for	O
14	O
days	O
)	O
,	O
paroxetine	B-O
AUC	O
and	O
T-1/2	O
were	O
reduced	O
(	O
by	O
an	O
average	O
of	O
50	O
%	O
and	O
35	O
%	O
,	O
respectively	O
)	O
compared	O
to	O
paroxetine	B-O
administered	O
alone	O
.	O

In	O
a	O
separate	O
study	O
,	O
when	O
a	O
single	O
oral	O
300	O
mg	O
dose	O
of	O
phenytoin	B-O
was	O
administered	O
at	O
paroxetine	B
steady	O
state	O
(	O
30	O
mg	O
once	O
daily	O
for	O
14	O
days	O
)	O
,	O
phenytoin	B-O
AUC	O
was	O
slightly	O
reduced	O
(	O
12	O
%	O
on	O
average	O
)	O
compared	O
to	O
phenytoin	B-O
administered	O
alone	O
.	O

In	O
1	O
study	O
,	O
daily	O
dosing	O
of	O
paroxetine	B
(	O
20	O
mg	O
once	O
daily	O
)	O
under	O
steady-state	O
conditions	O
increased	O
single	O
dose	O
desipramine	B-O
(	O
100	O
mg	O
)	O
Cmax	O
,	O
AUC	O
,	O
and	O
T-1/2	O
by	O
an	O
average	O
of	O
approximately	O
2-,	O
5-,	O
and	O
3-fold	O
,	O
respectively	O
.	O

In	O
1	O
study	O
,	O
daily	O
dosing	O
of	O
paroxetine	B
20	O
mg	O
in	O
patients	O
stabilized	O
on	O
risperidone	B-O
(	O
4	O
to	O
8	O
mg/day	O
)	O
increased	O
mean	O
plasma	O
concentrations	O
of	O
risperidone	B-O
approximately	O
4-fold	O
,	O
decreased	O
9-hydroxyrisperidone	B-O
concentrations	O
approximately	O
10	O
%	O
,	O
and	O
increased	O
concentrations	O
of	O
the	O
active	O
moiety	O
(	O
the	O
sum	O
of	O
risperidone	B-O
plus	O
9-hydroxyrisperidone	B-O
)	O
approximately	O
1.4-fold	O
.	O

Caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
tricyclic	B-O
antidepressants	I-O
(TCAs	O
)	O
with	O
paroxetine	B
,	O
because	O
paroxetine	B
may	O
inhibit	O
TCA	O
metabolism	O
.	O

Mean	O
digoxin	B-O
AUC	O
at	O
steady	O
state	O
decreased	O
by	O
15	O
%	O
in	O
the	O
presence	O
of	O
paroxetine	B
.	O

Procyclidine	B-O
Daily	O
oral	O
dosing	O
of	O
paroxetine	B
(	O
30	O
mg	O
once	O
daily	O
)	O
increased	O
steady-state	O
AUC0-24	O
,	O
Cmax	O
,	O
and	O
Cmin	O
values	O
of	O
procyclidine	B-O
(	O
5	O
mg	O
oral	O
once	O
daily	O
)	O
by	O
35	O
%	O
,	O
37	O
%	O
,	O
and	O
67	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
procyclidine	B-O
alone	O
at	O
steady	O
state	O
.	O

Theophylline	B-O
Reports	O
of	O
elevated	O
theophylline	B-O
levels	O
associated	O
with	O
treatment	O
with	O
paroxetine	B
have	O
been	O
reported	O
.	O

Fosamprenavir/Ritonavir	B
Coadministration	O
of	I
fosamprenavir/ritonavir	B
with	O
paroxetine	B-O
significantly	O
decreased	O
plasma	O
levels	O
of	O
paroxetine	B-O
.	O

Clinical	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
substrates	O
of	O
CYP2D6	O
and	O
show	O
that	O
paroxetine	B
can	O
inhibit	O
the	O
metabolism	O
of	O
drugs	B-O
metabolized	I-O
by	I-O
CYP2D6	I-O
including	O
desipramine	B-O
,	O
risperidone	B-O
,	O
and	O
atomoxetine	B-O
.	O

Probenecid	B
blocks	O
the	O
renal	O
tubular	O
secretion	O
of	O
penicillin	B-O
.	O

Therefore	O
,	O
the	O
concurrent	O
administration	O
of	O
probenecid	B
prolongs	O
the	O
elimination	O
of	O
penicillin	B-O
G	I-O
and	O
,	O
consequently	O
,	O
increases	O
the	O
serum	O
concentrations	O
.	O

CYP2D6	O
inhibitors	O
:	O
In	O
healthy	O
subjects	O
,	O
co-administration	O
of	O
pimozide	B-O
2	O
mg	O
(	O
single	O
dose	O
)	O
and	O
paroxetine	B
60	O
mg	O
resulted	O
in	O
a	O
151	O
%	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
a	O
62	O
%	O
increase	O
in	O
pimozide	B-O
Cmax	O
compared	O
to	O
pimozide	B-O
administered	O
alone	O
.	O

The	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
Cmax	O
is	O
related	O
to	O
the	O
CYP2D6	O
inhibitory	O
properties	O
of	O
paroxetine	B
.	O

Interaction	O
with	O
Food	O
Patients	O
should	O
avoid	O
grapefruit	B
juice	I
because	O
it	O
may	O
inhibit	O
the	O
metabolism	O
of	O
pimozide	B-O
by	O
CYP3A4	O
.	O

Other	O
macrolides	B
(	O
e	O
.g.	O
,	O
erythromycin	B
and	O
azithromycin	B
)	O
have	O
the	O
potential	O
to	O
increase	O
statin	B-O
exposures	O
while	O
used	O
in	O
combination	O
.	O

The	O
concomitant	O
use	O
of	O
PRISTIQ	B-O
with	O
other	I-O
desvenlafaxine-containing	B-O
products	I
or	O
venlafaxine	B
will	O
increase	O
desvenlafaxine	B-O
blood	O
levels	O
and	O
increase	O
dose-related	O
adverse	O
reactions	O
.	O

A	O
food-effect	O
study	O
involving	O
administration	O
of	O
PRISTIQ	B-O
to	O
healthy	O
subjects	O
under	O
fasting	O
and	O
fed	O
conditions	O
(	O
high-fat	B
meal	I
,	O
800	O
to	O
1000	O
calories	O
)	O
indicated	O
that	O
desvenlafaxine	B
Cmax	O
was	O
increased	O
about	O
16	O
%	O
in	O
the	O
fed	O
state	O
,	O
while	O
the	O
AUCs	O
were	O
similar	O
.	O

In	O
a	O
clinical	O
study	O
,	O
ketoconazole	B
(	O
200	O
mg	O
BID	O
)	O
increased	O
the	O
area	O
under	O
the	O
concentration	O
vs.	O
time	O
curve	O
(	O
AUC)	O
of	O
desvenlafaxine	B-O
(	O
400	O
mg	O
single	O
dose	O
)	O
by	O
about	O
43	O
%	O
and	O
Cmax	O
by	O
about	O
8	O
%	O
.	O

Concomitant	O
use	O
of	O
desvenlafaxine	B-O
with	O
potent	O
inhibitors	B
of	I
CYP3A4	I
may	O
result	O
in	O
higher	O
concentrations	O
of	O
desvenlafaxine	B-O
.	O

When	O
desvenlafaxine	B
succinate	I
was	O
administered	O
at	O
a	O
dose	O
of	O
100	O
mg	O
daily	O
in	O
conjunction	O
with	O
a	O
single	O
50	O
mg	O
dose	O
of	O
desipramine	B-O
,	O
a	O
CYP2D6	O
substrate	O
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
desipramine	B-O
increased	O
approximately	O
25	O
%	O
and	O
17	O
%	O
,	O
respectively	O
.	O

Fluoxetine	B
can	O
increase	O
the	O
level	O
of	O
pimozide	B-O
through	O
inhibition	O
of	O
CYP2D6	O
.	O

Thus	O
,	O
this	O
study	O
suggests	O
that	O
drugs	B
which	I
inhibit	I
CYP2D6	I
,	O
such	O
as	O
certain	O
SSRIs	O
,	O
including	O
fluoxetine	B
,	O
will	O
produce	O
elevated	O
plasma	O
levels	O
of	O
thioridazine	B-O
.	O

This	O
risk	O
is	O
expected	O
to	O
increase	O
with	I
fluoxetine-induced	B
inhibition	O
of	O
thioridazine	B-O
metabolism	O
.	O

Tricyclic	O
Antidepressants	O
(TCAs	O
)	O
In	O
2studies	O
,	O
previously	O
stable	O
plasma	O
levels	O
of	O
imipramine	B-O
and	O
desipramine	B-O
have	O
increased	O
greater	O
than	O
2-	O
to	O
10-fold	O
when	O
fluoxetine	B
has	O
been	O
administered	O
in	O
combination	O
.	O

Coadministration	O
of	O
alprazolam	B-O
and	O
fluoxetine	B
has	O
resulted	O
in	O
increased	O
alprazolam	B-O
plasma	O
concentrations	O
and	O
in	O
further	O
psychomotor	O
performance	O
decrement	O
due	O
to	O
increased	O
alprazolam	B-O
levels	O
.	O

Elevation	O
of	O
blood	O
levels	O
of	O
haloperidol	B-O
and	O
clozapine	B-O
has	O
been	O
observed	O
in	O
patients	O
receiving	O
concomitant	O
fluoxetine	B
.	O

Anticonvulsants	O
Patients	O
on	O
stable	O
doses	O
of	O
phenytoin	B-O
and	O
carbamazepine	B-O
have	O
developed	O
elevated	O
plasma	O
anticonvulsant	O
concentrations	O
and	O
clinical	O
anticonvulsant	O
toxicity	O
following	O
initiation	O
of	O
concomitant	O
fluoxetine	B
treatment	O
.	O

Lithium	B-O
There	O
have	O
been	O
reports	O
of	O
both	O
increased	O
and	O
decreased	O
lithium	B-O
levels	O
when	O
lithium	B-O
was	O
used	O
concomitantly	O
with	O
fluoxetine	B
.	O

Olanzapine	B-O
Fluoxetine	B
(60mg	O
single	O
dose	O
or	O
60	O
mg	O
daily	O
dose	O
for	O
8	O
days	O
)	O
causes	O
a	O
small	O
(	O
mean	O
16	O
%	O
)	O
increase	O
in	O
the	O
maximum	O
concentration	O
of	O
olanzapine	B-O
and	O
a	O
small	O
(	O
mean	O
16	O
%	O
)	O
decrease	O
in	O
olanzapine	B-O
clearance	O
.	O

Concomitant	O
treatment	O
with	O
CYP2D6	B
inhibitors	I
can	O
increase	O
the	O
concentration	O
of	I-O
PROZAC.	B-O

Concomitant	O
use	O
of	O
other	O
highly	B
protein-bound	I
drugs	I
can	O
increase	O
the	O
concentration	O
of	I-O
PROZAC.	B-O

Food	B
does	O
not	O
appear	O
to	O
affect	O
the	O
systemic	O
bioavailability	O
of	O
fluoxetine	B-O
,	O
although	O
it	O
may	O
delay	O
its	O
absorption	O
by	O
1	O
to	O
2	O
hours	O
,	O
which	O
is	O
probably	O
not	O
clinically	O
significant	O
.	O

Quetiapine	B-O
exposure	O
is	O
increased	O
by	O
the	O
prototype	O
CYP3A4	B
inhibitors	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
indinavir	B
,	O
ritonavir	B
,	O
nefazodone	B
,	O
etc	O
.	O
and	O
decreased	O
by	O
the	O
prototype	O
CYP3A4	B
inducers	I
(	O
e	O
..g	O
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
rifampin	B
,	O
avasimibe	B
,	O
St	B
.	I
John	I
's	I
wort	I
etc	O
.	O

CYP3A4	O
inhibitors	O
:Coadministration	O
of	O
ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
cytochrome	O
CYP3A4	O
,	O
resulted	O
in	O
significant	O
increase	O
in	O
quetiapine	B-O
exposure	O
.	O

CYP3A4	O
inducers	O
:Coadministration	O
of	O
quetiapine	B-O
and	O
phenytoin	B
,	O
a	O
CYP3A4	O
inducer	O
increased	O
the	O
mean	O
oral	O
clearance	O
of	O
quetiapine	B-O
by	O
5-fold	O
.	O

The	O
bioavailability	O
of	O
quetiapine	B-O
is	O
marginally	O
affected	O
by	O
administration	O
with	O
food	B
,	O
with	O
Cmax	O
and	O
AUC	O
values	O
increased	O
by	O
25	O
%	O
and	O
15	O
%	O
,	O
respectively	O
.	O

In	O
healthy	O
male	O
patients	O
(	O
n=24	O
)	O
,	O
carbamazepine	B
(	O
400	O
mg	O
b.i.d	O
.	O
)	O
clearance	O
about	O
2-fold	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
average	O
plasma	O
mirtazapine	B-O
concentrations	O
of	O
60	O
%	O
.	O

In	O
healthy	O
male	O
patients	O
(	O
n=12	O
)	O
,	O
when	O
cimetidine	B
,	O
a	O
weak	O
inhibitor	O
of	O
CYP1A2	O
,	O
CYP2D6	O
,	O
and	O
CYP3A4	O
,	O
given	O
at	O
800	O
mg	O
b.i.d	O
.	O
at	O
steady	O
state	O
was	O
coadministered	O
with	O
mirtazapine	B-O
(	O
30	O
mg	O
daily	O
)	O
at	O
steady	O
state	O
,	O
the	O
Area	O
Under	O
the	O
Curve	O
(	O
AUC)	O
of	O
mirtazapine	B-O
increased	O
more	O
than	O
50	O
%	O
.	O

In	O
healthy	O
,	O
male	O
,	O
Caucasian	O
patients	O
(	O
n=24	O
)	O
,	O
coadministration	O
of	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	B
(	O
200	O
mg	O
b.i.d	O
.	O
for	O
6.5	O
days	O
)	O
increased	O
the	O
peak	O
plasma	O
levels	O
and	O
the	O
AUC	O
of	O
a	O
single	O
30-mg	O
dose	O
of	O
mirtazapine	B-O
by	O
approximately	O
40	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Absorption	O
of	O
rifampin	B-O
is	O
reduced	O
by	O
about	O
30	O
%	O
when	O
the	O
drug	O
is	O
ingested	O
with	O
food	B
.	O

Carbamazepine	B
and	O
other	O
enzyme	B
inducers	I
decrease	O
plasma	O
concentrations	O
of	O
risperidone	B-O
.	O

Fluoxetine	B
,	O
paroxetine	B
,	O
and	O
other	O
CYP2D6	B
enzyme	I
inhibitors	I
increase	O
plasma	O
concentrations	O
of	O
risperidone	B-O
.	O

However	O
,	O
there	O
was	O
a	O
20	O
%	O
increase	O
in	O
valproate	B-O
peak	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
after	O
concomitant	O
administration	O
of	O
risperidone	B
.	O

Clozapine	B
Chronic	O
administration	O
of	O
clozapine	B
with	O
risperidone	B-O
may	O
decrease	O
the	O
clearance	O
of	O
risperidone	B-O
.	O

Second	O
,	O
co-administration	O
of	O
known	O
enzyme	B
inducers	I
(	O
e	O
.g.	O
,	O
carbamazepine	B
,	O
phenytoin	B
,	O
rifampin	B
,	O
and	O
phenobarbital	B
)	O
with	O
risperidone	B-O
may	O
cause	O
a	O
decrease	O
in	O
the	O
combined	O
plasma	O
concentrations	O
of	O
risperidone	B-O
and	O
9-hydroxyrisperidone	B-O
.	O

Full	O
therapeutic	O
dose	O
of	O
fluvoxamine	B
is	O
expected	O
to	O
cause	O
a	O
greater	O
increase	O
in	O
asenapine	B-O
exposure	O
.	O

CYP2D6	O
substrates	O
and	O
inhibitors	O
(	O
e	O
.g.	O
,	O
paroxetine	B-O
)	O
SAPHRIS	B
may	O
enhance	O
the	O
inhibitory	O
effects	O
of	O
paroxetine	B-O
on	O
its	O
own	O
metabolism	O
.	O

Concomitant	O
use	O
of	O
paroxetine	B-O
with	O
SAPHRIS	B
increased	O
the	O
paroxetine	B-O
exposure	O
by	O
2-fold	O
as	O
compared	O
to	O
use	O
paroxetine	B-O
alone	O
.	O

The	O
intake	O
of	O
water	B
several	O
(	O
2	O
or	O
5	O
)	O
minutes	O
after	O
asenapine	B-O
administration	O
resulted	O
in	O
decreased	O
asenapine	B-O
exposure	O
.	O

Consumption	O
of	O
food	B
immediately	O
prior	O
to	O
sublingual	O
administration	O
decreased	O
asenapine	B-O
exposure	O
by	O
20	O
%	O
;	O
consumption	O
of	O
food	B
4	O
hours	O
after	O
sublingual	O
administration	O
decreased	O
asenapine	B-O
exposure	O
by	O
about	O
10	O
%	O
.	O

Reduced	O
exposure	O
to	O
asenapine	B-O
was	O
observed	O
following	O
water	B
administration	O
at	O
2	O
minutes	O
(	O
19	O
%	O
decrease	O
)	O
and	O
5	O
minutes	O
(	O
10	O
%	O
decrease	O
)	O
.	O

Coadministration	O
of	O
paroxetine	B-O
with	O
SAPHRIS	B
caused	O
a	O
two-fold	O
increase	O
in	O
the	O
maximum	O
plasma	O
concentrations	O
and	O
systemic	O
exposure	O
of	O
paroxetine	B-O
.	O

Asenapine	B
enhances	O
the	O
inhibitory	O
effects	O
of	O
paroxetine	B-O
on	O
its	O
own	O
metabolism	O
by	O
CYP2D6	O
.	O

Cimetidine	B
In	O
a	O
study	O
assessing	O
disposition	O
of	O
Sertraline	B-O
hydrochloride	I-O
(	O
100	O
mg	O
)	O
on	O
the	O
second	O
of	O
8	O
days	O
of	O
cimetidine	B
administration	O
(	O
800	O
mg	O
daily	O
)	O
,	O
there	O
were	O
increases	O
in	O
Sertraline	B-O
hydrochloride	I-O
mean	O
AUC	O
(	O
50	O
%	O
)	O
,	O
Cmax	O
(	O
24	O
%	O
)	O
and	O
half-life	O
(	O
26	O
%	O
)	O
compared	O
to	O
the	O
placebo	O
group	O
.	O

There	O
was	O
a	O
23	O
%	O
increase	O
in	O
Tmax	O
for	O
desmethyldiazepam	B-O
in	O
the	O
sertraline	B
hydrochloride	I
group	O
compared	O
to	O
a	O
20	O
%	O
decrease	O
in	O
the	O
placebo	O
group	O
(	O
p	O
<	O
0.03	O
)	O
.	O

In	O
a	O
controlled	O
study	O
of	O
a	O
single	O
dose	O
(	O
2	O
mg	O
)	O
of	O
pimozide	B-O
,	O
200	O
mg	O
sertraline	B
(	O
q.d	O
.	O
)	O
co-administration	O
to	O
steady	O
state	O
was	O
associated	O
with	O
a	O
mean	O
increase	O
in	O
pimozide	B-O
AUC	O
and	O
Cmax	O
of	O
about	O
40	O
%	O
,	O
but	O
was	O
not	O
associated	O
with	O
any	O
changes	O
in	O
EKG.	O

Results	O
of	O
the	O
interaction	O
study	O
with	O
cisapride	B-O
indicate	O
that	O
sertraline	B
200	O
mg	O
(	O
q.d	O
.	O
)	O
induces	O
the	O
metabolism	O
of	O
cisapride	B-O
(	O
cisapride	B-O
AUC	O
and	O
Cmax	O
were	O
reduced	O
by	O
about	O
35	O
%	O
)	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co-administration	O
of	I-O
TCAs	B-O
with	O
sertraline	B
hydrochloride	I
,	O
because	O
sertraline	O
may	O
inhibit	O
TCA	B-O
metabolism	O
.	O

Hypoglycemic	O
Drugs	O
-	O
In	O
a	O
placebo-controlled	O
trial	O
in	O
normal	O
volunteers	O
,	O
administration	O
of	O
sertraline	B
for	O
22	O
days	O
(	O
including	O
200	O
mg/day	O
for	O
the	O
final	O
13	O
days	O
)	O
caused	O
a	O
statistically	O
significant	O
16	O
%	O
decrease	O
from	O
baseline	O
in	O
the	O
clearance	O
of	O
tolbutamide	B-O
following	O
an	O
intravenous	O
1000	O
mg	O
dose	O
.	O

Sertraline	B
hydrochloride	I
administration	O
did	O
not	O
noticeably	O
change	O
either	O
the	O
plasma	O
protein	O
binding	O
or	O
the	O
apparent	O
volume	O
of	O
distribution	O
of	O
tolbutamide	B-O
,	O
suggesting	O
that	O
the	O
decreased	O
clearance	O
was	O
due	O
to	O
a	O
change	O
in	O
the	O
metabolism	O
of	O
the	O
drug	O
.	O

In	O
clinical	O
studies	O
,	O
sertraline	B
hydrochloride	I
was	O
shown	O
to	O
induce	O
hepatic	O
enzymes	O
minimally	O
as	O
determined	O
by	O
a	O
small	O
(	O
5	O
%	O
)	O
but	O
statistically	O
significant	O
decrease	O
in	O
antipyrine	B-O
half-life	O
following	O
administration	O
of	O
200	O
mg/day	O
for	O
21	O
days	O
.	O

Reduced	O
cytochrome	O
P450	O
2D6	O
isozyme	O
activity	O
,	O
drugs	O
which	O
inhibit	O
this	O
isozyme	O
(	O
e	O
.g.	O
,	O
fluoxetine	B
and	O
paroxetine	B
)	O
,	O
and	O
certain	O
other	O
drugs	O
(	O
e	O
.g.	O
,	O
fluvoxamine	B
,	O
propranolol	B
,	O
and	O
pindolol	B
)	O
appear	O
to	O
appreciably	O
inhibit	O
the	O
metabolism	O
of	O
thioridazine	B-O
.	O

Concentrations	O
of	O
thioridazine	B-O
and	O
its	O
two	O
active	O
metabolites	O
,	O
mesoridazine	B-O
and	O
sulforidazine	B-O
,	O
increased	O
3-fold	O
following	O
coadministration	O
of	O
fluvoxamine	B
.	O

Concurrent	O
administration	O
of	O
propranolol	B
(	O
100	O
to	O
800	O
mg	O
daily	O
)	O
has	O
been	O
reported	O
to	O
produce	O
increases	O
in	O
plasma	O
levels	O
of	O
thioridazine	B-O
(	O
approximately	O
50	O
%	O
to	O
400	O
%	O
)	O
and	O
its	O
metabolites	O
(	O
approximately	O
80	O
%	O
to	O
300	O
%	O
)	O
.	O

Hepatic	B
microsomal	I
enzyme	I
inducing	I
agents	I
,	O
such	O
as	O
carbamazepine	B
,	O
were	O
found	O
to	O
significantly	O
increase	O
the	O
clearance	O
of	O
thiothixene	B-O
.	O

Drugs	O
metabolized	O
by	O
CYP2D6	O
:	O
Bupropion	B
inhibits	O
CYP2D6	O
and	O
can	O
increase	O
concentrations	O
of	O
:	O
antidepressants	B-O
(	O
e	O
.g.	O
,	O
venlafaxine	B-O
,	O
nortriptyline	B-O
,	O
imipramine	B-O
,	O
desipramine	B-O
,	O
paroxetine	B-O
,	O
fluoxetine	B-O
,	O
sertraline	B-O
)	O
,	O
antipsychotics	B-O
(	O
e	O
.g.	O
,	O
haloperidol	B-O
,	O
risperidone	B-O
,	O
thioridazine	B-O
)	O
,	O
beta-blockers	B-O
(	O
e	O
.g.	O
,	O
metoprolol	B-O
)	O
,	O
and	O
Type	B-O
1C	I-O
antiarrhythmics	I-O
(	O
e	O
.g.	O
,	O
propafenone	B-O
,	O
flecainide	B-O
)	O
.	O

Inhibitors	O
of	O
CYP2B6	O
Ticlopidine	B
and	O
Clopidogrel	B
:	O
Concomitant	O
treatment	O
with	O
these	O
drugs	O
can	O
increase	O
bupropion	B-O
exposures	O
but	O
decrease	O
hydroxybupropion	B-O
exposure	O
.	O

Inducers	O
of	O
CYP2B6	O
Ritonavir	B
,	O
Lopinavir	B
,	O
and	O
Efavirenz	B
:	O
Concomitant	O
treatment	O
with	O
these	O
drugs	O
can	O
decrease	O
bupropion	B-O
and	O
hydroxybupropion	B-O
exposure	O
.	O

Carbamazepine	B
,	O
Phenobarbital	B
,	O
Phenytoin	B
:	O
While	O
not	O
systemically	O
studied	O
,	O
these	O
drugs	O
may	O
induce	O
metabolism	O
of	O
bupropion	B-O
and	O
may	O
decrease	O
bupropion	B-O
exposure	O
.	O

Prasugrel	B
:	O
In	O
healthy	O
subjects	O
,	O
prasugrel	B
increased	O
bupropion	B-O
Cmax	O
and	O
AUC	O
values	O
by	O
14	O
%	O
and	O
18	O
%	O
,	O
respectively	O
,	O
and	O
decreased	O
Cmax	O
and	O
AUC	O
values	O
of	O
hydroxybupropion	B-O
by	O
32	O
%	O
and	O
24	O
%	O
,	O
respectively	O
.	O

Inducers	O
of	O
CYP2B6	O
Ritonavir	B
and	O
Lopinavir	O
:	O
In	O
a	O
healthy	O
volunteer	O
study	O
,	O
ritonavir	B
100	O
mg	O
twice	O
daily	O
reduced	O
the	O
AUC	O
and	O
Cmax	O
of	O
bupropion	B-O
by	O
22	O
%	O
and	O
21	O
%	O
,	O
respectively	O
.	O

In	O
a	O
second	O
healthy	O
volunteer	O
study	O
,	O
ritonavir	B
600	O
mg	O
twice	O
daily	O
decreased	O
the	O
AUC	O
and	O
Cmax	O
of	O
bupropion	B-O
by	O
66	O
%	O
and	O
62	O
%	O
,	O
respectively	O
.	O

In	O
another	O
healthy	O
volunteer	O
study	O
,	O
lopinavir	B
400	O
mg/ritonavir	B
100	O
mg	O
twice	O
daily	O
decreased	O
bupropion	B-O
AUC	O
and	O
Cmax	O
by	O
57	O
%	O
.	O

Efavirenz	B
:	O
In	O
a	O
study	O
of	O
healthy	O
volunteers	O
,	O
efavirenz	B
600	O
mg	O
once	O
daily	O
for	O
2	O
weeks	O
reduced	O
the	O
AUC	O
and	O
Cmax	O
of	O
bupropion	B-O
by	O
approximately	O
55	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

Carbamazepine	B
,	O
Phenobarbital	B
,	O
Phenytoin	B
:	O
While	O
not	O
systematically	O
studied	O
,	O
these	O
drugs	O
may	O
induce	O
the	O
metabolism	O
of	O
bupropion	B-O
.	O

In	O
a	O
clinical	O
study	O
of	O
15	O
male	O
subjects	O
(	O
ages	O
19	O
to	O
35	O
years	O
)	O
who	O
were	O
extensive	O
metabolizers	O
of	O
CYP2D6	O
,	O
bupropion	B
given	O
as	O
150	O
mg	O
twice	O
daily	O
followed	O
by	O
a	O
single	O
dose	O
of	O
50	O
mg	O
desipramine	B-O
increased	O
the	O
Cmax	O
,	O
AUC	O
,	O
and	O
T1/2	O
of	O
desipramine	B-O
by	O
an	O
average	O
of	O
approximately	O
2-,	O
5-,	O
and	O
2-fold	O
,	O
respectively	O
.	O

Citalopram	B-O
:	O
Although	O
citalopram	B-O
is	O
not	O
primarily	O
metabolized	O
by	O
CYP2D6	O
,	O
in	O
one	O
study	O
bupropion	B
increased	O
the	O
Cmax	O
and	O
AUC	O
of	O
citalopram	B-O
by	O
30	O
%	O
and	O
40	O
%	O
,	O
respectively	O
.	O

Promethazine	B
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	B-O
and	O
promethazine	B
(	O
10	O
and	O
25	O
mg	O
,	O
respectively	O
)	O
resulted	O
in	O
a	O
15	O
%	O
decrease	O
in	O
maximal	O
plasma	O
concentrations	O
of	O
zaleplon	B-O
,	O
but	O
no	O
change	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
.	O

Multiple-dose	O
administration	O
of	O
the	O
potent	O
CYP3A4	O
inducer	O
rifampin	B
(	O
600	O
mg	O
every	O
24	O
hours	O
,	O
q24h	O
,	O
for	O
14	O
days	O
)	O
,	O
however	O
,	O
reduced	O
zaleplon	B-O
Cmax	O
and	O
AUC	O
by	O
approximately	O
80	O
%	O
.	O

Coadministration	O
of	O
single	O
,	O
oral	O
doses	O
of	O
zaleplon	B-O
with	O
erythromycin	B
(	O
10	O
mg	O
and	O
800	O
mg	O
,	O
respectively	O
)	O
,	O
a	O
strong	O
,	O
selective	O
CYP3A4	O
inhibitor	O
,	O
produced	O
a	O
34	O
%	O
increase	O
in	O
zaleplon	B-O
's	O
maximal	O
plasma	O
concentrations	O
and	O
a	O
20	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
.	O

Other	O
strong	O
selective	B
CYP3A4	I
inhibitors	I
such	O
as	O
ketoconazole	B
can	O
also	O
be	O
expected	O
to	O
increase	O
the	O
exposure	O
of	O
zaleplon	B-O
.	O

Concomitant	O
administration	O
of	O
Zaleplon	B-O
(	O
10	O
mg	O
)	O
and	O
cimetidine	B
(	O
800	O
mg	O
)	O
produced	O
an	O
85	O
%	O
increase	O
in	O
the	O
mean	O
Cmax	O
and	O
AUC	O
of	O
zaleplon	B-O
.	O

Effect	O
of	O
Food	O
In	O
healthy	O
adults	O
a	O
high-fat/heavy	B
meal	I
prolonged	O
the	O
absorption	O
of	O
zaleplon	B-O
compared	O
to	O
the	O
fasted	O
state	O
,	O
delaying	O
tmax	O
by	O
approximately	O
2	O
hours	O
and	O
reducing	O
Cmax	O
by	O
approximately	O
35	O
%	O
.	O

Carbamazepine	B
Carbamazepine	B
is	O
an	O
inducer	O
of	O
CYP3A4	O
;	O
administration	O
of	O
200	O
mg	O
twice	O
daily	O
for	O
21	O
days	O
resulted	O
in	O
a	O
decrease	O
of	O
approximately	O
35	O
%	O
in	O
the	O
AUC	O
of	O
ziprasidone	B-O
.	O

Ketoconazole	B
Ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
at	O
a	O
dose	O
of	O
400	O
mg	O
QD	O
for	O
5	O
days	O
,	O
increased	O
the	O
AUC	O
and	O
Cmax	O
of	O
ziprasidone	B-O
by	O
about	O
35-40	O
%	O
.	O

The	O
absorption	O
of	O
ziprasidone	B-O
is	O
increased	O
up	O
to	O
two-fold	O
in	O
the	O
presence	O
of	O
food	B
.	O

Sertraline	B
Concomitant	O
administration	O
of	O
zolpidem	B-O
and	O
sertraline	B
increases	O
exposure	O
to	O
zolpidem	B-O
.	O

Fluoxetine	B
After	O
multiple	O
doses	O
of	O
zolpidem	B-O
tartrate	O
and	O
fluoxetine	B
an	O
increase	O
in	O
the	O
zolpidem	B-O
half-life	O
(	O
17	O
%	O
)	O
was	O
observed	O
.	O

CYP3A4	O
Inducers	O
Rifampin	B
Rifampin	B
,	O
a	O
CYP3A4	O
inducer	O
,	O
significantly	O
reduced	O
the	O
exposure	O
to	O
and	O
the	O
pharmacodynamic	O
effects	O
of	O
zolpidem	B-O
.	O

Use	O
of	O
St	B
.	I
John	I
's	I
wort	I
,	O
a	O
CYP3A4	O
inducer	O
,	O
in	O
combination	O
with	O
zolpidem	B-O
may	O
decrease	O
blood	O
levels	O
of	O
zolpidem	B-O
and	O
is	O
not	O
recommended	O
.	O

CYP3A4	O
Inhibitors	O
Ketoconazole	B
Ketoconazole	B
,	O
a	O
potent	O
CYP3A4	O
inhibitor	O
,	O
increased	O
the	O
exposure	O
to	O
and	O
pharmacodynamic	O
effects	O
of	O
zolpidem	B-O
.	O

Imipramine	B-O
in	O
combination	O
with	O
zolpidem	B
produced	O
no	O
pharmacokinetic	O
interaction	O
other	O
than	O
a	O
20	O
%	O
decrease	O
in	O
peak	O
levels	O
of	O
imipramine	B-O
,	O
but	O
there	O
was	O
an	O
additive	O
effect	O
of	O
decreased	O
alertness	O
.	O

Following	O
five	O
consecutive	O
nightly	O
doses	O
at	O
bedtime	O
of	O
oral	O
zolpidem	B-O
tartrate	O
10	O
mg	O
in	O
the	O
presence	O
of	O
sertraline	B
50	O
mg	O
(	O
17	O
consecutive	O
daily	O
doses	O
,	O
at	O
7:00	O
am	O
,	O
in	O
healthy	O
female	O
volunteers	O
)	O
,	O
zolpidem	B-O
Cmax	O
was	O
significantly	O
higher	O
(	O
43	O
%	O
)	O
and	O
Tmax	O
was	O
significantly	O
decreased	O
(-53	O
%	O
)	O
.	O

When	O
multiple	O
doses	O
of	O
zolpidem	B-O
and	O
fluoxetine	B
were	O
given	O
at	O
steady	O
state	O
and	O
the	O
concentrations	O
evaluated	O
in	O
healthy	O
females	O
,	O
an	O
increase	O
in	O
the	O
zolpidem	B-O
half-life	O
(	O
17	O
%	O
)	O
was	O
observed	O
.	O

A	O
single-dose	O
interaction	O
study	O
with	O
zolpidem	B-O
tartrate	I-O
10	O
mg	O
and	O
itraconazole	B
200	O
mg	O
at	O
steady-state	O
levels	O
in	O
male	O
volunteers	O
resulted	O
in	O
a	O
34	O
%	O
increase	O
in	O
AUC0-Infinity	O
of	O
zolpidem	B-O
tartrate	I-O
.	O

A	O
single-dose	O
interaction	O
study	O
with	O
zolpidem	B-O
tartrate	I-O
10	O
mg	O
and	O
rifampin	B
600	O
mg	O
at	O
steady-state	O
levels	O
in	O
female	O
subjects	O
showed	O
significant	O
reductions	O
of	O
the	O
AUC	O
(-73	O
%	O
)	O
,	O
Cmax	O
(-58	O
%	O
)	O
,	O
and	O
T1/2	O
(-36	O
%	O
)	O
of	O
zolpidem	O
together	O
with	O
significant	O
reductions	O
in	O
the	O
pharmacodynamic	O
effects	O
of	O
zolpidem	B-O
tartrate	I-O
.	O

Rifampin	B
,	O
a	O
CYP3A4	O
inducer	O
,	O
significantly	O
reduced	O
the	O
exposure	O
to	O
and	O
the	O
pharmacodynamic	O
effects	O
of	O
zolpidem	B-O
.	O

Similarly	O
,	O
St	B
.	I
John	I
's	I
wort	I
,	O
a	O
CYP3A4	O
inducer	O
,	O
may	O
also	O
decrease	O
the	O
blood	O
levels	O
of	O
zolpidem	B-O
.	O

A	O
single-dose	O
interaction	O
study	O
with	O
zolpidem	B-O
tartrate	O
5	O
mg	O
and	O
ketoconazole	B
,	O
a	O
potent	O
CYP3A4	O
inhibitor	O
,	O
given	O
as	O
200	O
mg	O
twice	O
daily	O
for	O
2	O
days	O
increased	O
Cmax	O
of	O
zolpidem	B-O
(	O
30	O
%	O
)	O
and	O
the	O
total	O
AUC	O
of	O
zolpidem	B-O
(	O
70	O
%	O
)	O
compared	O
to	O
zolpidem	B-O
alone	O
and	O
prolonged	O
the	O
elimination	O
half-life	O
(	O
30	O
%	O
)	O
along	O
with	O
an	O
increase	O
in	O
the	O
pharmacodynamic	O
effects	O
of	O
zolpidem	B-O
.	O

Additionally	O
,	O
fluvoxamine	B
(	O
a	O
strong	O
inhibitor	O
of	O
CYP1A2	O
and	O
a	O
weak	O
inhibitor	O
of	O
CYP3A4	O
and	O
CYP2C9	O
)	O
and	O
ciprofloxacin	B
(	O
a	O
strong	O
inhibitor	O
of	O
CYP1A2	O
and	O
a	O
moderate	O
inhibitor	O
of	O
CYP3A4	O
)	O
are	O
also	O
likely	O
to	O
inhibit	O
zolpidem	B-O
's	O
metabolic	O
pathways	O
,	O
potentially	O
leading	O
to	O
an	O
increase	O
in	O
zolpidem	B-O
exposure	O
.	O

Carbamazepine	B
:	O
Increased	O
clearance	O
of	O
olanzapine	B-O
.	O

Fluvoxamine	B
:	O
May	O
increase	O
olanzapine	B-O
levels	O
.	O

Inducers	O
of	O
CYP1A2	O
Carbamazepine	B
therapy	O
(	O
200mgbid	O
)	O
causes	O
an	O
approximately	O
50	O
%	O
increase	O
in	O
the	O
clearance	O
of	O
olanzapine	B-O
.	O

Higher	O
daily	O
doses	O
of	O
carbamazepine	B
may	O
cause	O
an	O
even	O
greater	O
increase	O
in	O
olanzapine	B-O
clearance	O
.	O

Inhibitors	O
of	O
CYP1A2	O
Fluvoxamine	B
:	O
Fluvoxamine	B
,	O
a	O
CYP1A2	O
inhibitor	O
,	O
decreases	O
the	O
clearance	O
of	O
olanzapine	B-O
.	O

This	O
results	O
in	O
a	O
mean	O
increase	O
in	O
olanzapine	B-O
Cmax	O
following	O
fluvoxamine	B
of	O
54	O
%	O
in	O
female	O
nonsmokers	O
and	O
77	O
%	O
in	O
male	O
smokers	O
.	O

Inhibitors	O
of	O
CYP2D6	O
Fluoxetine	B
:	O
Fluoxetine	B
(60mg	O
single	O
dose	O
or	O
60mg	O
daily	O
dose	O
for	O
8	O
days	O
)	O
causes	O
a	O
small	O
(	O
mean	O
16	O
%	O
)	O
increase	O
in	O
the	O
maximum	O
concentration	O
of	O
olanzapine	B-O
and	O
a	O
small	O
(	O
mean	O
16	O
%	O
)	O
decrease	O
in	O
olanzapine	B-O
clearance	O
.	O

Inducers	O
of	O
CYP1A2	O
or	O
Glucuronyl	O
Transferase	O
-	O
Omeprazole	B
and	O
rifampin	B
may	O
cause	O
an	O
increase	O
in	O
olanzapine	B-O
clearance	O
.	O

Charcoal	O
-	O
The	O
administration	O
of	O
activated	B
charcoal	I
(	O
1g	O
)	O
reduced	O
the	O
Cmax	O
and	O
AUC	O
of	O
oral	O
olanzapine	B-O
by	O
about	O
60	O
%	O
.	O

In	O
a	O
dedicated	O
drug	O
interaction	O
trial	O
,	O
co-administration	O
of	O
rifampin	B
,	O
a	O
strong	O
CYP3A4	O
inducer	O
,	O
decreased	O
exposure	O
of	O
abiraterone	B-O
by	O
55	O
%	O
.	O

In	O
a	O
CYP2D6	O
drug-drug	O
interaction	O
trial	O
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
dextromethorphan	B-O
(	O
CYP2D6	O
substrate	O
)	O
were	O
increased	O
2.8-	O
and	O
2.9-fold	O
,	O
respectively	O
,	O
when	O
dextromethorphan	B-O
was	O
given	O
with	O
abiraterone	B
acetate	I
1,000	O
mg	O
daily	O
and	O
prednisone	B
5	O
mg	O
twice	O
daily	O
.	O

In	O
a	O
CYP2C8	O
drug-drug	O
interaction	O
trial	O
in	O
healthy	O
subjects	O
,	O
the	O
AUC	O
of	O
pioglitazone	B-O
(	O
CYP2C8	O
substrate	O
)	O
was	O
increased	O
by	O
46	O
%	O
when	O
pioglitazone	B-O
was	O
given	O
together	O
with	O
a	O
single	O
dose	O
of	O
1,000	O
mg	O
abiraterone	B
acetate	I
.	O

Systemic	O
exposure	O
of	O
abiraterone	B-O
is	O
increased	O
when	O
abiraterone	B-O
acetate	O
is	O
administered	O
with	O
food	B
.	O

In	O
healthy	O
subjects	O
abiraterone	B-O
Cmax	O
and	O
AUC0-Infinity	O
were	O
approximately	O
7-	O
and	O
5-fold	O
higher	O
,	O
respectively	O
,	O
when	O
a	O
single	O
dose	O
of	O
abiraterone	B-O
acetate	O
was	O
administered	O
with	O
a	O
low-fat	B
meal	I
(	O
7	O
%	O
fat	O
,	O
300	O
calories	O
)	O
and	O
approximately	O
17	O
-	O
and	O
10-fold	O
higher	O
,	O
respectively	O
,	O
when	O
a	O
single	O
dose	O
of	O
abiraterone	B-O
acetate	O
was	O
administered	O
with	O
a	O
high-fat	B
meal	I
(	O
57	O
%	O
fat	O
,	O
825	O
calories	O
)	O
compared	O
to	O
overnight	O
fasting	O
.	O

Abiraterone	B-O
AUC0-Infinity	O
was	O
approximately	O
7-fold	O
or	O
1.6-fold	O
higher	O
,	O
respectively	O
,	O
when	O
a	O
single	O
dose	O
of	O
abiraterone	B-O
acetate	O
was	O
administered	O
2	O
hours	O
after	O
or	O
1	O
hour	O
before	O
a	O
medium	B
fat	I
meal	I
(	O
25	O
%	O
fat	O
,	O
491	O
calories	O
)	O
compared	O
to	O
overnight	O
fasting	O
.	O

Given	O
the	O
normal	O
variation	O
in	O
the	O
content	O
and	O
composition	O
of	O
meals	B
,	O
taking	O
ZYTIGA	B-O
with	O
meals	B
has	O
the	O
potential	O
to	O
result	O
in	O
increased	O
and	O
highly	O
variable	O
exposures	O
.	O

In	O
an	O
in	O
vivo	O
drug-drug	O
interaction	O
trial	O
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
dextromethorphan	B-O
(	O
CYP2D6	O
substrate	O
)	O
were	O
increased	O
2.8-	O
and	O
2.9-fold	O
,	O
respectively	O
when	O
dextromethorphan	B-O
30	O
mg	O
was	O
given	O
with	O
abiraterone	B
acetate	I
1,000	O
mg	O
daily	O
(	O
plus	O
prednisone	B
5	O
mg	O
twice	O
daily	O
)	O
.	O

In	O
a	O
clinical	O
pharmacokinetic	O
interaction	O
study	O
of	O
healthy	O
subjects	O
pretreated	O
with	O
a	O
strong	O
CYP3A4	O
inducer	O
(	O
rifampin	B
,	O
600	O
mg	O
daily	O
for	O
6	O
days	O
)	O
followed	O
by	O
a	O
single	O
dose	O
of	O
abiraterone	B-O
acetate	O
1,000	O
mg	O
,	O
the	O
mean	O
plasma	O
AUC	O
Infinity	O
of	O
abiraterone	B-O
was	O
decreased	O
by	O
55	O
%	O
.	O

Simultaneous	O
administration	O
of	O
tetracycline	B-O
with	O
quinapril	B
reduced	O
the	O
absorption	O
of	O
tetracycline	B-O
by	O
approximately	O
28	O
%	O
to	O
37	O
%	O
,	O
possibly	O
due	O
to	O
the	O
high	O
magnesium	O
content	O
in	O
quinapril	B
tablets	O
.	O

Digoxin	B-O
:	I
Thiazide-induced	B
electrolyte	O
disturbances	O
,	O
i	O
.e	O
.	O
hypokalemia	O
,	O
hypomagnesemia	O
,	O
increase	O
the	O
risk	O
of	O
digoxin	B-O
toxicity	O
,	O
which	O
may	O
lead	O
to	O
fatal	O
arrhythmic	O
events	O
.	O

Cholestyramine	B
and	O
Colestipol	B
Resin	I
-	O
absorption	O
of	O
hydrochlorothiazide	B-O
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	B
exchange	I
resins	I
.	O

Single	O
doses	O
of	O
either	O
cholestyramine	B
or	O
colestipol	B
resins	I
bind	O
the	O
hydrochlorothiazide	B-O
and	O
reduce	O
its	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
85	O
%	O
and	O
43	O
%	O
,	O
respectively	O
.	O

The	O
rate	O
of	O
quinapril	B-O
absorption	O
was	O
reduced	O
by	O
14	O
%	O
when	O
ACCURETIC	B-O
tablets	O
were	O
administered	O
with	O
a	O
high-fat	B
meal	I
as	O
compared	O
to	O
fasting	O
,	O
while	O
the	O
extent	O
of	O
absorption	O
was	O
not	O
affected	O
.	O

The	O
rate	O
of	O
hydrochlorothiazide	B-O
absorption	O
was	O
reduced	O
by	O
12	O
%	O
when	O
ACCURETIC	B-O
tablets	O
were	O
administered	O
with	O
a	O
high-fat	B
meal	I
,	O
while	O
the	O
extent	O
of	O
absorption	O
was	O
not	O
significantly	O
affected	O
.	O

Increases	O
in	O
serum	O
lithium	B-O
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-O
with	O
angiotensin	B
II	I
receptor	I
antagonists	I
,	O
including	I
ATACAND.	B

Simultaneous	O
administration	O
of	O
tetracycline	B-O
with	O
ACCUPRIL	B
reduced	O
the	O
absorption	O
of	O
tetracycline	B-O
by	O
approximately	O
28	O
%	O
to	O
37	O
%	O
,	O
possibly	O
due	O
to	O
the	O
high	O
magnesium	O
content	O
in	O
ACCUPRIL	B
tablets	O
.	O

Increased	O
serum	O
lithium	B-O
levels	O
and	O
symptoms	O
of	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	B-O
and	O
ACE	B
inhibitor	I
therapy	O
.	O

The	O
rate	O
and	O
extent	O
of	O
quinapril	B-O
absorption	O
are	O
diminished	O
moderately	O
(	O
approximately	O
25-30	O
%	O
)	O
when	O
ACCUPRIL	B-O
tablets	O
are	O
administered	O
during	O
a	O
high-fat	B
meal	I
.	O

The	O
bioavailability	O
of	O
perindoprilat	B-O
was	O
reduced	O
by	O
diuretics	B
,	O
however	O
,	O
and	O
this	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
plasma	O
ACE	O
inhibition	O
.	O

Increased	O
serum	O
lithium	B-O
and	O
symptoms	O
of	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	B-O
and	O
ACE	B
inhibitor	I
therapy	O
.	O

Co-administration	O
with	O
anticoagulants	O
,	O
antiplatelets	O
,	O
or	O
NSAIDs	O
can	O
increase	O
risk	O
of	O
bleeding	O
(	O
7.1	O
)	O
Decreased	O
renal	O
function	O
can	O
occur	O
with	O
co-administration	O
with	O
NSAIDs	O
(	O
7.1	O
)	O
Adenosine	B-O
:	O
Dipyridamole	B
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
and	O
cardiovascular	O
effects	O
of	O
adenosine	B-O
.	O

Concurrent	O
use	O
of	O
aspirin	B
and	O
acetazolamide	B-O
can	O
lead	O
to	O
high	O
serum	O
concentrations	O
of	O
acetazolamide	B-O
(	O
and	O
toxicity	O
)	O
due	O
to	O
competition	O
at	O
the	O
renal	O
tubule	O
for	O
secretion	O
.	O

Salicylic	B
acid	I
can	O
displace	O
protein-bound	O
phenytoin	B-O
and	O
valproic	B-O
acid	I-O
,	O
leading	O
to	O
a	O
decrease	O
in	O
the	O
total	O
concentration	O
of	O
phenytoin	B-O
and	O
an	O
increase	O
in	O
serum	O
valproic	B-O
acid	I-O
levels	O
.	O

Salicylate	B
can	O
inhibit	O
renal	O
clearance	O
of	O
methotrexate	B-O
,	O
leading	O
to	O
bone	O
marrow	O
toxicity	O
,	O
especially	O
in	O
the	O
elderly	O
or	O
renal	O
impaired	O
.	O

When	O
AGGRENOX	B-O
capsules	O
were	O
taken	O
with	O
a	O
high	B
fat	I
meal	I
,	O
dipyridamole	B-O
peak	O
plasma	O
levels	O
(	O
Cmax	O
)	O
and	O
total	O
absorption	O
(	O
AUC)	O
were	O
decreased	O
at	O
steady-state	O
by	O
20-30	O
%	O
compared	O
to	O
fasting	O
.	O

Effect	O
of	O
Food	O
When	O
AGGRENOX	B-O
capsules	O
were	O
taken	O
with	O
a	O
high	B
fat	I
meal	I
,	O
dipyridamole	B-O
peak	O
plasma	O
levels	O
(	O
Cmax	O
)	O
and	O
total	O
absorption	O
(	O
AUC)	O
were	O
decreased	O
at	O
steady-state	O
by	O
20-30	O
%	O
compared	O
to	O
fasting	O
.	O

Atropine	B
Sulfate	I
Injection	O
decreased	O
the	O
rate	O
of	O
mexiletine	B-O
absorption	O
without	O
altering	O
the	O
relative	O
oral	O
bioavailability	O
;	O
this	O
delay	O
in	O
mexiletine	B-O
absorption	O
was	O
reversed	O
by	O
the	O
combination	O
of	O
atropine	O
and	O
intravenous	O
metoclopramide	B
during	O
pretreatment	O
for	O
anesthesia	O
.	O

The	O
metabolism	O
of	O
atropine	B-O
is	O
inhibited	O
by	O
organophosphate	B
pesticides	I
.	O

Cholestyramine	B
and	O
colestipol	B
:	O
Reduced	O
absorption	O
of	O
thiazides	B-O
.	O

Absorption	O
of	O
hydrochlorothiazide	B-O
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	B
exchange	I
resins	I
.	O

Increases	O
in	O
serum	O
lithium	B-O
concentrations	O
and	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
irbesartan	B
or	O
thiazide	B
diuretics	I
.	O

In	O
vitro	O
studies	O
show	O
significant	O
inhibition	O
of	O
the	O
formation	O
of	O
oxidized	B-O
irbesartan	I-O
metabolites	I-O
with	O
the	O
known	O
cytochrome	O
CYP2C9	O
substrates/inhibitors	O
sulphenazole	B
,	O
tolbutamide	B
,	O
and	O
nifedipine	B
.	O

Increases	O
in	O
serum	O
lithium	B-O
concentrations	O
and	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
irbesartan	B
and	O
lithium	B-O
.	O

Colesevelam	B
hydrochloride	I
Concurrent	O
administration	O
of	O
bile	O
acid	O
sequestering	O
agent	O
colesevelam	B
hydrochloride	I
reduces	O
the	O
systemic	O
exposure	O
and	O
peak	O
plasma	O
concentration	O
of	O
olmesartan	B-O
.	O

Lithium	B-O
Increases	O
in	O
serum	O
lithium	B-O
concentrations	O
and	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-O
with	O
angiotensin	B
II	I
receptor	I
antagonists	I
,	O
including	O
BENICAR	B
.	O

Drug	O
Interaction	O
Bile	O
acid	O
sequestering	O
agent	O
colesevelam	O
Concomitant	O
administration	O
of	O
40	O
mg	O
olmesartan	B-O
medoxomil	O
and	O
3750	O
mg	O
colesevelam	B
hydrochloride	I
in	O
healthy	O
subjects	O
resulted	O
in	O
28	O
%	O
reduction	O
in	O
Cmax	O
and	O
39	O
%	O
reduction	O
in	O
AUC	O
of	O
olmesartan	B-O
.	O

CYP2D6	B
enzyme	I
inhibitors	I
may	O
increase	O
nebivolol	B-O
levels	O
(	O
7.1	O
)	O
Reserpine	O
or	O
clonidine	O
may	O
produce	O
excessive	O
reduction	O
of	O
sympathetic	O
activity	O
.	O

Fluoxetine	B
:	O
Fluoxetine	B
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
administered	O
at	O
20	O
mg	O
per	O
day	O
for	O
21	O
days	O
prior	O
to	O
a	O
single	O
10	O
mg	O
dose	O
of	O
nebivolol	O
to	O
10	O
healthy	O
adults	O
,	O
led	O
to	O
an	O
8-fold	O
increase	O
in	O
the	O
AUC	O
and	O
3-fold	O
increase	O
in	O
Cmax	O
for	O
d-nebivolol	B-O
.	O

Cimetidine	B
(	O
400	O
mg	O
twice	O
daily	O
)	O
causes	O
a	O
23	O
%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
d-nebivolol	B-O
.	O

Sildenafil	B-O
:	O
The	O
co-administration	O
of	O
nebivolol	B
and	O
sildenafil	B-O
decreased	O
AUC	O
and	O
Cmax	O
of	O
sildenafil	B-O
by	O
21	O
and	O
23	O
%	O
respectively	O
.	O

Clinically	O
significant	O
interactions	O
have	O
been	O
reported	O
with	O
inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
erythromycin	B
,	O
ritonavir	B
)	O
causing	O
elevation	O
of	O
plasma	O
levels	O
of	O
verapamil	B-O
while	O
inducers	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
rifampin	B
)	O
have	O
caused	O
a	O
lowering	O
of	O
plasma	O
levels	O
of	O
verapamil	B-O
.	O

Co-administration	O
of	O
multiple	O
doses	O
of	O
10	O
mg	O
of	O
verapamil	B
with	O
80	O
mg	O
simvastatin	B-O
resulted	O
in	O
exposure	O
to	O
simvastatin	B-O
2.5-fold	O
that	O
following	O
simvastatin	B-O
alone	O
.	O

Limit	O
the	O
daily	O
dose	O
of	O
lovastatin	B-O
to	O
40	O
mg	O
.	O
Lower	O
starting	O
and	O
maintenance	O
doses	O
of	O
other	O
CYP3A4	B-O
substrates	I-O
(	O
e	O
.g.	O
,	O
atorvastatin	B-O
)	O
may	O
be	O
required	O
as	O
verapamil	B
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
these	O
drugs	O
.	O

Concurrent	O
use	O
of	O
verapamil	B
increases	O
exposure	O
to	O
ivabradine	B-O
and	O
may	O
exacerbate	O
bradycardia	O
and	O
conduction	O
disturbances	O
.	O

Grapefruit	B
juice	I
may	O
increase	O
plasma	O
levels	O
of	O
verapamil	B-O
.	O

Verapamil	B
may	O
increase	O
blood	O
alcohol	B-O
concentrations	O
and	O
prolong	O
its	O
effects	O
.	O

A	O
decrease	O
in	O
metoprolol	B-O
and	O
propranolol	B-O
clearance	O
has	O
been	O
observed	O
when	O
either	O
drug	O
is	O
administered	O
concomitantly	O
with	O
verapamil	B
.	O

However	O
,	O
chronic	O
verapamil	B
treatment	O
can	O
increase	O
serum	O
digoxin	B-O
levels	O
by	O
50	O
%	O
to	O
75	O
%	O
during	O
the	O
first	O
week	O
of	O
therapy	O
,	O
and	O
this	O
can	O
result	O
in	O
digitalis	O
toxicity	O
.	O

Verapamil	B
may	O
reduce	O
total	O
body	O
clearance	O
and	O
extrarenal	O
clearance	O
of	O
digitoxin	B-O
by	O
27	O
%	O
and	O
29	O
%	O
,	O
respectively	O
.	O

There	O
has	O
been	O
a	O
report	O
of	O
increased	O
quinidine	B-O
levels	O
during	O
verapamil	B
therapy	O
.	O

Increased	O
sensitivity	O
to	O
the	O
effects	O
of	O
lithium	B-O
(	O
neurotoxicity	O
)	O
has	O
been	O
reported	O
during	O
concomitant	I
verapamil-lithium	B-O
therapy	O
;	O
lithium	B-O
levels	O
have	O
been	O
observed	O
sometimes	O
to	O
increase	O
,	O
sometimes	O
to	O
decrease	O
,	O
and	O
sometimes	O
to	O
be	O
unchanged	O
.	O

Verapamil	B
therapy	O
may	O
increase	O
carbamazepine	B-O
concentrations	O
during	O
combined	O
therapy	O
.	O

Therapy	O
with	O
rifampin	B
may	O
markedly	O
reduce	O
oral	O
verapamil	B-O
bioavailability	O
.	O

Phenobarbital	B
therapy	O
may	O
increase	O
verapamil	B-O
clearance	O
.	O

Verapamil	B
therapy	O
may	O
increase	O
serum	O
levels	O
of	O
cyclosporine	B-O
.	O

Verapamil	B
may	O
inhibit	O
the	O
clearance	O
and	O
increase	O
the	O
plasma	O
levels	O
of	O
theophylline	B-O
.	O

In	O
a	O
study	O
of	O
25	O
healthy	O
volunteers	O
with	O
co-administration	O
of	O
verapamil	B
with	O
sirolimus	B-O
,	O
whole	O
blood	O
sirolimus	B-O
Cmax	O
and	O
AUC	O
were	O
increased	O
130	O
%	O
and	O
120	O
%	O
,	O
respectively	O
.	O

Co-administration	O
of	O
verapamil	B
with	O
everolimus	B-O
in	O
16	O
healthy	O
volunteers	O
increased	O
the	O
Cmax	O
and	O
AUC	O
of	O
everolimus	B-O
by	O
130	O
%	O
and	O
250	O
%	O
,	O
respectively	O
.	O

COREG	B-O
should	O
be	O
taken	O
with	O
food	B
to	O
slow	O
the	O
rate	O
of	O
absorption	O
and	O
reduce	O
the	O
incidence	O
of	O
orthostatic	O
effects	O
.	O

CYP	B
P450	I
2D6	I
enzyme	I
inhibitors	I
may	O
increase	O
and	O
rifampin	B
may	O
decrease	O
carvedilol	B-O
levels	O
.	O

Amiodarone	B
may	O
increase	O
carvedilol	B-O
levels	O
resulting	O
in	O
further	O
slowing	O
of	O
the	O
heart	O
rate	O
or	O
cardiac	O
conduction	O
.	O

Interactions	O
of	O
carvedilol	B-O
with	O
potent	O
inhibitors	B
of	I
CYP2D6	I
isoenzyme	O
(	O
such	O
as	O
quinidine	B
,	O
fluoxetine	B
,	O
paroxetine	B
,	O
and	O
propafenone	B
)	O
have	O
not	O
been	O
studied	O
,	O
but	O
these	O
drugs	O
would	O
be	O
expected	O
to	O
increase	O
blood	O
levels	O
of	O
the	O
R(	O
+	O
)	O
enantiomer	O
of	O
carvedilol	B-O
.	O

Modest	O
increases	O
in	O
mean	O
trough	O
cyclosporine	B-O
concentrations	O
were	O
observed	O
following	O
initiation	O
of	O
carvedilol	B
treatment	O
in	O
21	O
renal	O
transplant	O
subjects	O
suffering	O
from	O
chronic	O
vascular	O
rejection	O
.	O

Digoxin	B-O
concentrations	O
are	O
increased	O
by	O
about	O
15	O
%	O
when	O
digoxin	B-O
and	O
carvedilol	B
are	O
administered	O
concomitantly	O
.	O

Rifampin	B
reduced	O
plasma	O
concentrations	O
of	O
carvedilol	B-O
by	O
about	O
70	O
%	O
.	O

Amiodarone	B
and	O
its	O
metabolite	O
desethyl	B
amiodarone	I
,	O
inhibitors	B
of	I
CYP2C9	I
,	O
and	O
P-glycoprotein	B
increased	O
concentrations	O
of	O
the	O
S(-)-enantiomer	O
of	O
carvedilol	B-O
by	O
at	O
least	O
2	O
fold	O
.	O

In	O
a	O
pharmacokinetic	O
trial	O
conducted	O
in	O
106	O
Japanese	O
subjects	O
with	O
heart	O
failure	O
,	O
coadministration	O
of	O
small	O
loading	O
and	O
maintenance	O
doses	O
of	O
amiodarone	B
with	O
carvedilol	B-O
resulted	O
in	O
at	O
least	O
a	O
2-fold	O
increase	O
in	O
the	O
steady-state	O
trough	O
concentrations	O
of	O
S(-)-carvedilol	B-O
.	O

In	O
a	O
pharmacokinetic	O
trial	O
conducted	O
in	O
10	O
healthy	O
male	O
subjects	O
,	O
cimetidine	B
(	O
1,000mg	O
per	O
day	O
)	O
increased	O
the	O
steady-state	O
AUC	O
of	O
carvedilol	B-O
by	O
30	O
%	O
with	O
no	O
change	O
in	O
Cmax	O
.	O

Following	O
concomitant	O
administration	O
of	O
carvedilol	B
(	O
25mg	O
once	O
daily	O
)	O
and	O
digoxin	B-O
(	O
0.25mg	O
once	O
daily	O
)	O
for	O
14days	O
,	O
steady-state	O
AUC	O
and	O
trough	O
concentrations	O
of	O
digoxin	B-O
were	O
increased	O
by	O
14	O
%	O
and	O
16	O
%	O
,	O
respectively	O
,	O
in	O
12subjects	O
with	O
hypertension	O
.	O

In	O
a	O
pharmacokinetic	O
trial	O
conducted	O
in	O
8	O
healthy	O
male	O
subjects	O
,	O
rifampin	B
(600mg	O
daily	O
for	O
12days	O
)	O
decreased	O
the	O
AUC	O
and	O
Cmax	O
of	O
carvedilol	B-O
by	O
about	O
70	O
%	O
.	O

Amlodipine	B-O
CYP3A	B
Inhibitors	I
Co-administration	O
with	O
CYP3A	B
inhibitors	I
(	O
moderate	O
and	O
strong	O
)	O
results	O
in	O
increased	O
systemic	O
exposure	O
to	O
amlodipine	B-O
and	O
may	O
require	O
dose	O
reduction	O
.	O

Immunosuppressants	O
Amlodipine	B
may	O
increase	O
the	O
systemic	O
exposure	O
of	O
cyclosporine	B-O
or	O
tacrolimus	B-O
when	O
co-administered	O
.	O

Concomitant	O
administration	O
of	O
atorvastatin	B-O
with	O
strong	O
inhibitors	B
of	I
CYP3A4	I
can	O
lead	O
to	O
increases	O
in	O
plasma	O
concentrations	O
of	O
atorvastatin	B-O
.	O

Clarithromycin	B
:	O
Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
atorvastatin	B-O
80	O
mg	O
with	O
clarithromycin	B
(	O
500	O
mg	O
twice	O
daily	O
)	O
compared	O
to	O
that	O
of	O
atorvastatin	B-O
alone	O
.	O

Combination	O
of	O
Protease	O
Inhibitors	O
:	O
Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
atorvastatin	B-O
with	O
several	O
combinations	O
of	O
HIV	B
protease	I
inhibitors	I
,	O
as	O
well	O
as	O
with	O
the	O
hepatitis	O
C	O
protease	O
inhibitor	O
telaprevir	B
,	O
compared	O
to	O
that	O
of	O
atorvastatin	B-O
alone	O
.	O

Itraconazole	B
:	O
Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
atorvastatin	B-O
40	O
mg	O
and	O
itraconazole	B
200	O
mg	O
.	O

Inhibitors	B
of	I
the	I
OATP1B1	I
(	O
e	O
.g.	O
,	O
cyclosporine	B
)	O
can	O
increase	O
the	O
bioavailability	O
of	O
atorvastatin	B-O
.	O

Atorvastatin	B-O
AUC	O
was	O
significantly	O
increased	O
with	O
concomitant	O
administration	O
of	O
atorvastatin	B-O
10	O
mg	O
and	O
cyclosporine	B
5.2	O
mg/kg/day	O
compared	O
to	O
that	O
of	O
atorvastatin	B-O
alone	O
.	O

Concomitant	O
administration	O
of	O
atorvastatin	B-O
with	O
inducers	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
efavirenz	B
,	O
rifampin	B
)	O
can	O
lead	O
to	O
variable	O
reductions	O
in	O
plasma	O
concentrations	O
of	O
atorvastatin	B-O
.	O

Because	O
of	O
the	O
dual	O
interaction	O
mechanism	O
of	O
rifampin	B
,	O
simultaneous	O
co-administration	O
of	O
atorvastatin	B-O
with	O
rifampin	B
is	O
recommended	O
,	O
as	O
delayed	O
administration	O
of	O
atorvastatin	B-O
after	O
administration	O
of	O
rifampin	B
has	O
been	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
atorvastatin	B-O
plasma	O
concentrations	O
.	O

When	O
multiple	O
doses	O
of	O
atorvastatin	B
and	O
digoxin	B-O
were	O
co-administered	O
,	O
steady-state	O
plasma	O
digoxin	B-O
concentrations	O
increased	O
by	O
approximately	O
20	O
%	O
.	O

Co-administration	O
of	O
atorvastatin	B
and	O
an	O
oral	B-O
contraceptive	I-O
increased	O
AUC	O
values	O
for	O
norethindrone	B-O
and	O
ethinyl	B-O
estradiol	I-O
.	O

Food	B
decreases	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
atorvastatin	B-O
from	O
CADUET	B-O
by	O
approximately	O
32	O
%	O
and	O
11	O
%	O
,	O
respectively	O
,	O
as	O
it	O
does	O
with	O
atorvastatin	B-O
when	O
given	O
alone	O
.	O

In	O
vitro	O
studies	O
suggest	O
the	O
importance	O
of	O
atorvastatin	B-O
metabolism	O
by	O
cytochrome	O
P4503A4	O
,	O
consistent	O
with	O
increased	O
plasma	O
concentrations	O
of	O
atorvastatin	B-O
in	O
humans	O
following	O
co-administration	O
with	O
erythromycin	B
,	O
a	O
known	O
inhibitor	O
of	O
this	O
isozyme	O
.	O

CYP3A	O
inhibitors	O
:	O
Co-administration	O
of	O
a	O
180	O
mg	O
daily	O
dose	O
of	O
diltiazem	B
with	O
5	O
mg	O
amlodipine	B-O
in	O
elderly	O
hypertensive	O
patients	O
resulted	O
in	O
a	O
60	O
%	O
increase	O
in	O
amlodipine	B-O
systemic	O
exposure	O
.	O

However	O
,	O
strong	O
inhibitors	B
of	I
CYP3A	I
(	O
e	O
.g.	O
,	O
itraconazole	B
,	O
clarithromycin	B
)	O
may	O
increase	O
the	O
plasma	O
concentrations	O
of	O
amlodipine	B-O
to	O
a	O
greater	O
extent	O
.	O

Rifampin	B
600	O
mg	O
QD	O
,	O
7	O
days	O
(	O
co-administered	O
)Because	O
of	O
the	O
dual	O
interaction	O
mechanism	O
of	O
rifampin	B
,	O
simultaneous	O
co-administration	O
of	O
atorvastatin	B-O
with	O
rifampin	B
is	O
recommended	O
,	O
as	O
delayed	O
administration	O
of	O
atorvastatin	B-O
after	O
administration	O
of	O
rifampin	B
has	O
been	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
atorvastatin	B-O
plasma	O
concentrations	O
.	O

Cyclosporine	B-O
:	O
A	O
prospective	O
study	O
in	O
renal	O
transplant	O
patients	O
(	O
N=11	O
)	O
showed	O
on	O
an	O
average	O
of	O
40	O
%	O
increase	O
in	O
trough	O
cyclosporine	B-O
levels	O
when	O
concomitantly	O
treated	O
with	O
amlodipine	B
.	O

Tacrolimus	B-O
:	O
A	O
prospective	O
study	O
in	O
healthy	O
Chinese	O
volunteers	O
(	O
N=9	O
)	O
with	O
CYP3A5	O
expressers	O
showed	O
a	O
2.5-	O
to	O
4-fold	O
increase	O
in	O
tacrolimus	B-O
exposure	O
when	O
concomitantly	O
administered	O
with	O
amlodipine	B
compared	O
to	O
tacrolimus	B-O
alone	O
.	O

However	O
,	O
a	O
3-fold	O
increase	O
in	O
plasma	O
exposure	O
to	O
tacrolimus	B-O
in	O
a	O
renal	O
transplant	O
patient	O
(	O
CYP3A5	O
non-expresser	O
)	O
upon	O
initiation	O
of	O
amlodipine	B
for	O
the	O
treatment	O
of	O
post-transplant	O
hypertension	O
resulting	O
in	O
reduction	O
of	O
tacrolimus	B-O
dose	O
has	O
been	O
reported	O
.	O

Benzodiazepines	O
:	O
Studies	O
showed	O
that	O
diltiazem	B
increased	O
the	O
AUC	O
of	O
midazolam	B-O
and	O
triazolam	B-O
by	O
3-	O
to	O
4-fold	O
and	O
the	O
Cmax	O
by	O
2-fold	O
,	O
compared	O
to	O
placebo	O
.	O

The	O
elimination	O
half-life	O
of	O
midazolam	B-O
and	O
triazolam	B-O
also	O
increased	O
(	O
1.5-	O
to	O
2.5-fold	O
)	O
during	O
coadministration	O
with	O
diltiazem	B
.	O

Administration	O
of	O
CARDIZEM	B
(	O
diltiazem	B
hydrochloride	I
)	O
concomitantly	O
with	O
propranolol	B-O
in	O
five	O
normal	O
volunteers	O
resulted	O
in	O
increased	O
propranolol	B-O
levels	O
in	O
all	O
subjects	O
and	O
bioavailability	O
of	O
propranolol	B-O
was	O
increased	O
approximately	O
50	O
%	O
.	O

In	O
vitro	O
,	O
propranolol	B-O
appears	O
to	O
be	O
displaced	O
from	O
its	O
binding	O
sites	O
by	O
diltiazem	B
.	O

Buspirone	B-O
:	O
In	O
nine	O
healthy	O
subjects	O
,	O
diltiazem	B
significantly	O
increased	O
the	O
mean	O
buspirone	B-O
AUC	O
5.5-fold	O
and	O
Cmax	O
4.1-fold	O
compared	O
to	O
placebo	O
.	O

Enhanced	O
effects	O
and	O
increased	O
toxicity	O
of	O
buspirone	B-O
may	O
be	O
possible	O
during	O
concomitant	O
administration	O
with	O
diltiazem	B
.	O

Carbamazepine	B-O
:	O
Concomitant	O
administration	O
of	O
diltiazem	B
with	O
carbamazepine	B-O
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
carbamazepine	B-O
(	O
40	O
%	O
to	O
72	O
%	O
increase	O
)	O
,	O
resulting	O
in	O
toxicity	O
in	O
some	O
cases	O
.	O

Cimetidine	B
:	O
A	O
study	O
in	O
six	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
diltiazem	B-O
plasma	O
levels	O
(	O
58	O
%	O
)	O
and	O
area	O
under	O
the	O
curve	O
(	O
53	O
%	O
)	O
after	O
a	O
1-week	O
course	O
of	O
cimetidine	B
at	O
1200	O
mg	O
per	O
day	O
and	O
a	O
single	O
dose	O
of	O
diltiazem	B-O
60	O
mg	O
.	O
Ranitidine	B
produced	O
smaller	O
,	O
nonsignificant	O
increases	O
.	O

In	O
renal	O
and	O
cardiac	O
transplant	O
recipients	O
,	O
a	O
reduction	O
of	O
cyclosporine	B-O
dose	O
ranging	O
from	O
15	O
%	O
to	O
48	O
%	O
was	O
necessary	O
to	O
maintain	O
cyclosporine	B-O
trough	O
concentrations	O
similar	O
to	O
those	O
seen	O
prior	O
to	O
the	O
addition	O
of	O
diltiazem	B
.	O

Digitalis	O
:	O
Administration	O
of	O
CARDIZEM	B
with	O
digoxin	B-O
in	O
24	O
healthy	O
male	O
subjects	O
increased	O
plasma	O
digoxin	B-O
concentrations	O
approximately	O
20	O
%	O
.	O

Ivabradine	B-O
:	O
Concurrent	O
use	O
of	O
diltiazem	B
increases	O
exposure	O
to	O
ivabradine	B-O
and	O
may	O
exacerbate	O
bradycardia	O
and	O
conduction	O
disturbances	O
.	O

Quinidine	B-O
:	O
Diltiazem	B
significantly	O
increases	O
the	O
AUC(0-Infinity	O
)	O
of	O
quinidine	B-O
by	O
51	O
%	O
,	O
T1/2	O
by	O
36	O
%	O
,	O
and	O
decreases	O
its	O
CLoral	O
by	O
33	O
%	O
.	O

Rifampin	B
:	O
Coadministration	O
of	O
rifampin	B
with	O
diltiazem	B-O
lowered	O
the	O
diltiazem	B-O
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Statins	B-O
:	O
Diltiazem	B
is	O
an	O
inhibitor	O
of	O
CYP3A4	O
and	O
has	O
been	O
shown	O
to	O
increase	O
significantly	O
the	O
AUC	O
of	O
some	O
statins	B-O
.	O

In	O
a	O
healthy	O
volunteer	O
crossover	O
study	O
(	O
N=10	O
)	O
,	O
coadministration	O
of	O
a	O
single	O
20	O
mg	O
dose	O
of	O
simvastatin	B-O
at	O
the	O
end	O
of	O
a	O
14-day	O
regimen	O
with	O
120	O
mg	O
BID	O
diltiazem	B
SR	O
resulted	O
in	O
a	O
5-fold	O
increase	O
in	O
mean	O
simvastatin	B-O
AUC	O
versus	O
simvastatin	B-O
alone	O
.	O

Subjects	O
with	O
increased	O
average	O
steady-state	O
exposures	O
of	O
diltiazem	B
showed	O
a	O
greater	O
fold	O
increase	O
in	O
simvastatin	B-O
exposure	O
.	O

Computer-based	O
simulations	O
showed	O
that	O
at	O
a	O
daily	O
dose	O
of	O
480	O
mg	O
of	O
diltiazem	B
,	O
an	O
8-	O
to	O
9-fold	O
mean	O
increase	O
in	O
simvastatin	B-O
AUC	O
can	O
be	O
expected	O
.	O

In	O
a	O
ten-subject	O
randomized	O
,	O
open-label	O
,	O
4-way	O
crossover	O
study	O
,	O
coadministration	O
of	O
diltiazem	B
(	O
120	O
mg	O
BID	O
diltiazem	B
SR	O
for	O
2	O
weeks	O
)	O
with	O
a	O
single	O
20	O
mg	O
dose	O
of	O
lovastatin	B-O
resulted	O
in	O
3-	O
to	O
4-fold	O
increase	O
in	O
mean	O
lovastatin	B-O
AUC	O
and	O
Cmax	O
versus	O
lovastatin	B-O
alone	O
.	O

Alcohol	B
:	O
Alcohol	B
increases	O
the	O
rate	O
at	O
which	O
CARDIZEM	B-O
CD	O
releases	O
diltiazem	B-O
in	O
vitro	O
.	O

The	O
effect	O
of	O
alcohol	B
on	O
the	O
release	O
rate	O
may	O
lead	O
to	O
a	O
change	O
in	O
the	O
pharmacokinetics	O
of	O
diltiazem	B-O
,	O
such	O
as	O
a	O
more	O
rapid	O
absorption	O
and/or	O
an	O
increase	O
in	O
the	O
systemic	O
exposure	O
of	O
diltiazem	B-O
.	O

Strong	O
cytochrome	O
P450	B
(	I
CYP	I
)	I
3A	I
inhibitors	I
may	O
increase	O
exposure	O
to	O
doxazosin	B-O
and	O
increased	O
risk	O
of	O
hypotension	O
.	O

Strong	O
CYP3A	B
inhibitors	I
may	O
increase	O
exposure	O
to	O
doxazosin	B-O
.	O

Reductions	O
of	O
18	O
%	O
in	O
mean	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
and	O
12	O
%	O
in	O
the	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC)	O
occurred	O
when	O
CARDURA	B-O
was	O
administered	O
with	O
food	B
.	O

Cimetidine	B
:	O
In	O
healthy	O
volunteers	O
,	O
the	O
administration	O
of	O
a	O
single	O
1	O
mg	O
dose	O
of	O
doxazosin	B-O
on	O
day	O
1	O
of	O
a	O
four-day	O
regimen	O
of	O
oral	O
cimetidine	B
(	O
400	O
mg	O
twice	O
daily	O
)	O
resulted	O
in	O
a	O
10	O
%	O
increase	O
in	O
mean	O
AUC	O
of	O
doxazosin	B-O
,	O
and	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
in	O
mean	O
Cmax	O
and	O
mean	O
half-life	O
of	O
doxazosin	B-O
.	O

Lithium	B-O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
increase	O
the	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

In	O
a	O
limited	O
study	O
involving	O
12subjects	O
,	O
coadministration	O
of	O
DYAZIDE	B-O
with	O
a	O
high-fat	B
meal	I
resulted	O
in	O
:	O
(	O
1	O
)	O
an	O
increase	O
in	O
the	O
mean	O
bioavailability	O
of	O
triamterene	B-O
by	O
about	O
67	O
%	O
(90	O
%	O
confidence	O
interval=0.99	O
,	O
1.90	O
)	O
,	O
p-hydroxytriamterene	B-O
sulfate	I-O
by	O
about	O
50	O
%	O
(90	O
%	O
confidence	O
interval=1.06	O
,	O
1.77	O
)	O
,	O
hydrochlorothiazide	B-O
by	O
about	O
17	O
%	O
(90	O
%	O
confidence	O
interval=0.90	O
,	O
1.34	O
)	O
;	O
(	O
2	O
)	O
increases	O
in	O
the	O
peak	O
concentrations	O
of	O
triamterene	B-O
and	O
p-hydroxytriamterene	B-O
;	O
and	O
(	O
3	O
)	O
a	O
delay	O
of	O
up	O
to	O
2hours	O
in	O
the	O
absorption	O
of	O
the	O
active	O
constituents	O
.	O

As	O
a	O
result	O
,	O
certain	O
antibiotics	B
may	O
increase	O
the	O
absorption	O
of	O
digoxin	B-O
in	O
such	O
patients	O
.	O

Drugs	B
that	I
inhibit	I
CYP2D6	I
such	O
as	O
quinidine	B
,	O
fluoxetine	B
,	O
paroxetine	B
,	O
and	O
propafenone	B
are	O
likely	O
to	O
increase	O
metoprolol	B-O
concentration	O
.	O

In	O
healthy	O
subjects	O
with	O
CYP2D6	O
extensive	O
metabolizer	O
phenotype	O
,	O
coadministration	O
of	O
quinidine	B
100	O
mg	O
and	O
immediate	O
release	O
metoprolol	B-O
200	O
mg	O
tripled	O
the	O
concentration	O
of	O
S-metoprolol	B-O
and	O
doubled	O
the	O
metoprolol	B-O
elimination	O
half-life	O
.	O

In	O
four	O
patients	O
with	O
cardiovascular	O
disease	O
,	O
coadministration	O
of	O
propafenone	B
150	O
mg	O
t.i.d	O
.	O
with	O
immediate-release	O
metoprolol	B-O
50	O
mg	O
t.i.d	O
.	O
resulted	O
in	O
two	O
-	O
to	O
five-fold	O
increases	O
in	O
the	O
steady-state	O
concentration	O
of	O
metoprolol	B-O
.	O

Cholestyramine	B
and	O
colestipol	B
resins	I
-	O
Absorption	O
of	O
hydrochlorothiazide	B-O
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	B
exchange	I
resins	I
.	O

Single	O
doses	O
of	O
either	O
cholestyramine	B
or	O
colestipol	B
resins	I
bind	O
the	O
hydrochlorothiazide	B-O
and	O
reduce	O
its	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
85	O
and	O
43	O
percent	O
,	O
respectively	O
.	O

Diuretic	B
agents	I
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

For	O
patients	O
receiving	O
ELIQUIS	B-O
doses	O
of	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
,	O
reduce	O
the	O
dose	O
by	O
50	O
%	O
when	O
ELIQUIS	B-O
is	O
coadministered	O
with	O
drugs	O
that	O
are	O
combined	O
P-glycoprotein	B
(P-gp	O
)	O
and	O
strong	O
cytochrome	O
P450	B
3A4	I
(	I
CYP3A4	I
)	I
inhibitors	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
ritonavir	B
)	O
.	O

Inhibitors	B
of	I
CYP3A4	I
and	I
P-gp	I
increase	O
exposure	O
to	O
apixaban	B-O
and	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

Inducers	B
of	I
CYP3A4	I
and	I
P-gp	I
decrease	O
exposure	O
to	O
apixaban	B-O
and	O
increase	O
the	O
risk	O
of	O
stroke	O
and	O
other	O
thromboembolic	O
events	O
.	O

Combined	B
P-gp	I
and	I
strong	I
CYP3A4	I
inhibitors	I
increase	O
blood	O
levels	O
of	O
apixaban	B-O
.	O

Avoid	O
concomitant	O
use	O
of	O
ELIQUIS	B-O
with	O
combined	B
P-gp	I
and	I
strong	I
CYP3A4	I
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
,	O
carbamazepine	B
,	O
phenytoin	B
,	O
St	B
.	I
John	I
's	I
wort	I
)	O
because	O
such	O
drugs	O
will	O
decrease	O
exposure	O
to	O
apixaban	O
.	O

Activated	B
oral	I
charcoal	I
reduces	O
absorption	O
of	O
apixaban	B-O
,	O
thereby	O
lowering	O
apixaban	B-O
plasma	O
concentration	O
.	O

Opioids	B
:	O
Decreased	O
exposure	O
to	O
prasugrel	B-O
.	O

Drug	O
Interactions	O
Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
Prasugrel	B-O
Inhibitors	O
of	O
CYP3A	O
-	I
Ketoconazole(	B
400mg	O
daily	O
)	O
,	O
a	O
selective	O
and	O
potent	O
inhibitor	O
of	O
CYP3A4	O
and	O
CYP3A5	O
,	O
did	O
not	O
affect	I-O
prasugrel-mediated	B-O
inhibition	O
of	O
platelet	O
aggregation	O
or	O
the	O
active	O
metabolite	O
's	O
AUC	O
and	O
Tmax	O
,	O
but	O
decreased	O
the	O
Cmax	O
by	O
34	O
%	O
to	O
46	O
%	O
.	O

Drugs	O
that	O
Elevate	O
Gastric	O
pH	O
-	O
Daily	O
coadministration	O
of	I
ranitidine(	B
an	O
H2	O
blocker	O
)	O
or	I
lansoprazole(	B
a	O
proton	O
pump	O
inhibitor	O
)	O
decreased	O
the	O
Cmax	O
of	O
the	O
prasugrel	B-O
active	O
metabolite	O
by	O
14	O
%	O
and	O
29	O
%	O
,	O
respectively	O
,	O
but	O
did	O
not	O
change	O
the	O
active	O
metabolite	O
's	O
AUC	O
and	O
Tmax	O
.	O

In	O
healthy	O
subjects	O
,	O
prasugrel	B
decreased	O
exposure	O
to	O
hydroxybupropion	B-O
,	O
a	O
CYP2B6-mediated	O
metabolite	O
of	O
bupropion	O
,	O
by	O
23	O
%	O
,	O
an	O
amount	O
not	O
considered	O
clinically	O
significant	O
.	O

Morphine	B
-	O
Co-administration	O
of	O
5	O
mg	O
intravenous	O
morphine	B
with	O
60	O
mg	O
loading	O
dose	O
of	O
prasugrel	O
in	O
healthy	O
adults	O
decreased	O
the	O
Cmax	O
of	O
prasugrel	B-O
's	I-O
active	I-O
metabolite	I-O
by	O
31	O
%	O
with	O
no	O
change	O
in	O
AUC	O
,	O
Tmax	O
,	O
or	O
inhibition	O
of	O
ADP-induced	O
platelet	O
aggregation	O
.	O

In	O
the	O
patients	O
with	O
a	O
2-hour	O
delay	O
in	O
the	O
onset	O
of	O
platelet	O
aggregation	O
(	O
5	O
of	O
11	O
)	O
,	O
Tmax	O
was	O
delayed	O
and	O
prasugrel	B-O
active	I-O
metabolite	I-O
levels	O
were	O
significantly	O
lower	O
at	O
30	O
min	O
(	O
5	O
vs	O
120	O
ng/mL	O
)	O
following	O
co-administration	O
with	O
morphine	B
.	O

Drug	O
Interaction	O
Studies	O
In	O
a	O
pharmacokinetic	O
substudy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
receiving	O
furosemide	B-O
in	O
whom	O
therapy	O
with	O
FLOLAN	B
was	O
initiated	O
,	O
apparent	O
oral	O
clearance	O
values	O
for	O
furosemide	B-O
(	O
n=23	O
)	O
were	O
decreased	O
by	O
13	O
%	O
on	O
the	O
second	O
day	O
of	O
therapy	O
and	O
returned	O
to	O
baseline	O
values	O
by	O
Day	O
87	O
.	O

In	O
a	O
pharmacokinetic	O
substudy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
receiving	O
digoxin	B-O
in	O
whom	O
therapy	O
with	O
FLOLAN	B
was	O
initiated	O
,	O
apparent	O
oral	O
clearance	O
values	O
for	O
digoxin	B-O
(	O
n=30	O
)	O
were	O
decreased	O
by	O
15	O
%	O
on	O
the	O
second	O
day	O
of	O
therapy	O
and	O
returned	O
to	O
baseline	O
values	O
by	O
Day	O
87	O
.	O

Inhibitors	B
of	I
CYP3A	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
,	O
saquinavir	B
)	O
increase	O
blood	O
levels	O
of	O
eplerenone	B-O
.	O

Administration	O
of	O
eplerenone	B-O
with	O
moderate	O
CYP3A	B
inhibitors	I
(	O
e	O
.g.	O
,	O
erythromycin	B
500	O
mg	O
BID	O
,	O
verapamil	B
240	O
mg	O
once	O
daily	O
,	O
saquinavir	B
1200	O
mg	O
three	O
times	O
a	O
day	O
,	O
fluconazole	B
200	O
mg	O
once	O
daily	O
)	O
resulted	O
in	O
increases	O
in	O
Cmax	O
of	O
eplerenone	B-O
ranging	O
from	O
40	O
%	O
to	O
60	O
%	O
and	O
AUC	O
from	O
100	O
%	O
to	O
190	O
%	O
.	O

St	B
.	I
John	I
's	I
wort	I
(	O
a	O
CYP3A	O
inducer	O
)	O
caused	O
a	O
small	O
(	O
about	O
30	O
%	O
)	O
decrease	O
in	O
eplerenone	B-O
AUC.	O

Multiple	O
dose	O
coadministration	O
of	O
ambrisentan	B-O
and	O
cyclosporine	B
resulted	O
in	O
an	O
approximately	O
2-fold	O
increase	O
in	O
ambrisentan	B-O
exposure	O
in	O
healthy	O
volunteers	O
;	O
therefore	O
,	O
limit	O
the	O
dose	O
of	O
ambrisentan	B-O
to	O
5	O
mg	O
once	O
daily	O
when	O
coadministered	O
with	O
cyclosporine	B
.	O

Cyclosporine	B
increases	O
ambrisentan	B-O
exposure	O
;	O
limit	O
ambrisentan	B-O
dose	O
to	O
5	O
mg	O
once	O
daily	O
(	O
7	O
)	O
.	O

Concomitant	O
treatment	O
with	O
drugs	O
which	O
are	O
inhibitors	B
of	I
CYP1A2	I
and/or	I
CYP3A4	I
has	O
the	O
potential	O
to	O
increase	O
lidocaine	B-O
plasma	O
levels	O
by	O
decreasing	O
lidocaine	B-O
clearance	O
and	O
thereby	O
prolonging	O
the	O
elimination	O
half-life	O
.	O

Monitor	O
toxicity	O
when	O
administering	O
lidocaine	B-O
with	O
CYP1A2	B
and/or	I
CYP3A4	I
inhibitors	I
.	O

Concomitant	O
use	O
of	O
lidocaine	B-O
at	O
steady-state	O
concentrations	O
of	O
the	O
CYP1A2	O
inhibitor	O
fluvoxamine	B
increases	O
intravenous	O
lidocaine	B-O
plasma	O
AUC	O
and	O
Cmax	O
by	O
71	O
%	O
and	O
22	O
%	O
,	O
and	O
decreases	O
MEGX	B-O
AUC	O
and	O
Cmax	O
by	O
54	O
%	O
and	O
65	O
%	O
.	O

Fluvoxamine	B
decreases	O
the	O
plasma	O
clearance	O
of	O
lidocaine	B-O
by	O
41%-60	O
%	O
and	O
prolonged	O
the	O
mean	O
half-life	O
by	O
one	O
hour	O
.	O

Concomitant	O
use	O
of	O
lidocaine	B-O
with	O
propofol	B
,	O
a	O
hypnotic	O
agent	O
and	O
CYP3A4	O
inhibitor	O
,	O
may	O
increase	O
lidocaine	B-O
plasma	O
levels	O
by	O
reducing	O
lidocaine	B-O
clearance	O
.	O

Concomitant	O
treatment	O
with	O
drugs	O
which	O
are	O
inducers	B
of	I
CYP1A2	I
and/or	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
phenytoin	B
)	O
has	O
the	O
potential	O
to	O
decrease	O
lidocaine	B-O
plasma	O
levels	O
and	O
higher	O
doses	O
may	O
be	O
required	O
.	O

Concomitant	O
use	O
of	O
lidocaine	B-O
with	O
a	O
weak	O
CYP1A2	B
and	I
CYP3A4	I
inhibitor	I
has	O
been	O
reported	O
to	O
increase	O
lidocaine	B-O
plasma	O
levels	O
by	O
24	O
%	O
-	O
75	O
%	O
and	O
may	O
result	O
in	O
toxic	O
accumulation	O
of	O
the	O
drug	O
.	O

Beta-adrenergic	B
blockers	I
(	O
e	O
.g	O
.	O
propranolol	B
)	O
:	O
Concomitant	O
use	O
of	O
lidocaine	B-O
with	O
beta-adrenergic	B
blockers	I
may	O
increase	O
lidocaine	B-O
plasma	O
levels	O
by	O
decreasing	O
hepatic	O
blood	O
flow	O
and	O
thereby	O
decrease	O
lidocaine	B-O
clearance	O
.	O

Pretreatment	O
with	O
propranolol	B
,	O
metoprolol	B
and	O
nadolol	B
increased	O
the	O
serum	O
concentration	O
of	O
lidocaine	B-O
.	O

Coadministration	O
of	O
losartan	B-O
and	O
cimetidine	B
led	O
to	O
an	O
increase	O
of	O
about	O
18	O
%	O
in	O
AUC	O
of	O
losartan	B-O
but	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
its	O
active	O
metabolite	O
.	O

Coadministration	O
of	O
losartan	B-O
and	O
phenobarbital	B
led	O
to	O
a	O
reduction	O
of	O
about	O
20	O
%	O
in	O
the	O
AUC	O
of	O
losartan	B-O
and	O
that	O
of	O
its	O
active	O
metabolite	O
.	O

A	O
somewhat	O
greater	O
interaction	O
(	O
approximately	O
40	O
%	O
reduction	O
in	O
the	O
AUC	O
of	O
active	O
metabolite	O
and	O
approximately	O
30	O
%	O
reduction	O
in	O
the	O
AUC	O
of	O
losartan	B-O
)	O
has	O
been	O
reported	O
with	O
rifampin	B
.	O

Fluconazole	B
,	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
2C9	O
,	O
decreased	O
the	O
AUC	O
of	O
the	O
active	O
metabolite	O
by	O
approximately	O
40	O
%	O
,	O
but	O
increased	O
the	O
AUC	O
of	O
losartan	B-O
by	O
approximately	O
70	O
%	O
following	O
multiple	O
doses	O
.	O

The	O
AUC	O
of	O
active	O
metabolite	O
following	O
oral	O
losartan	B-O
was	O
not	O
affected	O
by	O
erythromycin	B
,	O
another	O
inhibitor	O
of	O
P4503A4	O
,	O
but	O
the	O
AUC	O
of	O
losartan	B-O
was	O
increased	O
by	O
30	O
%	O
.	O

Rifampin	B
,	O
an	O
inducer	O
of	O
drug	O
metabolism	O
,	O
decreased	O
the	O
concentrations	O
of	O
losartan	B-O
and	O
its	O
active	O
metabolite	O
.	O

Fluconazole	B
,	O
an	O
inhibitor	O
of	O
P450	O
2C9	O
,	O
decreased	O
active	O
metabolite	O
concentration	O
and	O
increased	O
losartan	B-O
concentration	O
.	O

A	O
meal	B
slows	O
absorption	O
of	O
losartan	B-O
and	O
decreases	O
its	O
Cmax	O
but	O
has	O
only	O
minor	O
effects	O
on	O
losartan	B-O
AUC	O
or	O
on	O
the	O
AUC	O
of	O
the	O
metabolite	O
(	O
about	O
10	O
%	O
decreased	O
)	O
.	O

Lithium	B-O
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B-O
concomitantly	O
with	O
Lotensin	B
.	O

Lithium	B-O
toxicity	O
was	O
usually	O
reversible	O
upon	O
discontinuation	O
of	O
lithium	B-O
or	O
Lotensin	B
.	O

Digoxin	B-O
:	O
When	O
MICARDIS	B
was	O
co-administered	O
with	O
digoxin	B-O
,	O
median	O
increases	O
in	O
digoxin	B-O
peak	O
plasma	O
concentration	O
(	O
49	O
%	O
)	O
and	O
in	O
trough	O
concentration	O
(	O
20	O
%	O
)	O
were	O
observed	O
.	O

Lithium	B-O
:	O
Reversible	O
increases	O
in	O
serum	O
lithium	B-O
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-O
with	O
angiotensin	B
II	I
receptor	I
antagonists	I
including	I
MICARDIS.	B

Food	B
slightly	O
reduces	O
the	O
bioavailability	O
of	O
telmisartan	B-O
,	O
with	O
a	O
reduction	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC)	O
of	O
about	O
6	O
%	O
with	O
the	O
40	O
mg	O
tablet	O
and	O
about	O
20	O
%	O
after	O
a	O
160	O
mg	O
dose	O
.	O

Drug	O
Interaction	O
Studies	O
Telmisartan	B
Ramipril	B-O
and	I-O
Ramiprilat	B-O
:	O
Co-administration	O
of	O
telmisartan	B
80	O
mg	O
once	O
daily	O
and	O
ramipril	B-O
10	O
mg	O
once	O
daily	O
to	O
healthy	O
subjects	O
increases	O
steady-state	O
Cmax	O
and	O
AUC	O
of	O
ramipril	B-O
2.3-	O
and	O
2.1-fold	O
,	O
respectively	O
,	O
and	O
Cmax	O
and	O
AUC	O
of	I-O
ramiprilat	B-O
2.4-	O
and	O
1.5-fold	O
,	O
respectively	O
.	O

When	O
co-administering	O
telmisartan	B
and	O
ramipril	B-O
,	O
the	O
response	O
may	O
be	O
greater	O
because	O
of	O
the	O
possibly	O
additive	O
pharmacodynamic	O
effects	O
of	O
the	O
combined	O
drugs	O
,	O
and	O
also	O
because	O
of	O
the	O
increased	O
exposure	O
to	O
ramipril	B-O
and	I-O
ramiprilat	B-O
in	O
the	O
presence	O
of	O
telmisartan	B
.	O

Telmisartan	B
is	O
not	O
expected	O
to	O
interact	O
with	O
drugs	O
that	O
inhibit	O
cytochrome	O
P450	O
enzymes	O
;	O
it	O
is	O
also	O
not	O
expected	O
to	O
interact	O
with	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
enzymes	O
,	O
except	O
for	O
possible	O
inhibition	O
of	O
the	O
metabolism	O
of	O
drugs	B-O
metabolized	I-O
by	I-O
CYP2C19	I-O
.	O

Cholestyramine	B
and	O
colestipol	B
resins	I
-	O
Cholestyramine	B
and	O
colestipol	B
resins	I
bind	O
the	O
hydrochlorothiazide	B-O
and	O
reduce	O
its	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
85	O
and	O
43	O
percent	O
,	O
respectively	O
.	O

Diuretic	B
agents	I
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-O
and	O
greatly	O
increase	O
the	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

When	O
MICROZIDE	B-O
is	O
administered	O
with	O
food	B
,	O
its	O
bioavailability	O
is	O
reduced	O
by	O
10	O
%	O
,	O
the	O
maximum	O
plasma	O
concentration	O
is	O
reduced	O
by	O
20	O
%	O
,	O
and	O
the	O
time	O
to	O
maximum	O
concentration	O
increases	O
from	O
1.6	O
to	O
2.9	O
hours	O
.	O

Dronedarone	B
increases	O
exposure	O
to	O
digoxin	B-O
.	O

Ketoconazole	B
and	O
Other	O
Potent	O
CYP3A	B
Inhibitors	I
Concomitant	O
use	O
of	O
ketoconazole	B
as	O
well	O
as	O
other	O
potent	O
CYP3A	B
inhibitors	I
such	O
as	O
itraconazole	B
,	O
voriconazole	B
,	O
ritonavir	B
,	O
clarithromycin	B
,	O
and	O
nefazodone	B
is	O
contraindicated	O
because	O
exposure	O
to	O
dronedarone	B-O
is	O
significantly	O
increased	O
.	O

Grapefruit	B
Juice	I
Patients	O
should	O
avoid	O
grapefruit	B
juice	I
beverages	O
while	O
taking	O
MULTAQ	B-O
because	O
exposure	O
to	O
dronedarone	B-O
is	O
significantly	O
increased	O
.	O

Rifampin	B
and	O
Other	O
CYP3A	B
Inducers	I
Avoid	O
rifampin	B
or	O
other	O
CYP3A	B
inducers	I
such	O
as	O
phenobarbital	B
,	O
carbamazepine	B
,	O
phenytoin	B
,	O
and	O
St	B
.	I
John	I
's	I
wort	I
because	O
they	O
decrease	O
exposure	O
to	O
dronedarone	B-O
significantly	O
.	O

Calcium	O
Channel	O
Blockers	O
Verapamil	B
and	O
diltiazem	B
are	O
moderate	O
CYP3A	O
inhibitors	O
and	O
increase	O
dronedarone	B-O
exposure	O
.	O

Simvastatin	B-O
Dronedarone	B
increased	I-O
simvastatin/simvastatin	B-O
acid	I-O
exposure	O
.	O

Calcium	B-O
Channel	I-O
Blockers	I-O
Dronedarone	B
increased	O
the	O
exposure	O
of	O
calcium	B-O
channel	I-O
blockers	I-O
(verapamil	B-O
,	O
diltiazem	B-O
or	O
nifedipine	B-O
)	O
.	O

Sirolimus	B-O
,	O
Tacrolimus	B-O
,	O
and	O
Other	O
CYP3A	B-O
Substrates	I-O
with	I-O
Narrow	I-O
Therapeutic	I-O
Range	I-O
Dronedarone	B
can	O
increase	O
plasma	O
concentrations	O
of	O
tacrolimus	B-O
,	O
sirolimus	B-O
,	O
and	O
other	O
CYP3A	O
substrates	O
with	O
a	O
narrow	O
therapeutic	O
range	O
when	O
given	O
orally	O
.	O

Beta-Blockers	O
and	O
Other	O
CYP2D6	O
Substrates	O
Dronedarone	B
increased	O
the	O
exposure	O
of	O
propranolol	B-O
and	O
metoprolol	B-O
.	O

Other	O
CYP2D6	B-O
substrates	I-O
,	O
including	O
other	O
beta-blockers	B-O
,	O
tricyclic	B-O
antidepressants	I-O
,	O
and	O
selective	B-O
serotonin	I-O
reuptake	I-O
inhibitors	I-O
(	O
SSRIs	O
)	O
may	O
have	O
increased	O
exposure	O
upon	O
coadministration	O
with	O
dronedarone	B
.	O

P-glycoprotein	O
Substrates	O
Digoxin	B-O
Dronedarone	B
increased	O
digoxin	B-O
exposure	O
by	O
inhibiting	O
the	O
P-gp	O
transporter	O
.	O

Dabigatran	B-O
Exposure	O
to	O
dabigatran	B-O
is	O
higher	O
when	O
it	O
is	O
administered	O
with	O
dronedarone	B
than	O
when	O
it	O
is	O
administered	O
alone	O
.	O

Other	O
P-gp	B-O
substrates	I-O
are	O
expected	O
to	O
have	O
increased	O
exposure	O
when	O
coadministered	O
with	O
dronedarone	B
.	O

Warfarin	B-O
When	O
coadministered	O
with	O
dronedarone	B
exposure	O
to	O
S-warfarin	B-O
was	O
slightly	O
higher	O
than	O
when	O
warfarin	B-O
was	O
administered	O
alone	O
.	O

Cimetidine	B
increases	O
nicardipine	B-O
plasma	O
levels	O
(	O
7.3	O
)	O
.	O

Nicardipine	B
may	O
increase	O
cyclosporine	B-O
and	O
tacrolimus	B-O
plasma	O
levels	O
.	O

Cimetidine	B
has	O
been	O
shown	O
to	O
increase	O
nicardipine	B-O
plasma	O
concentrations	O
with	O
oral	O
nicardipine	B-O
administration	O
.	O

Concomitant	O
administration	O
of	O
oral	O
or	O
intravenous	O
nicardipine	B
and	O
cyclosporine	B-O
results	O
in	O
elevated	O
plasma	O
cyclosporine	B-O
levels	O
through	O
nicardipine	B
inhibition	O
of	O
hepatic	O
microsomal	O
enzymes	O
,	O
including	O
CYP3A4	O
.	O

Concomitant	O
administration	O
of	O
intravenous	O
nicardipine	B
and	O
tacrolimus	B-O
may	O
result	O
in	O
elevated	O
plasma	O
tacrolimus	B-O
levels	O
through	O
nicardipine	B
inhibition	O
of	O
hepatic	O
microsomal	O
enzymes	O
,	O
including	O
CYP3A4	O
.	O

CYP3A	B
Inhibitors	I
Co-administration	O
with	O
CYP3A	B
inhibitors	I
(	O
moderate	O
and	O
strong	O
)	O
results	O
in	O
increased	O
systemic	O
exposure	O
to	O
amlodipine	B-O
and	O
may	O
require	O
dose	O
reduction	O
.	O

Simvastatin	B-O
Co-administration	O
of	O
simvastatin	B-O
with	O
amlodipine	B
increases	O
the	O
systemic	O
exposure	O
of	O
simvastatin	B-O
.	O

Immunosuppressants	O
Amlodipine	B
may	O
increase	O
the	O
systemic	O
exposure	O
of	O
cyclosporine	B-O
or	O
tacrolimus	B-O
when	O
co-administered	O
.	O

CYP3A	O
inhibitors	O
:	O
Co-administration	O
of	O
a	O
180	O
mg	O
daily	O
dose	O
of	O
diltiazem	B
with	O
5	O
mg	O
amlodipine	B-O
in	O
elderly	O
hypertensive	O
patients	O
resulted	O
in	O
a	O
60	O
%	O
increase	O
in	O
amlodipine	B-O
systemic	O
exposure	O
.	O

However	O
,	O
strong	O
inhibitors	B
of	I
CYP3A	I
(	O
e	O
.g.	O
,	O
itraconazole	B
,	O
clarithromycin	B
)	O
may	O
increase	O
the	O
plasma	O
concentrations	O
of	O
amlodipine	B-O
to	O
a	O
greater	O
extent	O
.	O

Impact	O
of	O
amlodipine	B
on	O
other	O
drugs	O
Amlodipine	B
is	O
a	O
weak	O
inhibitor	O
of	O
CYP3A	O
and	O
may	O
increase	O
exposure	O
to	O
CYP3A	B-O
substrates	I-O
.	O

Simvastatin	B-O
:	O
Co-administration	O
of	O
multiple	O
doses	O
of	O
10	O
mg	O
of	O
amlodipine	B
with	O
80	O
mg	O
simvastatin	B-O
resulted	O
in	O
a	O
77	O
%	O
increase	O
in	O
exposure	O
to	O
simvastatin	B-O
compared	O
to	O
simvastatin	B-O
alone	O
.	O

Cyclosporine	B-O
:	O
A	O
prospective	O
study	O
in	O
renal	O
transplant	O
patients	O
(	O
N=11	O
)	O
showed	O
on	O
an	O
average	O
of	O
40	O
%	O
increase	O
in	O
trough	O
cyclosporine	B-O
levels	O
when	O
concomitantly	O
treated	O
with	O
amlodipine	B
.	O

Tacrolimus	B-O
:	O
A	O
prospective	O
study	O
in	O
healthy	O
Chinese	O
volunteers	O
(	O
N=9	O
)	O
with	O
CYP3A5	O
expressers	O
showed	O
a	O
2.5-	O
to	O
4-fold	O
increase	O
in	O
tacrolimus	B-O
exposure	O
when	O
concomitantly	O
administered	O
with	O
amlodipine	B
compared	O
to	O
tacrolimus	B-O
alone	O
.	O

However	O
,	O
a	O
3-fold	O
increase	O
in	O
plasma	O
exposure	O
to	O
tacrolimus	B-O
in	O
a	O
renal	O
transplant	O
patient	O
(	O
CYP3A5	O
non-expresser	O
)	O
upon	O
initiation	O
of	O
amlodipine	B
for	O
the	O
treatment	O
of	O
post-transplant	O
hypertension	O
resulting	O
in	O
reduction	O
of	O
tacrolimus	B-O
dose	O
has	O
been	O
reported	O
.	O

Adenosine	B-O
:	O
Dipyridamole	B
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
and	O
cardiovascular	O
effects	O
of	O
adenosine	B-O
.	O

PHOSLYRA	B
may	O
decrease	O
the	O
bioavailability	O
of	O
tetracyclines	B-O
fluoroquinolones	B-O
or	O
levothyroxine	B-O
.	O

Drug	O
Interactions	O
In	O
vivo	O
In	O
a	O
study	O
of	O
15	O
healthy	O
subjects	O
,	O
a	O
co-administered	O
single	O
dose	O
of	O
4	O
calcium	B
acetate	I
tablets	O
(	O
approximately	O
2.7	O
g	O
)	O
decreased	O
the	O
bioavailability	O
of	O
ciprofloxacin	B-O
by	O
approximately	O
50	O
%	O
.	O

Reduction	O
of	O
Risk	O
of	O
Stroke	O
and	O
Systemic	O
Embolism	O
in	O
Non-valvular	O
Atrial	O
Fibrillation	O
In	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
CrCl	O
30-50	O
mL/min	O
)	O
,	O
concomitant	O
use	O
of	O
the	O
P-gp	O
inhibitor	O
dronedarone	B
or	O
systemic	O
ketoconazole	B
can	O
be	O
expected	O
to	O
produce	O
dabigatran	B-O
exposure	O
similar	O
to	O
that	O
observed	O
in	O
severe	O
renal	O
impairment	O
.	O

P-gp	B
inducers	I
rifampin	B
:	O
Avoid	O
coadministration	O
with	O
PRADAXA	B-O
(	O
5.5	O
)	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
CrCl	O
30-50	O
mL/min	O
:	O
Reduce	O
dose	O
or	O
avoid	O
(	O
7	O
)	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
CrCl	O
<30	O
mL/min	O
:	O
Not	O
recommended	O
(	O
7	O
)	O
The	O
concomitant	O
use	O
of	O
PRADAXA	B-O
with	O
P-gp	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
)	O
reduces	O
exposure	O
to	O
dabigatran	B-O
and	O
should	O
generally	O
be	O
avoided	O
.	O

Concomitant	O
use	O
of	O
P-gp	B
inhibitors	I
in	O
patients	O
with	O
renal	O
impairment	O
is	O
expected	O
to	O
produce	O
increased	O
exposure	O
of	O
dabigatran	B-O
compared	O
to	O
that	O
seen	O
with	O
either	O
factor	O
alone	O
.	O

The	O
concomitant	O
use	O
of	O
PRADAXA	B-O
with	O
P-gp	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
)	O
reduces	O
exposure	O
to	O
dabigatran	B-O
and	O
should	O
generally	O
be	O
avoided	O
.	O

Coadministration	O
of	O
PRADAXA	B-O
with	O
a	O
high-fat	B
meal	I
delays	O
the	O
time	O
to	O
Cmax	O
by	O
approximately	O
2	O
hours	O
but	O
has	O
no	O
effect	O
on	O
the	O
bioavailability	O
of	O
dabigatran	B-O
;	O
PRADAXA	B-O
may	O
be	O
administered	O
with	O
or	O
without	O
food	O
.	O

There	O
have	O
been	O
rare	O
reports	O
of	O
an	O
interaction	O
between	O
quinidine	B-O
and	O
nifedipine	B
(	O
with	O
a	O
decreased	O
plasma	O
level	O
of	O
quinidine	B-O
)	O
.	O

A	O
study	O
in	O
six	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
nifedipine	B-O
plasma	O
levels	O
(	O
80	O
%	O
)	O
and	O
area-under-the-curve	O
(	O
74	O
%	O
)	O
after	O
a	O
one	O
week	O
course	O
of	O
cimetidine	B
at	O
1000	O
mg	O
per	O
day	O
and	O
nifedipine	B-O
at	O
40	O
mg	O
per	O
day	O
.	O

Co-administration	O
of	O
nifedipine	B-O
with	O
phenytoin	B
,	O
an	O
inducer	O
of	O
CYP3A4	O
,	O
lowers	O
the	O
systemic	O
exposure	O
to	O
nifedipine	B-O
by	O
approximately	O
70	O
%	O
.	O

CYP3A	B
inhibitors	I
such	O
as	O
fluconazole	B
,	O
itraconazole	B
,	O
clarithromycin	B
,	O
erythromycin	B
,	O
nefazodone	B
,	O
fluoxetine	B
,	O
saquinavir	B
,	O
indinavir	B
,	O
and	O
nelfinavir	B
may	O
result	O
in	O
increased	O
exposure	O
to	O
nifedipine	B-O
when	O
co-administered	O
.	O

Co-administration	O
of	O
nifedipine	B-O
with	O
grapefruit	B
juice	I
resulted	O
in	O
approximately	O
a	O
doubling	O
in	O
nifedipine	B-O
AUC	O
and	O
Cmax	O
with	O
no	O
change	O
in	O
half-life	O
.	O

Drug	O
interactions	O
-	O
Altered	O
pharmacokinetics	O
of	O
quinidine	B-O
:	O
Drugs	B
that	I
alkalinize	I
the	I
urine	I
(	O
carbonic-anhydrase	B
inhibitors	I
,	O
sodium	B
bicarbonate	I
,	O
thiazide	B
diuretics	I
)	O
reduce	O
renal	O
elimination	O
of	O
quinidine	B-O
.	O

By	O
pharmacokinetic	O
mechanisms	O
that	O
are	O
not	O
well	O
understood	O
,	O
quinidine	B-O
levels	O
are	O
increased	O
by	O
coadministration	O
of	O
amiodarone	B
or	O
cimetidine	B
.	O

Very	O
rarely	O
,	O
and	O
again	O
by	O
mechanisms	O
not	O
understood	O
,	O
quinidine	B-O
levels	O
are	O
decreased	O
by	O
coadministration	O
of	O
nifedipine	B
.	O

Hepatic	O
elimination	O
of	O
quinidine	B-O
may	O
be	O
accelerated	O
by	O
coadministration	O
of	O
drugs	O
(	O
phenobarbital	B
,	O
phenytoin	B
,	O
rifampin	B
)	O
that	O
induce	O
production	O
of	O
cytochrome	O
P450IIIA4	O
.	O

Perhaps	O
because	O
of	O
competition	O
of	O
the	O
P450IIIA4	O
metabolic	O
pathway	O
,	O
quinidine	B-O
levels	O
rise	O
when	O
ketaconazole	B
is	O
coadministered	O
.	O

Coadministration	O
of	O
propranolol	B
usually	O
does	O
not	O
affect	O
quinidine	B-O
pharmacokinetics	O
,	O
but	O
in	O
some	O
studies	O
,	O
the	O
beta-blocker	O
appeared	O
to	O
cause	O
increases	O
in	O
the	O
peak	O
serum	O
levels	O
of	O
quinidine	B-O
,	O
decreases	O
in	O
quinidine	B-O
's	O
volume	O
of	O
distribution	O
and	O
decreases	O
in	O
total	O
quinidine	B-O
clearance	O
.	O

Hepatic	O
clearance	O
of	O
quinidine	B-O
is	O
significantly	O
reduced	O
during	O
coadministration	O
of	O
verapamil	B
,	O
with	O
corresponding	O
increases	O
in	O
serum	O
levels	O
and	O
half-life	O
.	O

Altered	O
pharmacokinetics	O
of	O
other	O
drugs	O
:	O
Quinidine	B
slows	O
the	O
elimination	O
of	O
digoxin	B-O
and	O
simultaneously	O
reduces	O
digoxin	B-O
's	O
apparent	O
volume	O
of	O
distribution	O
.	O

Serum	O
levels	O
of	O
digitoxin	B-O
are	O
also	O
raised	O
when	O
quinidine	B
is	O
coadministered	O
,	O
although	O
the	O
effect	O
appears	O
to	O
be	O
smaller	O
.	O

By	O
a	O
mechanism	O
that	O
is	O
not	O
understood	O
,	O
quinidine	B
potentiates	O
the	O
anticoagulatory	O
action	O
of	O
warfarin	B-O
,	O
and	O
the	O
anticoagulant	O
dosage	O
may	O
need	O
to	O
be	O
reduced	O
.	O

Perhaps	O
by	O
competing	O
for	O
pathways	O
of	O
renal	O
clearance	O
,	O
coadministration	O
of	O
quinidine	B
causes	O
an	O
increase	O
in	O
serum	O
levels	O
of	O
procainamide	B-O
.	O

Serum	O
levels	O
of	O
haloperidol	B-O
are	O
increased	O
when	O
quinidine	B
is	O
coadministered	O
.	O

Presumably	O
because	O
both	O
drugs	O
are	O
metabolized	O
by	O
cyctochrome	O
P450IIIA4	O
,	O
coadministration	O
of	O
quinidine	B
causes	O
variable	O
slowing	O
of	O
the	O
metabolism	O
of	O
nifedipine	B-O
.	O

In	O
addition	O
,	O
in	O
vitro	O
addition	O
of	O
quinidine	B
to	O
the	O
serum	O
of	O
pregnant	O
women	O
reduces	O
the	O
activity	O
of	O
pseudocholinesterase	B-O
,	O
an	O
enzyme	O
that	O
is	O
essential	O
to	O
the	O
metabolism	O
of	O
succinylcholine	B-O
.	O

Diltiazem	B
significantly	O
decreases	O
the	O
clearance	O
and	O
increases	O
the	O
t1/2	O
of	O
quinidine	B-O
,	O
but	O
quinidine	B-O
does	O
not	O
alter	O
the	O
kinetics	O
of	O
diltiazem	B
.	O

In	O
preclinical	O
studies	O
in	O
rats	O
and	O
dogs	O
,	O
sevelamer	B
hydrochloride	I
,	O
which	O
contains	O
the	O
same	O
active	O
moiety	O
as	O
sevelamer	O
carbonate	O
,	O
reduced	O
vitamins	B-O
D	I-O
,	I-O
E	I-O
,	I-O
and	I-O
K	I-O
(	O
coagulation	O
parameters	O
)	O
and	O
folic	B-O
acid	I-O
levels	O
at	O
doses	O
of	O
6-10	O
times	O
the	O
recommended	O
human	O
dose	O
.	O

However	O
,	O
in	O
a	O
one-year	O
clinical	O
trial	O
,	O
25-hydroxyvitamin	B-O
D	I-O
(	O
normal	O
range	O
10	O
to	O
55	O
ng/mL	O
)	O
fell	O
from	O
39	O
plus/minus	O
22	O
ng/mL	O
to	O
34	O
plus/minus	O
22	O
ng/mL	O
(	O
p<0.01	O
)	O
with	O
sevelamer	B
hydrochloride	I
treatment	O
.	O

Coadministered	O
single	O
dose	O
of	O
2.8	O
grams	O
of	O
sevelamer	B
hydrochloride	I
in	O
fasted	O
state	O
decreased	O
the	O
bioavailability	O
of	O
ciprofloxacin	B-O
by	O
approximately	O
50	O
%	O
in	O
healthy	O
subjects	O
.	O

Concomitant	O
administration	O
of	O
sevelamer	B
and	O
mycophenolate	B-O
mofetil	I-O
in	O
adult	O
and	O
pediatric	O
patients	O
decreased	O
the	O
mean	O
MPA	B-O
Cmax	O
and	O
AUC0-12h	O
by	O
36	O
%	O
and	O
26	O
%	O
,	O
respectively	O
.	O

Reduction	O
in	O
concentrations	O
of	O
cyclosporine	B-O
and	O
tacrolimus	B-O
leading	O
to	O
dose	O
increases	O
has	O
also	O
been	O
reported	O
in	O
transplant	O
patients	O
when	O
coadministered	O
with	O
sevelamer	B
hydrochloride	I
without	O
any	O
clinical	O
consequences	O
(	O
for	O
example	O
,	O
graft	O
rejection	O
)	O
.	O

When	O
REVATIO	B-O
is	O
taken	O
with	O
a	O
high-fat	B
meal	I
,	O
the	O
rate	O
of	O
absorption	O
is	O
reduced	O
,	O
with	O
a	O
mean	O
delay	O
in	O
Tmax	O
of	O
60	O
minutes	O
and	O
a	O
mean	O
reduction	O
in	O
Cmax	O
of	O
29	O
%	O
.	O

Effects	O
of	O
Other	O
Drugs	O
on	O
Sildenafil	B-O
Pharmacokinetics	O
Figure	O
8	O
Effects	O
of	O
Sildenafil	B-O
on	O
Other	O
Drugs	O
Figure	O
7	O
Figure	O
8	O
CYP3A	B
Inhibitors	I
and	O
Beta	O
Blockers	O
Population	O
pharmacokinetic	O
analysis	O
of	O
data	O
from	O
patients	O
in	O
clinical	O
trials	O
indicated	O
an	O
approximately	O
30	O
%	O
reduction	O
in	O
sildenafil	B-O
clearance	O
when	O
it	O
was	O
co-administered	O
with	O
mild/moderate	O
CYP3A	B
inhibitors	I
and	O
an	O
approximately	O
34	O
%	O
reductions	O
in	O
sildenafil	B-O
clearance	O
when	O
co-administered	O
with	O
beta-blockers	B
.	O

CYP3A4	O
inducers	O
including	O
bosentan	B
Concomitant	O
administration	O
of	O
potent	O
CYP3A	B
inducers	I
is	O
expected	O
to	O
cause	O
substantial	O
decreases	O
in	O
plasma	O
levels	O
of	O
sildenafil	B-O
.	O

Population	O
pharmacokinetic	O
analysis	O
of	O
data	O
from	O
patients	O
in	O
clinical	O
trials	O
indicated	O
approximately	O
3-fold	O
the	O
sildenafil	B-O
clearance	O
when	O
it	O
was	O
co-administered	O
with	O
mild	O
CYP3A	B
inducers	I
.	O

Epoprostenol	B
The	O
mean	O
reduction	O
of	O
sildenafil	B-O
(	O
80	O
mg	O
three	O
times	O
a	O
day	O
)	O
bioavailability	O
when	O
co-administered	O
with	O
epoprostenol	B
was	O
28	O
%	O
,	O
resulting	O
in	O
about	O
22	O
%	O
lower	O
mean	O
average	O
steady	O
state	O
concentrations	O
.	O

Therefore	O
,	O
the	O
slight	O
decrease	O
of	O
sildenafil	B-O
exposure	O
in	O
the	O
presence	O
of	O
epoprostenol	B
is	O
not	O
considered	O
clinically	O
relevant	O
.	O

A	O
30	O
to	O
45	O
%	O
increase	O
in	O
AUC	O
and	O
Cmax	O
of	O
nisoldipine	B-O
was	O
observed	O
with	O
concomitant	O
administration	O
of	O
cimetidine	B
400	O
mg	O
twice	O
daily	O
.	O

Coadministration	O
of	O
phenytoin	B
with	O
a	O
dose	O
bioequivalent	O
to	O
34	O
mg	O
SULAR	B-O
tablets	O
in	O
epileptic	O
patients	O
lowered	O
the	O
nisoldipine	B-O
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Quinidine	B
at	O
648	O
mg	O
bid	O
decreased	O
the	O
bioavailability	O
(	O
AUC)	O
of	O
nisoldipine	B-O
by	O
26	O
%	O
,	O
but	O
not	O
the	O
peak	O
concentration	O
.	O

Immediate	O
release	O
nisoldipine	B
increased	O
plasma	O
quinidine	B-O
concentrations	O
by	O
about	O
20	O
%	O
.	O

Grapefruit	B
juice	I
,	O
which	O
has	O
been	O
shown	O
to	O
increase	O
significantly	O
the	O
bioavailability	O
of	O
nisoldipine	B-O
and	O
other	O
dihydropyridine	B-O
type	I-O
calcium	I-O
channel	I-O
blockers	I-O
,	O
should	O
not	O
be	O
taken	O
with	O
SULAR	B-O
.	O

A	O
pronounced	O
food-effect	O
is	O
observed	O
when	O
SULAR	B-O
is	O
administered	O
with	O
a	O
high-fat	B
meal	I
resulting	O
in	O
an	O
increased	O
peak	O
concentration	O
(	O
Cmax	O
)	O
of	O
up	O
to	O
245	O
%	O
.	O

Nisoldipine	B-O
should	O
not	O
be	O
administered	O
with	O
grapefruit	B
juice	I
,	O
as	O
this	O
has	O
been	O
shown	O
,	O
in	O
a	O
study	O
of	O
12	O
subjects	O
,	O
to	O
interfere	O
with	O
nisoldipine	B-O
metabolism	O
,	O
resulting	O
in	O
a	O
mean	O
increase	O
in	O
Cmax	O
of	O
about	O
3-fold	O
(	O
ranging	O
up	O
to	O
about	O
7-fold	O
)	O
and	O
AUC	O
of	O
almost	O
2-fold	O
(	O
ranging	O
up	O
to	O
about	O
5-fold	O
)	O
.	O

Lithium	B-O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

Lithium	B-O
renal	O
clearance	O
is	O
reduced	O
by	O
chlorthalidone	B
,	O
increasing	O
the	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

CYP2D6	B
Inhibitors	I
are	O
likely	O
to	O
increase	O
metoprolol	B-O
concentration	O
.	O

Drugs	B
that	I
inhibit	I
CYP2D6	I
such	O
as	O
quinidine	B
,	O
fluoxetine	B
,	O
paroxetine	B
,	O
and	O
propafenone	B
are	O
likely	O
to	O
increase	O
metoprolol	B-O
concentration	O
.	O

In	O
healthy	O
subjects	O
with	O
CYP2D6	O
extensive	O
metabolizer	O
phenotype	O
,	O
coadministration	O
of	O
quinidine	B
100	O
mg	O
and	O
immediate-release	O
metoprolol	B-O
200	O
mg	O
tripled	O
the	O
concentration	O
of	O
S-metoprolol	B-O
and	O
doubled	O
the	O
metoprolol	B-O
elimination	O
half-life	O
.	O

In	O
four	O
patients	O
with	O
cardiovascular	O
disease	O
,	O
coadministration	O
of	O
propafenone	B
150	O
mg	O
t.i.d	O
.	O
with	O
immediate-release	O
metoprolol	B-O
50	O
mg	O
t.i.d	O
.	O
resulted	O
in	O
two	O
-	O
to	O
five-fold	O
increases	O
in	O
the	O
steady-state	O
concentration	O
of	O
metoprolol	B-O
.	O

Poor	O
metabolizers	O
and	O
extensive	O
metabolizers	O
who	O
concomitantly	O
use	O
CYP2D6	B
inhibiting	I
drugs	I
will	O
have	O
increased	O
(	O
several-fold	O
)	O
metoprolol	B-O
blood	O
levels	O
,	O
decreasing	O
metoprolol	B-O
's	O
cardioselectivity	O
.	O

Clinically	O
significant	O
interactions	O
have	O
been	O
reported	O
with	O
inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g	O
.	O
erythromycin	B
,	O
ritonavir	B
)	O
causing	O
elevation	O
of	O
plasma	O
levels	O
of	O
verapamil	B-O
while	O
inducers	B
of	I
CYP3A4	I
(	O
e	O
.g	O
.	O
rifampin	B
)	O
have	O
caused	O
a	O
lowering	O
of	O
plasma	O
levels	O
of	O
verapamil	B-O
.	O

Concurrent	O
use	O
of	O
verapamil	B
increases	O
exposure	O
to	O
ivabradine	B-O
and	O
may	O
exacerbate	O
bradycardia	O
and	O
conduction	O
disturbances	O
.	O

Chronic	O
verapamil	B
treatment	O
can	O
increase	O
serum	O
digoxin	B-O
levels	O
by	O
50	O
to	O
75	O
%	O
during	O
the	O
first	O
week	O
of	O
therapy	O
,	O
and	O
this	O
can	O
result	O
in	O
digoxin	B-O
toxicity	O
.	O

Verapamil	B
may	O
reduce	O
total	O
body	O
clearance	O
and	O
extrarenal	O
clearance	O
of	O
digitoxin	B-O
by	O
27	O
%	O
and	O
29	O
%	O
,	O
respectively	O
.	O

Maintenance	O
digoxin	B-O
doses	O
should	O
be	O
reduced	O
when	O
verapamil	B
is	O
administered	O
,	O
and	O
the	O
patient	O
should	O
be	O
carefully	O
monitored	O
to	O
avoid	O
over-	O
or	O
under-digitalization	O
.	O

Verapamil	B
Component	O
Increased	O
sensitivity	O
to	O
the	O
effects	O
of	O
lithium	B-O
(	O
neurotoxicity	O
)	O
has	O
been	O
reported	O
during	O
concomitant	I
verapamil-lithium	B-O
therapy	O
with	O
either	O
no	O
change	O
or	O
an	O
increase	O
in	O
serum	O
lithium	B-O
levels	O
.	O

Increased	O
serum	O
lithium	B-O
levels	O
and	O
symptoms	O
of	O
lithium	B-O
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	B-O
and	O
ACE	B
inhibitor	I
therapy	O
.	O

If	O
a	O
diuretic	B
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	B-O
toxicity	O
may	O
be	O
increased	O
.	O

There	O
has	O
been	O
a	O
report	O
of	O
increased	O
quinidine	B-O
levels	O
during	O
verapamil	B
therapy	O
.	O

There	O
are	O
reports	O
that	O
verapamil	B
may	O
result	O
in	O
higher	O
concentrations	O
of	O
the	O
alpha-agonists	O
prazosin	B-O
and	O
terazosin	B-O
.	O

Drug	O
interaction	O
studies	O
have	O
indicated	O
that	O
the	O
maximum	O
concentrations	O
of	O
metoprolol	B-O
and	O
propanolol	B-O
are	O
increased	O
after	O
the	O
administration	O
of	O
verapamil	B
.	O

Co-administration	O
of	O
multiple	O
doses	O
of	O
10	O
mg	O
of	O
verapamil	B
with	O
80	O
mg	O
simvastatin	B-O
resulted	O
in	O
exposure	O
to	O
simvastatin	B-O
2.5-fold	O
that	O
following	O
simvastatin	B-O
alone	O
.	O

Limit	O
the	O
daily	O
dose	O
of	O
lovastatin	O
to	O
40	O
mg	O
.	O
Lower	O
starting	O
and	O
maintenance	O
doses	O
of	O
other	O
CYP3A4	B-O
substrates	I-O
(	O
e	O
.g.	O
,	O
atorvastatin	B-O
)	O
may	O
be	O
required	O
as	O
verapamil	B
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
these	O
drugs	O
.	O

Carbamazepine	B-O
Verapamil	B
may	O
increase	O
carbamazepine	B-O
concentrations	O
during	O
combined	O
therapy	O
.	O

Anti-infective	O
Agents	O
Therapy	O
with	O
rifampin	B
may	O
markedly	O
reduce	O
oral	O
verapamil	B-O
bioavailability	O
.	O

There	O
have	O
been	O
reports	O
that	O
erythromycin	B
and	O
telithromycin	B
may	O
increase	O
concentrations	O
of	O
verapamil	B-O
.	O

Barbiturates	O
Phenobarbital	B
therapy	O
may	O
increase	O
verapamil	B-O
clearance	O
.	O

Immunosuppressive	O
Agents	O
Verapamil	B
therapy	O
may	O
increase	O
serum	O
levels	O
of	O
cyclosporin	B-O
,	O
sirolimus	B-O
and	O
tacrolimus	B-O
.	O

Theophylline	B-O
Verapamil	B
therapy	O
may	O
inhibit	O
the	O
clearance	O
and	O
increase	O
the	O
plasma	O
levels	O
of	O
theophylline	B-O
.	O

Tranquilizers	O
/	O
Anti-depressants	O
Due	O
to	O
metabolism	O
via	O
the	O
CYP	O
enzyme	O
system	O
,	O
there	O
have	O
been	O
reports	O
that	O
verapamil	B
may	O
increase	O
the	O
concentrations	O
of	O
buspirone	B-O
,	O
midazolam	B-O
,	O
almotriptan	B-O
and	O
imipramine	B-O
.	O

When	O
verapamil	B
and	O
colchicine	B-O
are	O
administered	O
together	O
,	O
the	O
potential	O
inhibition	O
of	O
P-gp	O
and/or	O
CYP3A	O
by	O
verapamil	B
may	O
lead	O
to	O
increased	O
exposure	O
to	O
colchicine	B-O
.	O

Dabigatran	B-O
Verapamil	B
,	O
a	O
P-gp	O
inhibitor	O
,	O
increases	O
exposure	O
to	O
dabigatran	B-O
(	O
a	O
thrombin	O
inhibitor	O
)	O
when	O
administered	O
concomitantly	O
;	O
however	O
,	O
no	O
dose	O
adjustment	O
of	O
dabigatran	B-O
is	O
required	O
when	O
administered	O
with	O
verapamil	B
.	O

Other	O
Concentrations	O
of	O
verapamil	B-O
may	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
protease	B
inhibitors	I
such	O
as	O
ritonavir	B
,	O
and	O
reduced	O
by	O
the	O
concomitant	O
administration	O
of	O
sulfinpyrazone	B
,	O
or	O
St	B
John	I
's	I
Wort	I
.	O

Concentrations	O
of	O
doxorubicin	B-O
may	O
be	O
increased	O
by	O
the	O
administration	O
of	O
verapamil	B
.	O

There	O
have	O
been	O
reports	O
that	O
verapamil	B
may	O
elevate	O
the	O
concentrations	O
of	O
the	O
oral	O
anti-diabetic	O
glyburide	B-O
.	O

Administration	O
of	O
TARKA	B-O
4/240	O
(	O
4	O
mg	O
trandolapril	O
and	O
240	O
mg	O
verapamil	B-O
hydrochloride	O
ER	O
)	O
with	O
a	O
high-fat	B
meal	I
does	O
not	O
alter	O
the	O
bioavailability	O
of	O
trandolapril	O
whereas	O
verapamil	B-O
peak	O
concentrations	O
and	O
area	O
under	O
the	O
curve	O
(	O
AUC)	O
decrease	O
37	O
%	O
and	O
28	O
%	O
,	O
respectively	O
.	O

Food	B
thus	O
decreases	O
verapamil	B-O
bioavailability	O
and	O
the	O
time	O
to	O
peak	O
plasma	O
concentration	O
for	O
both	O
verapamil	B-O
and	O
norverapamil	B-O
are	O
delayed	O
by	O
approximately	O
7	O
hours	O
.	O

The	O
concomitant	O
use	O
of	O
verapamil	B
or	O
the	O
cation	O
transport	O
system	O
inhibitors	O
cimetidine	B
,	O
trimethoprim	B
(	O
alone	O
or	O
in	O
combination	O
with	O
sulfamethoxazole	B
)	O
,	O
or	O
ketoconazole	B
with	O
TIKOSYN	B-O
is	O
contraindicated	O
,	O
as	O
each	O
of	O
these	O
drugs	O
cause	O
a	O
substantial	O
increase	O
in	O
dofetilide	B-O
plasma	O
concentrations	O
.	O

The	O
concomitant	O
use	O
of	O
hydrochlorothiazide	B
(	O
alone	O
or	O
in	O
combinations	O
such	O
as	O
with	O
triamterene	B
)	O
with	O
TIKOSYN	B-O
is	O
contraindicated	O
because	O
this	O
has	O
been	O
shown	O
to	O
significantly	O
increase	O
dofetilide	B-O
plasma	O
concentrations	O
and	O
QT	O
interval	O
prolongation	O
.	O

Cimetidine	B
at	O
400	O
mg	O
BID	O
(	O
the	O
usual	O
prescription	O
dose	O
)	O
co-administered	O
with	O
TIKOSYN	B-O
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B-O
plasma	O
levels	O
by	O
58	O
%	O
.	O

Cimetidine	B
at	O
doses	O
of	O
100	O
mg	O
BID	O
(	O
OTC	O
dose	O
)	O
resulted	O
in	O
a	O
13	O
%	O
increase	O
in	O
dofetilide	B-O
plasma	O
levels	O
(	O
500	O
mcg	O
single	O
dose	O
)	O
.	O

Co-administration	O
of	O
TIKOSYN	B-O
with	O
verapamil	B
resulted	O
in	O
increases	O
in	O
dofetilide	B-O
peak	O
plasma	O
levels	O
of	O
42	O
%	O
,	O
although	O
overall	O
exposure	O
to	O
dofetilide	B-O
was	O
not	O
significantly	O
increased	O
.	O

Ketoconazole	B
at	O
400	O
mg	O
daily	O
(	O
the	O
maximum	O
approved	O
prescription	O
dose	O
)	O
co-administered	O
with	O
TIKOSYN	B-O
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B-O
Cmax	O
by	O
53	O
%	O
in	O
males	O
and	O
97	O
%	O
in	O
females	O
,	O
and	O
AUC	O
by	O
41	O
%	O
in	O
males	O
and	O
69	O
%	O
in	O
females	O
.	O

Trimethoprim	B
160	O
mg	O
in	O
combination	O
with	O
800	O
mg	O
sulfamethoxazole	B
co-administered	O
BID	O
with	O
TIKOSYN	B-O
(	O
500	O
mcg	O
BID	O
)	O
for	O
4	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B-O
AUC	O
by	O
103	O
%	O
and	O
Cmax	O
by	O
93	O
%	O
.	O

In	O
patients	O
receiving	O
HCTZ	B
alone	O
,	O
dofetilide	B-O
AUC	O
increased	O
by	O
27	O
%	O
and	O
Cmax	O
by	O
21	O
%	O
.	O

In	O
patients	O
receiving	O
HCTZ	B
in	O
combination	O
with	O
triamterene	B
,	O
dofetilide	B-O
AUC	O
increased	O
by	O
30	O
%	O
and	O
Cmax	O
by	O
16	O
%	O
.	O

In	O
addition	O
,	O
drugs	O
that	O
are	O
actively	O
secreted	O
via	O
this	O
route	O
(	O
e	O
.g.	O
,	O
triamterene	B
,	O
metformin	B
,	O
and	O
amiloride	B
)	O
should	O
be	O
co-administered	O
with	O
care	O
as	O
they	O
might	O
increase	O
dofetilide	B-O
levels	O
.	O

Inhibitors	B
of	I
the	I
CYP3A4	I
isoenzyme	O
could	O
increase	O
systemic	O
dofetilide	B-O
exposure	O
.	O

Inhibitors	O
of	O
this	O
isoenzyme	O
(	O
e	O
.g.	O
,	O
macrolide	B
antibiotics	I
,	O
azole	B
antifungal	I
agents	I
,	O
protease	B
inhibitors	I
,	O
serotonin	B
reuptake	I
inhibitors	I
,	O
amiodarone	B
,	O
cannabinoids	B
,	O
diltiazem	B
,	O
grapefruit	B
juice	I
,	O
nefazadone	B
,	O
norfloxacin	O
,	O
quinine	B
,	O
zafirlukast	B
)	O
should	O
be	O
cautiously	O
co-administered	O
with	O
TIKOSYN	B-O
as	O
they	O
can	O
potentially	O
increase	O
dofetilide	B-O
levels	O
.	O

The	O
mean	O
clearances	O
of	O
dofetilide	B-O
were	O
16	O
%	O
and	O
15	O
%	O
lower	O
in	O
patients	O
on	O
thiazide	B
diuretics	I
and	O
inhibitors	B
of	I
tubular	I
organic	I
cation	I
transport	I
,	O
respectively	O
.	O

Lithium	B-O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

Digoxin	B-O
:	O
When	O
telmisartan	B
was	O
co-administered	O
with	O
digoxin	B-O
,	O
median	O
increases	O
in	O
digoxin	B-O
peak	O
plasma	O
concentration	O
(	O
49	O
%	O
)	O
and	O
in	O
trough	O
concentration	O
(	O
20	O
%	O
)	O
were	O
observed	O
.	O

Lithium	B-O
:	O
Reversible	O
increases	O
in	O
serum	O
lithium	B-O
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-O
with	O
angiotensin	B
II	I
receptor	I
antagonists	I
including	O
telmisartan	B
.	O

Simvastatin	B-O
:	O
Co-administration	O
of	O
multiple	O
doses	O
of	O
10	O
mg	O
of	O
amlodipine	B
with	O
80	O
mg	O
simvastatin	B-O
resulted	O
in	O
a	O
77	O
%	O
increase	O
in	O
exposure	O
to	O
simvastatin	B-O
compared	O
to	O
simvastatin	B-O
alone	O
.	O

Immunosuppressants	O
:	O
Amlodipine	B
may	O
increase	O
the	O
systemic	O
exposure	O
of	O
cyclosporine	B-O
or	O
tacrolimus	B-O
when	O
co-administered	O
.	O

CYP3A4	O
Inhibitors	O
:	O
Co-administration	O
of	O
a	O
180	O
mg	O
daily	O
dose	O
of	O
diltiazem	B
with	O
5	O
mg	O
amlodipine	B-O
in	O
elderly	O
hypertensive	O
patients	O
resulted	O
in	O
a	O
60	O
%	O
increase	O
in	O
amlodipine	B-O
systemic	O
exposure	O
.	O

However	O
,	O
strong	O
inhibitors	B
of	I
CYP3A4	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
ritonavir	B
)	O
may	O
increase	O
the	O
plasma	O
concentrations	O
of	O
amlodipine	B-O
to	O
a	O
greater	O
extent	O
.	O

After	O
administering	O
TWYNSTA	B-O
80/10	O
mg	O
tablet	O
with	O
a	O
high-fat	B
meal	I
,	O
the	O
total	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC)	O
and	O
Cmax	O
for	O
telmisartan	B-O
decreased	O
by	O
about	O
24	O
%	O
and	O
60	O
%	O
,	O
respectively	O
.	O

Food	B
slightly	O
reduces	O
the	O
bioavailability	O
of	O
telmisartan	B-O
,	O
with	O
a	O
reduction	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC)	O
of	O
about	O
6	O
%	O
with	O
the	O
40	O
mg	O
tablet	O
and	O
about	O
20	O
%	O
after	O
a	O
160	O
mg	O
dose	O
.	O

Drug	O
Interaction	O
Studies	O
Telmisartan	B
Ramipril	B-O
and	I-O
Ramiprilat	B-O
:	O
Co-administration	O
of	O
telmisartan	B
80	O
mg	O
once	O
daily	O
and	O
ramipril	B-O
10	O
mg	O
once	O
daily	O
to	O
healthy	O
subjects	O
increases	O
steady-state	O
Cmax	O
and	O
AUC	O
of	O
ramipril	B-O
2.3-	O
and	O
2.1-fold	O
,	O
respectively	O
,	O
and	O
Cmax	O
and	O
AUC	O
of	I-O
ramiprilat	B-O
2.4-	O
and	O
1.5-fold	O
,	O
respectively	O
.	O

When	O
co-administering	O
telmisartan	B
and	O
ramipril	B-O
,	O
the	O
response	O
may	O
be	O
greater	O
because	O
of	O
the	O
possibly	O
additive	O
pharmacodynamic	O
effects	O
of	O
the	O
combined	O
drugs	O
,	O
and	O
also	O
because	O
of	O
the	O
increased	O
exposure	O
to	O
ramipril	B-O
and	I-O
ramiprilat	B-O
in	O
the	O
presence	O
of	O
telmisartan	B
.	O

Concurrent	O
use	O
of	O
rifampin	B
increases	O
the	O
metabolic	O
clearance	O
of	O
bisoprolol	B-O
fumarate	I-O
,	O
shortening	O
its	O
elimination	O
half-life	O
.	O

Cholestyramine	B
and	O
colestipol	B
resins	I
-	O
Absorption	O
of	O
hydrochlorothiazide	B-O
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	B
exchange	I
resins	I
.	O

Single	O
doses	O
of	O
cholestyramine	B
and	O
colestipol	B
resins	I
bind	O
the	O
hydrochlorothiazide	B-O
and	O
reduce	O
its	O
absorption	O
in	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
85	O
percent	O
and	O
43	O
percent	O
,	O
respectively	O
.	O

Diuretic	B
agents	I
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

